Salts and free bases of bifunctional compound and polymorph forms thereof

Abstract

The present disclosure is directed to salts and free bases of Compounds of Formula (I), including crystalline, semi-crystalline, amorphous, and polymorph forms thereof, and processes for their preparation.

Description

Attorney Docket No.121843.00291 NU-3500 PCT SALTS AND FREE BASES OF BIFUNCTIONAL COMPOUND AND POLYMORPH FORMS THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims the benefit of U.S. provisional patent application no. 63 / 545,346, filed October 23, 2023, and provisional patent application no.63 / 670,621, filed July 12, 2024, the contents of which are hereby incorporated by reference in its entirety. FIELD

[0002] The present disclosure is directed to salts of Compounds of Formula (I), including crystalline and polymorph forms thereof, and processes for their preparation. Also provided are free bases of Compounds of Formula (I) and crystalline and polymorph forms thereof, and processes for their preparation. BACKGROUND

[0003] B cell receptor (BCR) signaling controls B cell development, as well as mature B cell activation, signaling, and survival. Mis-regulation of the BCR signaling pathway is associated with numerous disease indications involving B cell function, and targeting B cells and BCR signaling has clear therapeutic potential (Woyach, et al.; Blood, 120(6); 1175-1184, 2012). For example, depletion of B cells with monoclonal antibodies targeting CD20 has significant effects in treatment of B cell malignancies and auto-immune and inflammatory diseases (Cang, et al.; J. Hematolo. Oncol.5; 64, 2012.).

[0004] BTK is a member of the TEC family of kinases and is a crucial signaling hub in the BCR pathway. Mutations in BTK result in X-linked agammaglobulinaemia (XLA), in which B cell maturation is impaired, resulting in reduced immunoglobulin production (Hendriks, et al.; Expert Opin. Ther. Targets 15; 1002-1021, 2011). The central role of BTK in B cell signaling and function makes BTK an attractive therapeutic target for B cell malignancies as well as autoimmune and inflammatory diseases. Ibrutinib, a covalent inhibitor of BTK, has been approved to treat chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies, as well as graft-versus-host disease (GvHD) (Miklos, et al.; Blood, 120(21); 2243-2250, 2017). Currently, ibrutinib and second-generation BTK inhibitors are being investigated for oncology and immune-related indications such as rheumatoid arthritis (Akinleye, 1 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT et al.; J of Hematolo Oncol. 6: 59, 2013; Liu, et al.; J. Pharm. and Exper. Ther. 338(1): 154- 163.2011; Di Paolo, et al.; Nat Chem Biol.7(1): 41-50, 2011).

[0005] As an alternative to stoichiometric inhibition, proteolytic degradation of BTK could have dramatic consequences for B cell function by effectively blocking BCR signaling. Removal of BTK protein would eliminate BTK kinase activity as well as any protein interaction or scaffolding function of BTK. Specific degradation of BTK could be accomplished using heterobifunctional small molecules to recruit BTK to a ubiquitin ligase and thus promoting ubiquitylation and proteasomal degradation of BTK. Thalidomide derivatives, such as lenalidomide or pomalidomide, can be used to recruit potential substrates to cereblon (CRBN), a component of a ubiquitin ligase complex. This unique therapeutic approach could present a mechanism of action for interfering with BTK activity and BCR signaling that is distinct from the mechanism of stoichiometric BTK inhibition. Furthermore, this degradative approach could effectively target the C481S mutated form of BTK, which mutation has been clinically observed and confers resistance to inhibition by ibrutinib (Woyach, et al.; Blood, 120(6): 1175- 1184, 2012).

[0006] Given the importance of bifunctional molecules such as the compound of Formula (I), it would be beneficial to develop highly purified and stable forms of compounds of Formula (I) that can be easily manufactured and formulated. There is also a need for salts and polymorph forms of compounds of Formula (I) that can act as and provide these advantageous forms. SUMMARY

[0007] In one aspect, provided herein is a free base of a compound of Formula (I) (or free base compound of Formula (I)).2 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0008] In one aspect, provided herein is a free base of a compound of Formula (I) selected from the group consisting of Free Base Form A, Free Base Amorphous Form, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, and Free Base Form J.

[0009] In another aspect, provided herein is a solvate of a compound of Formula (I). In one or more embodiments, the free base can be or is a solvate of a compound of Formula (I).

[0010] In another aspect, provided herein is a hydrate of a compound of Formula (I). In one or more embodiments, the salt or the free base can be or is a hydrate of a compound of Formula (I).

[0011] In another aspect, provided herein is an amorphous form of a compound of Formula (I). In one or more embodiments, the salt or the free base can be or is an amorphous form of a compound of Formula (I).

[0012] In one aspect, provided is an amorphous solid dispersion of a free base of a compound of Formula (I). In one aspect, provided is an amorphous solid dispersion that comprises a dispersion agent and a free base. In one aspect, provided is an amorphous solid dispersion of a free base of a compound of Formula (I) selected from the group consisting of Free Base Form A, Free Base Amorphous Form, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, and Free Base Form J.

[0013] In another aspect, the present disclosure provides salts of a compound of Formula (I).

[0014] In one aspect, provided herein is a salt of a compound of Formula (I) selected from the group consisting of Fumarate Salt Form A, Fumarate Salt Amorphous Form, Fumarate Salt Form B, Fumarate Salt Form C, Fumarate Salt Form D, Fumarate Salt Form E, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Besylate Salt Form A, Cyclamate Salt Form A, Malate Salt Form A, Malonate Salt Form A, Napsylate Salt Form A, Napsylate Salt Form B, 3 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Napsylate Salt Form C, Napsylate Salt Form D, Succinate Salt Form A, Succinate Salt Form B, and Succinate Salt Form C.

[0015] In one or more embodiments, the salt of the compound of Formula (I) is provided as a fumarate salt, a maleate salt, or a tosylate salt. In one or more embodiments, the fumarate salt is a salt of fumaric acid, the maleate salt is a salt of maleic acid, and the tosylate salt is a salt of p- toluenesulfonic acid.

[0016] In one or more embodiments, the salt of the salt of the compound of Formula (I) is provided as a fumarate salt, a maleate salt, a tosylate salt, a besylate salt, a cyclamate salt, a malate salt, a malonate salt, a napsylate salt, or a succinate salt.

[0017] In one or more embodiments, the besylate salt is a salt of benzene sulfonate, the cyclamate salt is a salt of cyclohexylsulfamic acid, the malate salt is a salt of malic acid, a malonate salt is a salt of malonic acid, a napsylate salt is a salt of naphthalene sulfonic acid (including but not limited to naphthalene-1- sulfonic acid, naphthalene-2-sulfonic acid), or a succinate salt is a salt of succinic acid.

[0018] In the following schemes, salts of Formula (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I- G), (I-H), and (I-J) are depicted without ionic charges. One of ordinary skill in the art would understand structures of salts that form between organic molecules depicted in schemes Formula (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (I-H), and (I-J), and possibilities of ionic charge placement in these schemes. Without wanting to be bound by theory, an ionic charge on a molecule may be a mixture of contributing ionic charges within a probability distribution. As well, ionic charges on the salts of Formula (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (I-H), and (I-J) may include ionic character on a molecule therein, portion(s) of a molecule therein (multiple atoms or substituents), or on an atom or substituent. Thus, salts of Formula (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (I-H), and (I-J) are understood to include ionic charges. 4 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0019] In one or more embodiments, the salt of the compound of Formula (I) is provided as Formula (I-A).

[0020] In(I) is provided as a hemi-fumarate salt of Formula (I-A): .5 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0021] In one or more embodiments, the salt of the compound of Formula (I) is provided as Formula (I-B).

[0022] In(I) is provided as Formula (I-C).

[0023] In one or more embodiments, the salt of the compound of Formula (I) is provided as Formula (I-D).6 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0024] In one or more embodiments, the salt of the compound of Formula (I) is provided as Formula (I-E).

[0025] In one or more embodiments, the salt of the compound of Formula (I) is provided as Formula (I-F).

[0026] In one or more embodiments, the salt of the compound of Formula (I) is provided as Formula (I-G).

[0027] In one or more embodiments, the salt of the compound of Formula (I) is provided as Formula (I-H). 7 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0028] In one or more embodiments, the salt of the compound of Formula (I) is provided as Formula (I-J).

[0029] In one aspect, provided is an amorphous solid dispersion of a salt of a compound of Formula (I). In one aspect, provided is an amorphous solid dispersion that comprises a dispersion agent and a salt. In one aspect, provided is an amorphous solid dispersion of a salt of a compound of Formula (I) selected from the group consisting of Fumarate Salt Form A, Fumarate Salt Amorphous Form, Fumarate Salt Form B, Fumarate Salt Form C, Fumarate Salt Form D, Fumarate Salt Form E, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Besylate Salt Form A, Cyclamate Salt Form A, Malate Salt Form A, Malonate Salt Form A, Napsylate Salt Form A, Napsylate Salt Form B, Napsylate Salt Form C, Napsylate Salt Form D, Succinate Salt Form A, Succinate Salt Form B, and Succinate Salt Form C.

[0030] Also provided herein is a pharmaceutical composition comprising a salt or free base of the compound of Formula (I) and a pharmaceutically acceptable carrier, vehicle, or adjuvant.

[0031] Provided herein is a method of treating a disease, disorder, or condition mediated by degrading Bruton’s tyrosine kinase comprising administering to a patient or biological sample a 8 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT salt or free base of the compound of Formula (I) or a pharmaceutical composition comprising a salt or free base of the compound of Formula (I) and a pharmaceutically acceptable carrier, vehicle, or adjuvant.

[0032] Further provided is a method of degrading splenocyte Bruton’s tyrosine kinase in a subject in need thereof comprising the step of orally administering to the subject an amount of the salt or the free base of the compound of Formula (I) or the pharmaceutical composition comprising the compound of Formula (I) and a pharmaceutically acceptable carrier, vehicle, or adjuvant, wherein said salt or free base is capable of inducing proteolytic degradation of Bruton’s tyrosine kinase, and wherein said amount is effective to degrade splenocyte Bruton’s tyrosine kinase in the subject. BRIEF DESCRIPTION OF FIGURES

[0033] FIG.1 shows an X-ray powder diffraction (XRPD) analysis of Free Base Form A.

[0034] FIG.2 shows a thermogravimetric analysis-differential scanning calorimetry (TGA- DSC) thermogram of Free Base Form A.

[0035] FIG.3 shows a dynamic vapor sorption (DVS) analysis of Free Base Form A.

[0036] FIG.4 shows an XRPD pattern of Free Base Amorphous Form.

[0037] FIG.5 shows a proton nuclear magnetic resonance imaging (1H NMR) spectrum of Free Base Amorphous Form.

[0038] FIG.6 shows a thermogravimetric analysis / differential thermal analysis (TGA / DTA) thermogram of Free Base Amorphous Form.

[0039] FIG.7 shows a DSC thermogram of Free Base Amorphous Form.

[0040] FIG.8 shows an XRPD comparison of Free Base Amorphous Form after one week stress at 40°C / 75% relative humidity (RH) (top), and after DVS analysis (bottom).

[0041] FIG.9 shows a DVS analysis of Free Base Amorphous Form (weight change dry- bulb (DB) % vs. relative humidity (RH) %).

[0042] FIG.10 shows an overlay plot of Free Base Forms A, B, C, and D.

[0043] FIG.11 shows an XRPD analysis of Free Base Form B. 9 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0044] FIG.12 shows a TGA-DSC thermogram of Free Base Form B.

[0045] FIG.13 shows an XRPD analysis of Free Base Form C.

[0046] FIG.14 shows a TGA-DSC thermogram of Free Base Form C.

[0047] FIG.15 shows an XRPD analysis of Free Base Form D.

[0048] FIG.16 shows a TGA-DSC thermogram of Free Base Form D.

[0049] FIG.17 shows a TGA / DTA analysis of Free Base Form D.

[0050] FIG.18 shows an XPRD pattern of Free Base Form E.

[0051] FIG.19 shows a1H NMR spectrum of Free Base Form E in DMSO-d6.

[0052] FIG.20 shows a TGA / DTA thermogram of Free Base Form E.

[0053] FIG.21 shows an XRPD pattern of Free Base Form F.

[0054] FIG.22 shows an XRPD pattern of Free Base Form G.

[0055] FIG.23 shows a1H NMR spectrum of Free Base Form G in DMSO-d6.

[0056] FIG.24 shows a TGA / DTA thermogram of Free Base Form G.

[0057] FIG.25 shows an XRPD pattern of Free Base Form H.

[0058] FIG.26 shows a1H NMR spectrum of Free Base Form H in DMSO-d6.

[0059] FIG.27 shows a TGA / DTA thermogram of Free Base Form H.

[0060] FIG.28 shows an XRPD pattern of Free Base Form J.

[0061] FIG.29 shows a1H NMR spectrum of Free Base Form J in DMSO-d6.

[0062] FIG.30 shows a TGA / DTA thermogram of Free Base Form J.

[0063] FIG.31 shows an overlay plot of XRPD patterns for Fumarate Salt Form A (top: scale up in 90 acetone:10 water, slurry at 45°C; upper middle: milling free base and Fumaric acid in 95 methanol:5 water; lower middle: dioxane, slurry at 60°C; bottom: 1-pentanol, slurry at 60°C).

[0064] FIG.32 shows an XRPD analysis of Fumarate Salt Form A. 10 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0065] FIG.33 shows an overlay plot of XRPD patterns for fumarate salt (of the compound of Formula (I); top: vacuum dried Fumarate Salt Form A; bottom: before drying Fumarate Salt Form A).

[0066] FIG.34 shows an FT-IR spectra of Fumarate Salt Form A.

[0067] FIG.35 shows a Raman spectra of Fumarate Salt Form A.

[0068] FIG.36 shows an overlay plot of XRPD patterns stability samples – fumarate salt (top to bottom: 0%, 20%, 40%, 60%, 75%, 97% relative humidity (RH) Fumarate Salt Form A).

[0069] FIG.37 shows a thermogravimetric analysis-differential scanning calorimetry thermogram (TGA-DSC) of Fumarate Salt Form A.

[0070] FIG.38 shows a dynamic vapor sorption (DVS) analysis of Fumarate Salt Form A.

[0071] FIG.39 shows an XRPD pattern of Fumarate Salt Amorphous Form.

[0072] FIG.40 shows a1H NMR spectrum of Fumarate Salt Amorphous Form.

[0073] FIG.41 shows a TGA / DTA thermogram of Fumarate Salt Amorphous Form.

[0074] FIG.42 shows a DSC thermogram of Fumarate Salt Amorphous Form.

[0075] FIG.43 shows an XRPD comparison of Fumarate Salt Amorphous Form after one week stress at 40°C / 75% relative humidity (RH) (top), and after DVS analysis (bottom).

[0076] FIG.44 shows a DVS analysis of Fumarate Salt Amorphous Form (weight change DB% vs. RH%).

[0077] FIG.45 shows an XRPD comparison of Fumarate Salt Form A and Fumarate Salt Form B: Fumarate Salt Form A (top); Fumarate Salt Form A + Fumarate Salt Form B (2ndfrom top); Fumarate Salt Form B (2ndfrom bottom); and Fumarate Salt Form B after stressing for one week at 40°C and 75% relative humidity (bottom).

[0078] FIG.46 shows a1H NMR spectrum of Fumarate Salt Form B.

[0079] FIG.47 shows an XRPD comparison of Fumarate Salt Form A and Fumarate Salt Form C: Fumarate Salt Form A (top); Fumarate Salt Form A + Fumarate Salt Form C (2ndfrom top); Fumarate Salt Form C (2ndfrom bottom); and Fumarate Salt Form C after stressing for one week at 40°C and 75% relative humidity (bottom). 11 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0080] FIG.48 shows a1H NMR spectrum of Fumarate Salt Form C.

[0081] FIG.49 shows an XRPD pattern of Fumarate Salt Form D.

[0082] FIG.50 shows a thermogravimetric analysis-differential scanning calorimetry thermogram (TGA / DTA) of Fumarate Salt Form D.

[0083] FIG.51 shows an XRPD pattern of Fumarate Salt Form E.

[0084] FIG.52 shows a thermogravimetric analysis-differential scanning calorimetry thermogram (TGA / DTA) of Fumarate Salt Form E.

[0085] FIG.53 shows an overlay plot of a fumarate salt (top) and a maleate salt (bottom).

[0086] FIG.54 shows an overlay plot of tosylate salts (top: Tosylate Salt Form A; bottom: Tosylate Salt Form B).

[0087] FIG.55 shows an XRPD analysis of Maleate Salt Form A.

[0088] FIG.56 shows a TGA-DSC thermogram of Maleate Salt Form A.

[0089] FIG.57 shows an XRPD analysis of Tosylate Salt Form A.

[0090] FIG.58 shows an XRPD analysis of Tosylate Salt Form B.

[0091] FIG.59 shows an XRPD analysis of Besylate Salt Form A.

[0092] FIG.60 shows a TGA / DTA thermogram of Besylate Salt Form A.

[0093] FIG.61 shows an XRPD analysis of Cyclamate Salt Form A.

[0094] FIG.62 shows a TGA / DTA thermogram of Cyclamate Salt Form A.

[0095] FIG.63 shows an XRPD analysis of Malate Salt Form A.

[0096] FIG.64 shows a TGA / DTA thermogram of Malate Salt Form A.

[0097] FIG.65 shows an XRPD analysis of Malonate Salt Form A.

[0098] FIG.66 shows a TGA / DTA thermogram of Malonate Salt Form A.

[0099] FIG.67 shows an XRPD analysis of Napsylate Salt Form A.

[0100] FIG.68 shows a TGA / DTA thermogram of Napsylate Salt Form A. 12 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0101] FIG.69 shows XRPD patterns of Napsylate Salt Forms A, B, C, and D: Napsylate Salt Form A (top); Napsylate Salt Form B (2ndfrom top); Napsylate Salt Form C (2ndfrom bottom); and Napsylate Salt Form D (bottom).

[0102] FIG.70 shows an XRPD analysis of Napsylate Salt Form D.

[0103] FIG.71 shows a TGA / DTA thermogram of Napsylate Salt Form D.

[0104] FIG.72 shows XRPD patterns of Succinate Salt Form A and Succinate Salt Form B, compared to Succinate Salt Form A: Free Base Form A (top); Succinate Salt Form A obtained after stressing Succinate Salt Form B at 40°C / 75% RH for 1 week (2ndfrom top); Succinate Salt Form B (2ndfrom bottom); and Succinate Salt Form A formed from the reaction in THF (bottom).

[0105] FIG.73 shows an XRPD analysis of Succinate Salt Form A.

[0106] FIG.74 shows a TGA / DTA thermogram of Succinate Salt Form B.

[0107] FIG.75 shows an XRPD analysis of Succinate Salt Form C.

[0108] FIG.76 shows a TGA / DTA thermogram of Succinate Salt Form C.

[0109] FIG.77 shows an XRPD of an amorphous solid dispersion (ASD) prepared from Fumarate Salt Form A. When converted and presented in the amorphous solid dispersion, the form is amorphous.

[0110] FIG.78 shows a DSC of an amorphous solid dispersion (ASD) prepared from Fumarate Salt Form A. When converted and presented in the amorphous solid dispersion, the form is amorphous. DETAILED DESCRIPTION

[0111] The present disclosure provides free bases of compounds of Formula (I), and crystalline, semi-crystalline, and non-crystalline forms thereof. In one or more embodiments, the free base of compound of Formula (I) is crystalline. In one or more embodiments, the free base of compound of Formula (I) is semi-crystalline or non-crystalline. In one or more embodiments, the semi-crystalline free base has lower crystallinity than crystalline free base without being amorphous. In one or more embodiments, the non-crystalline free base is amorphous. In one or more embodiments, the free base of compound of Formula (I) is amorphous. 13 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0112] The present disclosure provides a crystalline form of free base form of compound of Formula (I). In one or more embodiments, the free base is Free Base Form A.

[0113] In one or more embodiments, the amorphous form of free base of compound of Formula (I) is Free Base Amorphous Form.

[0114] The present disclosure also provides a semi-crystalline or non-crystalline form of a free base of compound of Formula (I). In one or more embodiments, the semi-crystalline form of free base of compound of Formula (I) is Free Base Form D.

[0115] In one or more embodiments, the free base is selected from the group consisting of Free Base Form A, B, C, and D.

[0116] In one or more embodiments, the free base is selected from the group consisting of Free Base Form A, B, C, D, E, F, G, H, and J. In one or more embodiments, the free base is selected from the group consisting of Free Base Form A, B, C, D, E, F, G, H, J, and Free Base Amorphous Form.

[0117] The present disclosure provides salts of compounds of Formula (I), and crystalline, semi-crystalline, and non-crystalline forms thereof. In one or more embodiments, the salt form of compound of Formula (I) is a fumarate salt, a maleate salt, a tosylate salt, a besylate salt, a cyclamate salt, a malate salt, a malonate salt, a napsylate salt, or a succinate salt. In one or more embodiments, the salt form of a compound of Formula (I) is crystalline. For example, a compound of Formula (I) that is a fumarate salt, a maleate salt, a tosylate salt, a besylate salt, a cyclamate salt, a malate salt, a malonate salt, a napsylate salt, or a succinate salt can be a crystalline salt. In one or more embodiments, the salt form of compound of Formula (I) is semi-crystalline or non- crystalline. In one or more embodiments, the semi-crystalline salt has lower crystallinity than crystalline salt without being amorphous. In one or more embodiments, the non-crystalline salt is amorphous. In one or more embodiments, the salt form of compound of Formula (I) is amorphous. In one or more embodiments, the salt is a hemi- salt including, but not limited to, a hemi-fumarate salt, wherein a hemi- salt has a stoichiometry of 1 equivalent counterion (such as 1 equivalent fumarate) with 2 equivalents of a compound of Formula (I).

[0118] The present disclosure provides a crystalline form of compound of Formula (I), fumarate salt. In one or more embodiments, the fumarate salt is Fumarate Salt Form A. 14 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0119] The present disclosure provides an amorphous form of a compound of Formula (I), fumarate salt. In one or more embodiments, the compound of Formula (I), fumarate salt, is Fumarate Salt Amorphous Form.

[0120] The present disclosure provides a crystalline form of compound of Formula (I), maleate salt. In one or more embodiments, the maleate salt is Maleate Salt Form A.

[0121] The present disclosure also provides a crystalline form of compound of Formula (I), tosylate salt. In one or more embodiments, the tosylate salt is Tosylate Salt Form A or Tosylate Salt Form B.

[0122] The present disclosure provides at least the following embodiments: a) salt or free base of a compound of Formula (I); b) crystalline, semi-crystalline, or non-crystalline fumarate salt(s) of compound of Formula (I), for example, Fumarate Salt Forms A-E, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Besylate Salt Form A, Cyclamate Salt Form A, Malate Salt Form A, Malonate Salt Form A, Napsylate Salt Forms A-D, Succinate Salt Forms A-C and Fumarate Salt Amorphous Form; c) crystalline, semi-crystalline, or non-crystalline free bases of compound of Formula (I), for example, Free Base Forms A, B, C, D, E, F, G, H, J, and Free Base Amorphous Form; d) amorphous form of compound of Formula (I), for example, Fumarate Salt Amorphous Form and Free Base Amorphous Form; e) a hydrate or solvate of any one of (a)-(d); f) a pharmaceutical composition comprising any one of (a)-(e); g) the pharmaceutical composition of (f) further comprising a pharmaceutically acceptable carrier, vehicle, or adjuvant; h) a method to treat a disease, disorder, or condition mediated by degrading Bruton’s tyrosine kinase comprising administering to a patient in need thereof any one of (a)-(g); i) a method of degrading splenocyte Bruton’s tyrosine kinase in a subject in need thereof, comprising the step of orally administering to the subject an amount of any one of (a)-(g) in a patient in need thereof.

[0123] In one or more embodiments, the compound of Formula (I) is a solvate and the solvate is selected from the group consisting of: an acetonitrile solvate, a tetrahydrofuran solvate, 15 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT a dioxane solvate, an ethanol solvate, an ethyl acetate solvate, a methanol solvate, a 2-methyl- tetrahydrofuran solvate, a methyl ethyl ketone solvate, an isopropanol solvate, a toluene solvate, a dimethylacetamide solvate, a dimethylsulfonamide solvate, a dimethylsulfoxide solvate, a dimethylformamide solvate, a diethyl ether solvate, an anisole solvate, an acetone solvate, a dimethylacetamide solvate, or a combination thereof.

[0124] In one or more embodiments, the compound of Formula (I) is a solvate and the solvate is selected from the group consisting of: an acetonitrile solvate, a tetrahydrofuran solvate, a dioxane solvate, an ethanol solvate, an ethyl acetate solvate, a methanol solvate, a 2-methyl- tetrahydrofuran solvate, a methyl ethyl ketone solvate, an isopropanol solvate, a toluene solvate, a dimethylacetamide solvate, a dimethylsulfonamide solvate, a dimethylsulfoxide solvate, a dimethylformamide solvate, a diethyl ether solvate, and an anisole solvate.

[0125] In one or more embodiments, a salt of a compound of Formula (I) exhibits at least one diffraction peak at about 5.0-40°2θ in its X-ray powder diffraction pattern. For example, the salt of a compound of Formula (I) can exhibit at least one diffraction peak at about 5.0-35.0°2θ, 5.0-30.0°2θ, 5.0-25.0°2θ, 5.0-20.0°2θ, 10.0-40.0°2θ, 10.0-35.0°2θ, 10.0-30.0°2θ, 10.0-25.0°2θ, 10.0-20.0°2θ, 15.0-40.0°2θ, 15.0-35.0°2θ, 15.0-30.0°2θ, 15.0-25.0°2θ, 15.0-20.0°2θ, 17.0-25.0°2θ, 17.0-21.0°2θ, 19.0-20.0°2θ, or 20.0-22.0°2θ in its X-ray powder diffraction pattern.

[0126] In one or more embodiments, the salt of a compound of Formula (I) is a solvate, and the solvate is a tetrahydrofuran (THF) solvate, a methyl ethyl ketone (MEK) solvate, a dimethyl sulfoxide (DMSO) solvate, a dimethylformamide (DMF) solvate, or a diethyl ether solvate.

[0127] In one or more embodiments, a free base of a compound of Formula (I) exhibits at least one diffraction peak at about 5.0-40°2θ in its X-ray powder diffraction pattern. For example, the free base of a compound of Formula (I) can exhibit at least one diffraction peak at about 5.0-35.0°2θ, 5.0-30.0°2θ, 5.0-25.0°2θ, 5.0-20.0°2θ, 10.0-40.0°2θ, 10.0-35.0°2θ, 10.0- 30.0°2θ, 10.0-25.0°2θ, 10.0-20.0°2θ, 15.0-40.0°2θ, 15.0-35.0°2θ, 15.0-30.0°2θ, 15.0-25.0°2θ, 15.0-20.0°2θ, 17.0-25.0°2θ, 17.0-21.0°2θ, 19.0-20.0°2θ, or 20.0-22.0°2θ in its X-ray powder diffraction pattern.

[0128] In one or more embodiments, a free base of a compound of Formula (I) exhibits at least one diffraction peak at about 3.9-40°2θ in its X-ray powder diffraction pattern. 16 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0129] In one or more embodiments, the free base of a compound of Formula (I) is a solvate, and the solvate is a tetrahydrofuran (THF) solvate, a methyl ethyl ketone (MEK) solvate, a dimethyl sulfoxide (DMSO) solvate, a dimethylformamide (DMF) solvate, or a diethyl ether solvate.

[0130] In one or more embodiments, the free base of a compound of Formula (I) is a solvate and the solvate is an acetonitrile solvate, a tetrahydrofuran solvate, a dioxane solvate, an ethanol solvate, an ethyl acetate solvate, a methanol solvate, a 2-methyl-tetrahydrofuran solvate, an isopropanol solvate, a toluene solvate, a dimethylacetamide solvate, a dimethylsulfonamide solvate, or an anisole solvate.

[0131] In one or more embodiments, the compound of Formula (I) is a solvate and the solvate is a tetrahydrofuran (THF) solvate, a methyl ethyl ketone (MEK) solvate, a dimethyl sulfoxide (DMSO) solvate, a dimethylformamide (DMF) solvate, a diethyl ether solvate, an acetone solvate, a dimethylacetamide (DMAc) solvate, or a combination thereof.

[0132] Definitions

[0133] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures known in the art that are described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art.

[0134] As used herein, the singular forms “a,” “an,” and “the” include the plural referents unless the context clearly indicates otherwise.

[0135] As used herein, the term “about” refers to the stated value plus or minus 10%, plus or minus 5%, or plus or minus 1%. For example, a value of “about 10” can encompass a range of 9 to 11. For logarithmic scales, the term “about” refers to the stated value plus or minus 0.3 log units, or plus or minus 0.2 log units, or plus or minus 0.1 log units. For example, a value of “about pH 17 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 4.6” can encompass a pH range of 4.5-4.7. For 2 theta (2θ) values, the term “about” refers to the stated value plus or minus 0.3, 0.2, or 0.1 degrees 2 theta (2θ).

[0136] The term “substantially free of” or “substantially in the absence of” with respect to a composition refers to a composition that includes at least about 85 or 90% by weight, in one or more embodiments at least about 95%, 98%, 99% or 100% by weight, of a designated enantiomer or stereoisomer of a compound. For example, “substantially free of” or “substantially in the absence of” with respect to a composition can refer to a composition that includes about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% by weight of a designated enantiomer or stereoisomer of a compound. In one or more embodiments, in the methods and compounds provided herein, the compounds are substantially free of other enantiomers or stereoisomers.

[0137] Similarly, the term “isolated” with respect to a composition refers to a composition that includes at least 85%, 90%, 95%, 98%, and 99% to 100% by weight, of a designated compound, enantiomer, or stereoisomer, the remainder comprising other chemical species, enantiomers, or stereoisomers. For example, “isolated” with respect to a composition can refer to a composition that includes about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% by weight of a designated compound, enantiomer, or stereoisomer, the remainder comprising other chemical species, enantiomers, or stereoisomers.

[0138] As used herein, the terms “subject” and “patient” are used interchangeably herein. The terms “subject” and “subjects” refer to an animal, such as a mammal including a non-primate (e.g., a cow, pig, horse, cat, dog, rat, and mouse) and a primate (e.g., a monkey such as a cynomolgus monkey, a chimpanzee and a human), and for example, a human. In one or more embodiments, the subject is a farm animal (e.g., a horse, a cow, a pig, etc.) or a pet (e.g., a dog or a cat). In one or more embodiments, the subject is a human.

[0139] “Therapeutically effective amount” refers to an amount of a compound or composition that, when administered to a subject for treating a disease, disorder, or condition, is sufficient to effect such treatment for the disease, disorder, or condition. A “therapeutically effective amount” can vary depending on, inter alia, the compound, the disease, disorder, or condition and its severity, and the age, weight, etc., of the subject to be treated. 18 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0140] “Treating” or “treatment” of any disease, disorder, or condition refers, in one or more embodiments, to ameliorating a disease, disorder, or condition that exists in a subject. In one or more embodiments, “treating” or “treatment” includes ameliorating at least one physical parameter, which may be indiscernible by the subject. In one or more embodiments, “treating” or “treatment” includes modulating the disease, disorder, or condition, either physically (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter) or both. In one or more embodiments, “treating” or “treatment” includes delaying the onset of the disease, disorder, or condition.

[0141] As used herein, the term “free base” refers to a conjugate base (deprotonated) form of a basic group. In some instances, a free base form or free base may be a standard form of a molecule as it exists at equilibrium, standard temperature and pressure, and / or as it sits on a shelf (not a salt); this may also be called a free form. In other instances, a free base form or free base may be a form that is briefly identified, such as a molecule produced by a reaction under inert gas that is identified and then decomposes, reverts, or otherwise changes to another form. In one or more embodiments, the basic group is an amine.

[0142] As used herein, the terms “prophylactic agent” and “prophylactic agents” as used refer to any agent(s) which can be used in the prevention of a disease, disorder, or condition or one or more symptoms thereof. In one or more embodiments, the term “prophylactic agent” includes a compound provided herein. In one or more other embodiments, the term “prophylactic agent” does not refer a compound provided herein. For example, a prophylactic agent is an agent which is known to be useful for, or has been or is currently being used to prevent or impede the onset, development, progression and / or severity of a disease, disorder, or condition.

[0143] As used herein, the phrase “prophylactically effective amount” refers to the amount of a therapy (e.g., prophylactic agent) which is sufficient to result in the prevention or reduction of the development, recurrence or onset of one or more symptoms associated with a disease, disorder, or condition (or to enhance or improve the prophylactic effect(s) of another therapy, e.g., another prophylactic agent).

[0144] “Substantially” when describing XRPD patterns is meant that the reported peaks can vary by + 0.2°. 19 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0145] “Substantially” when describing differential scanning calorimetry (DSC) thermograms and thermogravimetric analysis (TGA) is meant that the reported temperatures can vary by + 0.5°C.

[0146] Free Base Form A

[0147] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Form A.

[0148] In one or more embodiments, Free Base Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 1. In one or more embodiments, Free Base Form A is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 21. In one or more embodiments, Free Base Form A is characterized by an XRPD pattern comprising: a) 2θ values of about 4.96, 14.26, 15.86, 18.90, 19.98, 22.12, 23.68, and 25.00 + 0.2°2θ; b) 2θ values of about 4.96, 7.44, 9.92, 14.26, 15.86, 17.00, 18.04, 18.90, 19.98, 22.12, 23.68, and 25.00 + 0.2°2θ; c) 2θ values including at least or selected from about 4.96, 7.44, 9.42, 9.92, 11.42, 12.42, 14.00, 14.26, 14.86, 15.86, 16.24, 17.00, 18.04, 18.90, 19.98, 20.82, 22.12, 23.06, 23.68, 25.00, 26.36, 27.32, 28.50, 30.06, 31.88, and 32.32 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 4.96, 14.00, 14.26, 15.86, 16.24, 17.00, 18.04, 18.90, 19.98, 20.82, 20.82, 23.68, and 25.00 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 4.96, 9.92, 14.00, 14.26, 15.86, 16.24, 17.00, 18.04, 18.90, 19.98, 20.82, 20.82, 23.06, 23.68, and 25.00 + 0.2°2θ; f) 2θ values of about 9.92, 14.00, 14.26, 15.86, 16.24, 17.00, 18.04, 18.90, 19.98, 20.82, 20.82, 23.06, 23.68, and 25.00 + 0.2°2θ; g) 2θ values including at least or selected from about 9.92, 14.00, 14.26, 15.86, 16.24, 17.00, 18.04, 18.90, 19.98, 20.82, 20.82, 23.06, 23.68, and 25.00 + 0.2°2θ; h) 2θ values of about 4.96, 14.26, 15.86, and 19.98 + 0.2°2θ; i) 2θ values including at least or selected from about 4.96, 14.26, 15.86, and 19.98 + 0.2°2θ; j) 2θ values of about 4.96, 14.26, and 19.98 + 0.2°2θ; k) 2θ values including at least or selected from about 4.96, 14.26, and 19.98 + 0.2°2θ; 20 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT l) 2θ values of about 14.26, 15.86, 16.24, 17.00, 18.04, 18.90, 19.98, 20.82, 22.12, 23.06, 23.68, and 25.00 + 0.2°2θ; m) 2θ values including at least or selected from about 14.26, 15.86, 16.24, 17.00, 18.04, 18.90, 19.98, 20.82, 22.12, 23.06, 23.68, and 25.00 + 0.2°2θ; n) 2θ values of about 14.26, 15.86, 17.00, 18.04, 18.90, 19.98, 22.12, 23.68, and 25.00 + 0.2°2θ; o) 2θ values including at least or selected from about 14.26, 15.86, 17.00, 18.04, 18.90, 19.98, 22.12, 23.68, and 25.00 + 0.2°2θ; p) 2θ values of about 4.96, 14.26, 18.90, and 19.98 + 0.2°2θ; q) 2θ values including at least or selected from about 4.96, 14.26, 18.90, and 19.98 + 0.2°2θ; r) 2θ values of about 4.96, 14.26, 9.98, and 22.12 + 0.2°2θ; s) 2θ values including at least or selected from about 4.96, 14.26, 9.98, and 22.12 + 0.2°2θ; t) 2θ values of about 4.96, 14.26, 9.98, and 23.68 + 0.2°2θ; u) 2θ values including at least or selected from about 4.96, 14.26, 9.98, and 23.68 + 0.2°2θ; v) 2θ values of about 4.96, 14.26, 9.98, and 25.00 + 0.2°2θ; and w) 2θ values including at least or selected from about 4.96, 14.26, 9.98, and 25.00 ± 0.2°2θ.

[0149] In one or more embodiments, Free Base Form A is characterized by a differential scanning calorimetry (DSC) thermogram having four endotherms with endotherm maxima between about 60°C and about 70°C, between about 95°C and about 105°C, between about 210°C and about 220°C, and between about 225°C and about 235°C. In one or more embodiments, Free Base Form A is characterized by a differential scanning calorimetry (DSC) thermogram having four endotherms with endotherm maxima at about 64°C, 100°C, 213°C, and 231°C. In one or more embodiments, Free Base Form A is characterized by DSC thermogram substantially similar to that set forth in FIG.2.

[0150] In one or more embodiments, Free Base Form A is characterized by a weight loss in the range of about 0.1% to about 5% when heated from about 25°C to about 75°C in a thermogravimetric analysis (TGA). In one or more embodiments, Free Base Form A is characterized by a weight loss of about 3.5% when heated from about 25°C to about 75°C in a TGA. In one or more embodiments, Free Base Form A is characterized by a TGA substantially similar to that set forth in FIG.2.

[0151] A DVS analysis of Free Base Form A is shown in FIG.3. 21 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0152] Free Base Form A can be synthesized as described in Synthetic Example 1. In one or more embodiments, Free Base Form A is synthesized by mixing free base compound of Formula (I) in an aprotic solvent. In one or more embodiments, the solvent is selected from the group consisting of tetrahydrofuran, acetone, ethyl acetate, diethyl ether, toluene, hexane, dichloromethane, methyl ethyl ketone, dimethylsulfoxide, dimethylformamide, acetonitrile, and water. In one or more embodiments, the mixture comprises more than one solvent. In one or more embodiments, the mixture comprises tetrahydrofuran and methyl ethyl ketone. After stirring, for instance overnight, additional solvent may be added. The additional solvent is selected from the group in this paragraph, such as methyl ethyl ketone. The mixture is allowed to sit for 1-6 days and then cooled for 1-2 days. In one or more embodiments, evaporating the mixture provides a precipitate. The precipitate is dried to afford Free Base Form A.

[0153] In one or more embodiments, Free Base Form A is synthesized by a method comprising: a) mixing free base compound of Formula (I) in tetrahydrofuran and methyl ethyl ketone; b) stirring overnight; c) adding additional methyl ethyl ketone; d) sitting, cooling, and evaporating to afford a precipitate; and e) isolating the precipitate to afford Free Base Form A.

[0154] In one or more embodiments, the mixture is allowed to cool for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, or at least 48 hours in step (d).

[0155] Free Base Amorphous Form

[0156] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Amorphous Form. In one or more embodiments, the Free Base Amorphous Form is a hydrate.

[0157] In one or more embodiments, Free Base Amorphous Form is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.4. In one or more embodiments, Free Base Amorphous Form is shown to be amorphous by XRPD. 22 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0158] In one or more embodiments, Free Base Amorphous Form is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with an endotherm maxima between about 140°C and about 180°C. In one or more embodiments, Free Base Amorphous Form is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at about 144°C and about 177°C. In one or more embodiments, Free Base Amorphous Form is characterized by DTA thermogram substantially similar to that set forth in FIG.6.

[0159] In one or more embodiments, Free Base Amorphous Form is characterized by a weight loss in the range of about 0.1% to about 1% when heated from about 35°C to about 190°C in a thermogravimetric analysis (TGA). In one or more embodiments, Free Base Amorphous Form is characterized by a weight loss of about 0.5% when heated from about 36°C to about 184°C in a TGA. In one or more embodiments, Free Base Amorphous Form is characterized by a TGA substantially similar to that set forth in FIG.6.

[0160] Free Base Amorphous Form can be synthesized as described in Synthetic Example 2. In one or more embodiments, Free Base Amorphous Form is synthesized by melt and quench (melt / quench) of free base compound of Formula (I) (Free Base Form A). In one or more embodiments, the melt is at 260°C and the quench is in liquid nitrogen.

[0161] In one or more embodiments, Free Base Amorphous Form is synthesized by a method comprising: a) heating Free Base Form A to 260°C; and b) removing from heat and quenching in liquid nitrogen.

[0162] In one or more embodiments, Free Base Amorphous Form is characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with an endotherm maxima between about 30°C and about 100°C. In one or more embodiments, Free Base Amorphous Form is characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with endotherm maxima at about 65°C. In one or more embodiments, Free Base Amorphous Form is characterized by DSC thermogram substantially similar to that set forth in FIG.7.

[0163] A DVS analysis of Free Base Amorphous Form is shown in FIG.9. 23 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0164] Free Base Form B

[0165] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Form B.

[0166] In one or more embodiments, Free Base Form B is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 11. In one or more embodiments, Free Base Form B is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 22. In one or more embodiments, Free Base Form B is characterized by an XRPD pattern comprising: a) 2θ values of about 16.46, 17.98, 21.22, 21.70, 22.92, and 24.46 + 0.2°2θ; b) 2θ values of about 3.76, 7.48, 10.20, 15.80, 16.14, 16.46, 17.98, 21.22, 21.70, 21.96, 22.92, 24.46, and 24.70 + 0.2°2θ; c) 2θ values including at least or selected from about 3.76, 7.48, 10.20, 10.70, 11.18, 11.46, 12.50, 13.68, 14.92, 15.80, 16.04, 16.14, 16.46, 16.98, 17.38, 17.70, 17.98, 18.28, 18.56, 19.30, 19.58, 20.10, 20.44, 20.82, 21.22, 21.42, 21.70, 21.96, 22.18, 22.42, 22.92, 23.78, 24.00, 24.46, 24.70, 25.08, 25.36, 25.78, 25.94, 26.38, 26.94, 27.50, 27.68, 28.16, 29.06, 29.48, 30.00, 30.48, 30.86, 31.24, 31.72, 32.36, 33.24, 33.60, 34.28, 34.82, 35.78, 36.38, 36.90, 38.52, and 39.40 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 15.80, 16.04, 16.14, 16.46, 17.98, 18.28, 21.22, 21.70, 21.96, 22.92, 24.46, 24.70 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 15.80, 16.04, 16.14, 16.46, 16.98, 17.70, 17.98, 18.28, 18.56, 19.58, 20.10, 20.44, 21.22, 21.42, 21.70, 21.96, 22.18, 22.92, 24.46, 24.70 + 0.2°2θ; f) 2θ values of about 15.80, 16.14, 16.46, 17.98, 21.22, 21.70, 22.92, 24.46, and 24.70 + 0.2°2θ; g) 2θ values including at least or selected from about 15.80, 16.14, 16.46, 17.98, 21.22, 21.70, 22.92, 24.46, and 24.70 + 0.2°2θ; h) 2θ values of about 16.46, 17.98, 21.70, and 22.92 + 0.2°2θ; i) 2θ values including at least or selected from about 16.46, 17.98, 21.70, and 22.92 + 0.2°2θ; j) 2θ values of about 16.46, 21.70, and 22.92 + 0.2°2θ; 24 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT k) 2θ values including at least or selected from about 16.46, 21.70, and 22.92 + 0.2°2θ; l) 2θ values of about 10.20, 14.92, 15.80, 16.14, 16.46, 17.98, 21.22, 21.70, 22.92, 24.46, and 24.70 + 0.2°2θ; m) 2θ values including at least or selected from about 10.20, 14.92, 15.80, 16.14, 16.46, 17.98, 21.22, 21.70, 22.92, 24.46, and 24.70 + 0.2°2θ; n) 2θ values of about 15.80, 16.14, 16.46, 17.98, 21.22, 21.70, 22.92, 24.46, 24.70, and 25.94 + 0.2°2θ; o) 2θ values including at least or selected from about 15.80, 16.14, 16.46, 17.98, 21.22, 21.70, 22.92, 24.46, 24.70, and 25.94 + 0.2°2θ; p) 2θ values of about 16.46, 21.22, 21.70, and 22.92 + 0.2°2θ; q) 2θ values including at least or selected from about 16.46, 21.22, 21.70, and 22.92 + 0.2°2θ; r) 2θ values of about 16.46, 21.70, 21.96, and 22.92 + 0.2°2θ; s) 2θ values including at least or selected from about 16.46, 21.70, 21.96, and 22.92 + 0.2°2θ; t) 2θ values of about 16.46, 21.70, 22.92, and 24.46 + 0.2°2θ; u) 2θ values including at least or selected from about 16.46, 21.70, 22.92, and 24.46 + 0.2°2θ; v) 2θ values of about 16.46, 21.70, 22.92, and 24.70 + 0.2°2θ; and w) 2θ values including at least or selected from about 16.46, 21.70, 22.92, and 24.70 ± 0.2°2θ.

[0167] In one or more embodiments, Free Base Form B is characterized by a differential scanning calorimetry (DSC) thermogram having three endotherms with endotherm maxima between about 120°C and about 130°C, between about 220°C and about 230°C, and between about 230°C and about 240°C. In one or more embodiments, Free Base Form B is characterized by a differential scanning calorimetry (DSC) thermogram having three endotherms with endotherm maxima at about 124°C, 226°C, and 236°C. In one or more embodiments, Free Base Form B is characterized by DSC thermogram substantially similar to that set forth in FIG.12.

[0168] In one or more embodiments, Free Base Form B is characterized by a weight loss in the range of about 10% to about 15% when heated from about 25°C to about 175°C (single ramp) in a thermogravimetric analysis (TGA). In one or more embodiments, Free Base Form B is characterized by a weight loss of about 13.4% when heated from about 25°C to about 175°C in a TGA. In one or more embodiments, Free Base Form B is characterized by a TGA substantially similar to that set forth in FIG.12. 25 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0169] Free Base Form B can be synthesized as described in Synthetic Example 3. In one or more embodiments, Free Base Form B is synthesized by mixing free base compound of Formula (I) in an aprotic solvent. In one or more embodiments, the solvent is selected from the group consisting of tetrahydrofuran, acetone, ethyl acetate, diethyl ether, toluene, hexane, dichloromethane, methyl ethyl ketone, dimethylsulfoxide, and dimethylformamide. After stirring, for instance overnight to 1 week, a precipitate is formed. The precipitate is centrifuged, decanted, and dried to afford Free Base Form B.

[0170] In one or more embodiments, Free Base Form B is synthesized by a method comprising: a) mixing free base compound of Formula (I) in DMSO; b) stirring; and c) isolating the precipitate to afford Free Base Form B.

[0171] In one or more embodiments, the mixture is allowed to stir for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 48 hours, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days in step (b).

[0172] Free Base Form C

[0173] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Form C.

[0174] In one or more embodiments, Free Base Form C is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 13. In one or more embodiments, Free Base Form C is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 23. In one or more embodiments, Free Base Form C is characterized by an XRPD pattern comprising: a) 2θ values of about 6.40, 8.40, 12.76, 16.76, and 17.98 + 0.2°2θ; b) 2θ values of about 3.18, 5.80, 6.40, 8.40, 12.76, 15.18, 16.76, 17.34, 17.98, 19.68, 20.58, and 23.28 + 0.2°2θ; c) 2θ values including at least or selected from about 3.18, 5.80, 6.40, 7.30, 8.40, 9.44, 10.96, 11.18, 12.30, 12.76, 13.68, 14.54, 15.18, 15.72, 16.16, 16.76, 17.06, 17.34, 17.98, 18.44, 26 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 18.82, 19.68, 20.02, 20.58, 21.16, 21.76, 22.46, 22.80, 23.28, 23.64, 24.20, 25.16, 25.48, 26.20, 26.46, 27.34, 27.98, 29.18, 30.40, 31.48, 32.06, 33.30, 33.70, 34.56, and 36.84 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 6.40, 8.40, 12.76, 16.76, 17.34, 17.98, 19.68, 20.58, and 23.28 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 5.80, 6.40, 8.40, 12.76, 15.18, 16.76, 17.06, 17.34, 17.98, 19.68, 20.58, and 23.28 + 0.2°2θ; f) 2θ values of about 5.80, 6.40, 8.40, 12.76, 15.18, 16.76, 17.06, 17.34, 17.98, 18.44, 19.68, 20.58, and 23.28 + 0.2°2θ; g) 2θ values including at least or selected from about 5.80, 6.40, 8.40, 12.76, 15.18, 16.76, 17.06, 17.34, 17.98, 18.44, 19.68, 20.58, and 23.28 + 0.2°2θ; h) 2θ values of about 6.40, 12.76, 16.76, and 17.98 + 0.2°2θ; i) 2θ values including at least or selected from about 6.40, 12.76, 16.76, and 17.98 + 0.2°2θ; j) 2θ values of about 12.76, 16.76, and 17.98 + 0.2°2θ; k) 2θ values including at least or selected from about 12.76, 16.76, and 17.98 + 0.2°2θ; l) 2θ values of about 5.80, 6.40, 8.40, 12.76, 15.18, 16.76, 17.06, 17.34, 17.98, 18.44, 19.68, and 20.58 + 0.2°2θ; m) 2θ values including at least or selected from about 5.80, 6.40, 8.40, 12.76, 15.18, 16.76, 17.06, 17.34, 17.98, 18.44, 19.68, and 20.58 + 0.2°2θ; n) 2θ values of about 8.40, 12.76, 15.18, 16.76, 17.06, 17.34, 17.98, 18.44, 19.68, 20.58, and 23.28 + 0.2°2θ; o) 2θ values including at least or selected from about 8.40, 12.76, 15.18, 16.76, 17.06, 17.34, 17.98, 18.44, 19.68, 20.58, and 23.28 + 0.2°2θ; p) 2θ values of about 8.40, 12.76, 16.76, and 17.98 + 0.2°2θ; q) 2θ values including at least or selected from about 8.40, 12.76, 16.76, and 17.98 + 0.2°2θ; r) 2θ values of about 12.76, 16.76, 17.34, and 17.98 + 0.2°2θ; s) 2θ values including at least or selected from about 12.76, 16.76, 17.34, and 17.98 + 0.2°2θ; t) 2θ values of about 12.76, 16.76, 17.98, and 20.58 + 0.2°2θ; u) 2θ values including at least or selected from about 12.76, 16.76, 17.98, and 20.58 + 0.2°2θ; v) 2θ values of about 12.76, 16.76, 17.98, and 23.28 + 0.2°2θ; and w) 2θ values including at least or selected from about 12.76, 16.76, 17.98, and 23.28 ± 0.2°2θ. 27 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0175] In one or more embodiments, Free Base Form C is characterized by a differential scanning calorimetry (DSC) thermogram having two endotherms with endotherm maxima between about 60°C and about 70°C and between about 195°C and about 205°C. In one or more embodiments, Free Base Form C is characterized by a differential scanning calorimetry (DSC) thermogram having two endotherms with endotherm maxima at about 64°C and about 202°C. In one or more embodiments, Free Base Form C is characterized by DSC thermogram substantially similar to that set forth in FIG.14.

[0176] In one or more embodiments, Free Base Form C is characterized by a weight loss in the range of about 10% to about 15% when heated from about 25°C to about 205°C (such as to about 200°C) in a thermogravimetric analysis (TGA). In one or more embodiments, Free Base Form C is characterized by a weight loss of about 11.4% when heated from about 25°C to about 205°C (such as to about 200°C) in a TGA. In one or more embodiments, Free Base Form C is characterized by a TGA substantially similar to that set forth in FIG.14.

[0177] Free Base Form C can be synthesized as described in Synthetic Example 4. In one or more embodiments, Free Base Form C is synthesized by mixing free base compound of Formula (I) in an aprotic solvent. In one or more embodiments, the solvent is selected from the group consisting of tetrahydrofuran, acetone, ethyl acetate, diethyl ether, toluene, hexane, dichloromethane, methyl ethyl ketone, dimethylsulfoxide, and dimethylformamide. After stirring, for instance overnight to 1 week, a precipitate is formed. The precipitate is centrifuged, decanted, and dried to afford Free Base Form C.

[0178] In one or more embodiments, Free Base Form C is synthesized by a method comprising: a) mixing free base compound of Formula (I) in DMF; b) stirring; and c) isolating the precipitate to afford Free Base Form C.

[0179] In one or more embodiments, the mixture is allowed to stir for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 48 hours, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days in step (b). 28 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0180] Free Base Form D

[0181] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Form D.

[0182] In one or more embodiments, Free Base Form D is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 15. In one or more embodiments, Free Base Form D is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 24. In one or more embodiments, Free Base Form D is characterized by an XRPD pattern comprising: a) 2θ values of about 4.18, 17.20, 17.52, 19.32, and 19.64 + 0.2°2θ; b) 2θ values of about 4.18, 17.20, 17.52, 18.06, 19.32, 19.64, and 24.84 + 0.2°2θ; c) 2θ values including at least or selected from about 4.18, 5.98, 8.48, 9.54, 11.42, 12.68, 13.78, 15.48, 17.20, 17.52, 18.06, 18.74, 19.32, 19.64, 20.26, 21.62, 22.44, 23.12, 24.84, 27.78, 30.74, 31.68, 32.68, 35.84, and 36.84 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 4.18, 17.20, 17.52, 19.32, 19.64, and 24.84 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 4.18, 8.48, 17.20, 17.52, 18.06, 18.74, 19.32, 19.64, 20.26, 21.62, 24.84, and 27.78 + 0.2°2θ; f) 2θ values of about 4.18, 8.48, 17.20, 17.52, 18.74, 19.32, 19.64, 20.26, 21.62, and 24.84 + 0.2°2θ; g) 2θ values including at least or selected from about 4.18, 8.48, 17.20, 17.52, 18.74, 19.32, 19.64, 20.26, 21.62, and 24.84 + 0.2°2θ; h) 2θ values of about 4.18, 17.20, 17.52, and 19.64 + 0.2°2θ; i) 2θ values including at least or selected from about 4.18, 17.20, 17.52, and 19.64 + 0.2°2θ; j) 2θ values of about 4.18, 17.20, and 19.64 + 0.2°2θ; k) 2θ values including at least or selected from about 4.18, 17.20, and 19.64 + 0.2°2θ; l) 2θ values of about 4.18, 8.48, 17.20, 17.52, 18.06, 18.74, 19.32, 19.64, 20.26, and 21.62 + 0.2°2θ; m) 2θ values including at least or selected from about 4.18, 8.48, 17.20, 17.52, 18.06, 18.74, 19.32, 19.64, 20.26, and 21.62 + 0.2°2θ; 29 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT n) 2θ values of about 17.20, 17.52, 18.06, 18.74, 19.32, 19.64, 20.26, 21.62, 24.84, and 27.78 + 0.2°2θ; o) 2θ values including at least or selected from about 17.20, 17.52, 18.06, 18.74, 19.32, 19.64, 20.26, 21.62, 24.84, and 27.78 + 0.2°2θ; p) 2θ values of about 4.18, 17.20, 18.06, and 19.64 + 0.2°2θ; q) 2θ values including at least or selected from about 4.18, 17.20, 18.06, and 19.64 + 0.2°2θ; r) 2θ values of about 4.18, 17.20, 19.32, and 19.64 + 0.2°2θ; s) 2θ values including at least or selected from about 4.18, 17.20, 19.32, and 19.64 + 0.2°2θ; t) 2θ values of about 4.18, 17.20, 19.64, and 24.84 + 0.2°2θ; u) 2θ values including at least or selected from about 4.18, 17.20, 19.64, and 24.84 + 0.2°2θ; v) 2θ values of about 4.18, 17.20, 18.74, and 19.64 + 0.2°2θ; and w) 2θ values including at least or selected from about 4.18, 17.20, 18.74, and 19.64 ± 0.2°2θ.

[0183] In one or more embodiments, Free Base Form D is characterized by a differential scanning calorimetry (DSC) thermogram having three endotherms with an endotherm maxima between about 50°C and about 60°C, between about 155°C and about 165°C, and between about 170°C and about 180°C. In one or more embodiments, Free Base Form D is characterized by a differential scanning calorimetry (DSC) thermogram having three endotherms with endotherm maxima at about 57°C, 162°C, and 177°C. In one or more embodiments, Free Base Form D is characterized by DSC thermogram substantially similar to that set forth in FIG.16.

[0184] In one or more embodiments, Free Base Form D is characterized by a weight loss in the range of about 0.1% to about 5% when heated from about 25°C to about 80°C (such as to about 75°C) in a thermogravimetric analysis (TGA). In one or more embodiments, Free Base Form D is characterized by a weight loss of about 1.94% when heated from about 25°C to about 80°C (such as to about 75°C) in a TGA. In one or more embodiments, Free Base Form D is characterized by a weight loss of about 2.97% when heated from about 43°C to about 193°C in a TGA. In one or more embodiments, Free Base Form D is characterized by a TGA substantially similar to that set forth in FIG. 16. In one or more embodiments, Free Base Form D is characterized by a TGA substantially similar to that set forth in FIG.16 and / or FIG.17.

[0185] Free Base Form D can be synthesized as described in Synthetic Example 5. In one or more embodiments, Free Base Form D is synthesized by mixing free base compound of Formula (I) in an aprotic solvent. In one or more embodiments, the solvent is selected from the group 30 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT consisting of tetrahydrofuran, acetone, ethyl acetate, diethyl ether, toluene, hexane, dichloromethane, methyl ethyl ketone, dimethylsulfoxide, and dimethylformamide. After stirring and heating, for instance overnight to 1 week, a precipitate is formed. The precipitate is centrifuged, decanted, and dried to afford Free Base Form D.

[0186] In one or more embodiments, Free Base Form D is synthesized by a method comprising: a) mixing free base compound of Formula (I) in diethyl ether; b) stirring and heating; and c) isolating the precipitate to afford Free Base Form D.

[0187] In one or more embodiments, the mixture is allowed to stir and heat for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 48 hours, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days in step (b).

[0188] Free Base Form E

[0189] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Form E.

[0190] In one or more embodiments, Free Base Form E is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 18. In one or more embodiments, Free Base Form E is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 25. In one or more embodiments, Free Base Form E is characterized by an XRPD pattern comprising: a) 2θ values of about 4.6, 14.6, 17.4, 20.0, and 24.5 + 0.2°2θ; b) 2θ values of about 4.6, 14.6, 15.7, 17.4, 20.0, 22.1, and 24.5 + 0.2°2θ; c) 2θ values including at least or selected from about 4.6, 6.9, 9.4, 12.3, 14.6, 15.7, 17.4, 18.6, 19.2, 20.0, 22.1, and 24.5 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 4.6, 14.6, 15.7, 17.4, 20.0, and 24.5 + 0.2°2θ; 31 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT e) at least six, seven, or eight 2θ values selected from about 4.6, 6.9, 9.4, 14.6, 15.7, 17.4, 18.6, 19.2, 20.0, 22.1, and 24.5 + 0.2°2θ; f) 2θ values of about 4.6, 6.9, 9.4, 14.6, 15.7, 17.4, 18.6, 20.0, 22.1, and 24.5 + 0.2°2θ; g) 2θ values including at least or selected from about 4.6, 6.9, 9.4, 14.6, 15.7, 17.4, 18.6, 20.0, 22.1, and 24.5 + 0.2°2θ; h) 2θ values of about 4.6, 14.6, 17.4, and 24.5 + 0.2°2θ; i) 2θ values including at least or selected from about 4.6, 14.6, 17.4, and 24.5 + 0.2°2θ; j) 2θ values of about 4.6, 14.6, and 17.4 + 0.2°2θ; k) 2θ values including at least or selected from about 4.6, 14.6, and 17.4 + 0.2°2θ; l) 2θ values of about 4.6, 6.9, 9.4, 14.6, 15.7, 17.4, 19.2, 20.0, 22.1, and 24.5 + 0.2°2θ; m) 2θ values including at least or selected from about 4.6, 6.9, 9.4, 14.6, 15.7, 17.4, 19.2, 20.0, 22.1, and 24.5 + 0.2°2θ; n) 2θ values of about 9.4, 12.3, 14.6, 15.7, 17.4, 18.6, 19.2, 20.0, 22.1, and 24.5 + 0.2°2θ; o) 2θ values including at least or selected from about 9.4, 12.3, 14.6, 15.7, 17.4, 18.6, 19.2, 20.0, 22.1, and 24.5 + 0.2°2θ; p) 2θ values of about 4.6, 14.6, 17.4, and 20.0 + 0.2°2θ; q) 2θ values including at least or selected from about 4.6, 14.6, 17.4, and 20.0 + 0.2°2θ; r) 2θ values of about 4.6, 14.6, 15.7, and 17.4 + 0.2°2θ; s) 2θ values including at least or selected from about 4.6, 14.6, 15.7, and 17.4 + 0.2°2θ; t) 2θ values of about 4.6, 14.6, 17.4, and 22.1 + 0.2°2θ; u) 2θ values including at least or selected from about 4.6, 14.6, 17.4, and 22.1 + 0.2°2θ; v) 2θ values of about 14.6, 17.4, 20.0, and 24.5 + 0.2°2θ; and w) 2θ values including at least or selected from about 14.6, 17.4, 20.0, and 24.5 + 0.2°2θ.

[0191] In one or more embodiments, Free Base Form E is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with an endotherm maxima between about 169°C and about 190°C, or between about 170°C and about 180°C. In one or more embodiments, Free Base Form E is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at about 175°C. In one or more embodiments, Free Base Form E is characterized by DTA thermogram substantially similar to that set forth in FIG.20. 32 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0192] In one or more embodiments, Free Base Form E is characterized by a weight loss in the range of about 0.1% to about 5% when heated from about 40°C to about 150°C in a thermogravimetric analysis (TGA). In one or more embodiments, Free Base Form E is characterized by a weight loss of about 2.42% when heated from about 44°C to about 150°C in a TGA. In one or more embodiments, Free Base Form E is characterized by a TGA substantially similar to that set forth in FIG.20.

[0193] Free Base Form E can be synthesized as described in Synthetic Example 6. In one or more embodiments, Free Base Form E is synthesized by mixing free base compound of Formula (I) in an aprotic solvent and temperature cycling or evaporating. In one or more embodiments, when temperature cycling, the solvent is selected from ethanol, ethyl acetate, methanol, 2-methyl- THF, or isopropanol. In one or more embodiments, when evaporating, the solvent is dioxane.

[0194] When temperature cycling, after mixing, two temperature cycles (heating followed by cooling) were performed. One temperature cycle (heat cycle) is as follows: heated at a rate of 0.5°C / min (heating rate) from 20°C to 75°C, and cooled at a rate of 0.2°C / min (cooling rate) from 75°C to 20°C. This temperature cycle was repeated twice, and a solid was formed. The solid was dried to afford Free Base Form E.

[0195] When evaporating, after mixing, dioxane was evaporated and a solid was formed. The solid was dried to afford Free Base Form E.

[0196] In one or more embodiments, Free Base Form E is synthesized by a method comprising: a1) mixing free base compound of Formula (I) in ethanol, ethyl acetate, methanol, 2-methyl- tetrahydrofuran, or isopropanol; b1) heating at a rate of about 0.5°C / min (heating rate) from about 20°C to about 75°C, then cooling at a rate of about 0.2°C / min (cooling rate) from about 75°C to about 20°C; c1) heating at a rate of about 0.5°C / min (heating rate) from about 20°C to about 75°C, then cooling at a rate of about 0.2°C / min (cooling rate) from about 75°C to about 20°C; and d1) isolating the solid to afford Free Base Form E; or a2) mixing free base compound of Formula (I) in dioxane; b2) evaporating dioxane; and c2) isolating the solid to afford Free Base Form E. 33 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0197] Free Base Form F

[0198] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Form F.

[0199] In one or more embodiments, Free Base Form F is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 21. In one or more embodiments, Free Base Form F is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 26. In one or more embodiments, Free Base Form F is characterized by an XRPD pattern comprising: a) 2θ values of about 4.3, 9.5, 16.8, 18.5, and 19.8 + 0.2°2θ; b) 2θ values of about 4.3, 9.5, 14.0, 15.6, 16.8, 17.4, 18.5, 18.9, 19.2, 19.8, 21.3, 21.6, 22.9, 24.4 + 0.2°2θ; c) 2θ values including at least or selected from about 4.3, 6.6, 8.8, 9.5, 9.9, 10.1, 11.0, 11.9, 12.4, 13.2, 13.5, 14.0, 14.1, 14.2, 14.6, 14.8, 15.1, 15.6, 15.9, 16.4, 16.8, 17.4, 18.5, 18.9, 19.2, 19.6, 19.8, 20.6, 21.3, 21.6, 22.3, 22.9, 23.6, 24.2, 24.4, 24.9, 25.7, 25.9, 26.6, 27.0, 27.5, 28.4, 29.4, 30.0, 30.6, 31.7 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 4.3, 9.5, 16.8, 18.5, 19.8, and 22.9 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 4.3, 9.5, 14.0, 15.6, 16.8, 17.4, 18.5, 18.9, 19.2, 19.8, 21.6, 22.9, and 24.4 + 0.2°2θ; f) 2θ values of about 4.3, 9.5, 14.0, 15.6, 16.8, 17.4, 18.5, 18.9, 19.8, and 22.9 + 0.2°2θ; g) 2θ values including at least or selected from about 4.3, 9.5, 14.0, 15.6, 16.8, 17.4, 18.5, 18.9, 19.8, and 22.9 + 0.2°2θ; h) 2θ values of about 4.3, 9.5, 18.5, and 19.8 + 0.2°2θ; i) 2θ values including at least or selected from about 4.3, 9.5, 18.5, and 19.8 + 0.2°2θ; j) 2θ values of about 4.3, 9.5, and 18.5 + 0.2°2θ; k) 2θ values including at least or selected from about 4.3, 9.5, and 18.5 + 0.2°2θ; l) 2θ values of about 4.3, 9.5, 14.0, 15.6, 16.8, 17.4, 18.5, 18.9, 19.2, and 19.8 + 0.2°2θ; m) 2θ values including at least or selected from about 4.3, 9.5, 14.0, 15.6, 16.8, 17.4, 18.5, 18.9, 19.2, and 19.8 + 0.2°2θ; 34 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT n) 2θ values of about 15.6, 16.8, 17.4, 18.5, 18.9, 19.2, 19.8, 21.6, 22.9, and 24.4 + 0.2°2θ; o) 2θ values including at least or selected from about 15.6, 16.8, 17.4, 18.5, 18.9, 19.2, 19.8, 21.6, 22.9, and 24.4 + 0.2°2θ; p) 2θ values of about 4.3, 9.5, 16.8, and 18.5 + 0.2°2θ; q) 2θ values including at least or selected from about 4.3, 9.5, 16.8, and 18.5 + 0.2°2θ; r) 2θ values of about 4.3, 9.5, 18.5, and 22.9 + 0.2°2θ; s) 2θ values including at least or selected from about 4.3, 9.5, 18.5, and 22.9 + 0.2°2θ; t) 2θ values of about 4.3, 9.5, 17.4, and 18.5 + 0.2°2θ; u) 2θ values including at least or selected from about 4.3, 9.5, 17.4, and 18.5 + 0.2°2θ; v) 2θ values of about 9.5, 16.8, 18.5, and 19.8 + 0.2°2θ; and w) 2θ values including at least or selected from about 9.5, 16.8, 18.5, and 19.8 + 0.2°2θ.

[0200] Free Base Form F can be synthesized as described in Synthetic Example 7. In one or more embodiments, Free Base Form F is synthesized by mixing free base compound of Formula (I) in an aprotic solvent and temperature cycling. In one or more embodiments, the solvent is toluene. After mixing, two temperature cycles (heating followed by cooling) were performed. One temperature cycle (heat cycle) is as follows: heated at a rate of 0.5°C / min (heating rate) from 20°C to 100°C, and cooled at a rate of 0.2°C / min (cooling rate) from 100°C to 20°C. This temperature cycle was repeated twice, and a solid was formed. The solid was dried to afford Free Base Form F.

[0201] In one or more embodiments, Free Base Form F is synthesized by a method comprising: a) mixing free base compound of Formula (I) in toluene; b) heating at a rate of about 0.5°C / min (heating rate) from about 20°C to about 100°C, then cooling at a rate of about 0.2°C / min (cooling rate) from about 100°C to about 20°C; c) heating at a rate of about 0.5°C / min (heating rate) from about 20°C to about 100°C, then cooling at a rate of about 0.2°C / min (cooling rate) from about 100°C to about 20°C; and d) isolating the solid to afford Free Base Form F.

[0202] Free Base Form G

[0203] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Form G. 35 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0204] In one or more embodiments, Free Base Form G is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 22. In one or more embodiments, Free Base Form G is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 27. In one or more embodiments, Free Base Form G is characterized by an XRPD pattern comprising: a) 2θ values of about 7.8, 16.0, 16.5, 18.2, and 21.9 + 0.2°2θ; b) 2θ values of about 7.8, 10.1, 16.0, 16.5, 18.2, 21.6, 21.9, and 25.5 + 0.2°2θ; c) 2θ values including at least or selected from about 3.9, 7.8, 10.1, 10.6, 11.1, 12.4, 13.2, 15.1, 15.4, 15.7, 16.0, 16.4, 16.5, 17.2, 17.6, 18.2, 19.1, 19.3, 19.7, 20.5, 21.4, 21.6, 21.9, 22.9, 23.5, 24.9, 25.5, 26.5, 28.1, 29.0, 30.3, and 30.8 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 7.8, 10.1, 16.0, 16.5, 18.2, and 21.9 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 3.9, 7.8, 10.1, 16.0, 16.5, 17.2, 18.2, 19.3, 21.6, 21.9, 23.5, 24.9, and 25.5 + 0.2°2θ; f) 2θ values of about 3.9, 7.8, 10.1, 16.0, 16.5, 18.2, 21.6, 21.9, 23.5, and 25.5 + 0.2°2θ; g) 2θ values including at least or selected from about 3.9, 7.8, 10.1, 16.0, 16.5, 18.2, 21.6, 21.9, 23.5, and 25.5 + 0.2°2θ; h) 2θ values of about 7.8, 16.5, 18.2, and 21.9 + 0.2°2θ; i) 2θ values including at least or selected from about 7.8, 16.5, 18.2, and 21.9 + 0.2°2θ; j) 2θ values of about 16.5, 18.2, and 21.9 + 0.2°2θ; k) 2θ values including at least or selected from about 16.5, 18.2, and 21.9 + 0.2°2θ; l) 2θ values of about 7.8, 10.1, 16.0, 16.5, 18.2, 19.3, 21.6, 21.9, 23.5, and 25.5 + 0.2°2θ; m) 2θ values including at least or selected from about 7.8, 10.1, 16.0, 16.5, 18.2, 19.3, 21.6, 21.9, 23.5, and 25.5 + 0.2°2θ; n) 2θ values of about 16.0, 16.5, 17.2, 18.2, 19.3, 21.6, 21.9, 23.5, 24.9, and 25.5 + 0.2°2θ; o) 2θ values including at least or selected from about 16.0, 16.5, 17.2, 18.2, 19.3, 21.6, 21.9, 23.5, 24.9, and 25.5 + 0.2°2θ; p) 2θ values of about 16.0, 16.5, 18.2, and 21.9 + 0.2°2θ; q) 2θ values including at least or selected from about 16.0, 16.5, 18.2, and 21.9 + 0.2°2θ; r) 2θ values of about 10.1, 16.5, 18.2, and 21.9 + 0.2°2θ; s) 2θ values including at least or selected from about 10.1, 16.5, 18.2, and 21.9 + 0.2°2θ; 36 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT t) 2θ values of about 16.5, 18.2, 21.9, and 25.5 + 0.2°2θ; u) 2θ values including at least or selected from about 16.5, 18.2, 21.9, and 25.5 + 0.2°2θ; v) 2θ values of about 16.5, 18.2, 19.3, and 21.9 + 0.2°2θ; and w) 2θ values including at least or selected from about 16.5, 18.2, 19.3, and 21.9 + 0.2°2θ.

[0205] In one or more embodiments, Free Base Form G is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with two endotherm maxima between about 120°C and about 170°C and between about 205°C and about 250°C. In one or more embodiments, Free Base Form G is characterized by a differential thermal analysis (DTA) thermogram having two endotherms with endotherm maxima at about 145°C and about 225°C. In one or more embodiments, Free Base Form G is characterized by DTA thermogram substantially similar to that set forth in FIG.24.

[0206] In one or more embodiments, Free Base Form G is characterized by a weight loss in the range of about 5% to about 10% when heated from about 65°C to about 295°C in a thermogravimetric analysis (TGA). In one or more embodiments, Free Base Form G is characterized by a weight loss of about 8.99% when heated from about 65°C to about 295°C in a TGA. In one or more embodiments, Free Base Form G is characterized by a TGA substantially similar to that set forth in FIG.24.

[0207] Free Base Form G can be synthesized as described in Synthetic Example 8. In one or more embodiments, Free Base Form G is synthesized by mixing free base compound of Formula (I) in an aprotic solvent and evaporating. In one or more embodiments, the solvent is dimethylacetamide.

[0208] After mixing, dimethylacetamide was evaporated under vacuum at about 50°C and a solid was formed. The solid was dried to afford Free Base Form G.

[0209] In one or more embodiments, Free Base Form G is synthesized by a method comprising: a) mixing free base compound of Formula (I) in dimethylacetamide; b) evaporating dimethylacetamide under vacuum at about 50°C; and c) isolating the solid to afford Free Base Form G. 37 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0210] Free Base Form H

[0211] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Form H.

[0212] In one or more embodiments, Free Base Form H is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 25. In one or more embodiments, Free Base Form H is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 28. In one or more embodiments, Free Base Form H is characterized by an XRPD pattern comprising: a) 2θ values of about 4.2, 10.2, 15.7, 16.5, and 20.9 + 0.2°2θ; b) 2θ values of about 4.2, 10.2, 15.7, 16.5, 18.1, 20.9, and 23.4 + 0.2°2θ; c) 2θ values including at least or selected from about 4.2, 6.4, 8.4, 10.2, 15.1, 15.7, 16.5, 16.9, 17.2, 18.1, 19.0, 20.6, 20.9, 21.9, 23.4, 25.6, 26.4, 27.0, 28.6, 28.8, 30.0, and 39.7 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 4.2, 10.2, 15.7, 16.5, 20.9, and 23.4 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 4.2, 8.4, 10.2, 15.1, 15.7, 16.5, 17.2, 18.1, 20.6, 20.9, 21.9, and 23.4 + 0.2°2θ; f) 2θ values of about 4.2, 10.2, 15.1, 15.7, 16.5, 17.2, 18.1, 20.6, 20.9, and 23.4 + 0.2°2θ; g) 2θ values including at least or selected from about 4.2, 10.2, 15.1, 15.7, 16.5, 17.2, 18.1, 20.6, 20.9, and 23.4 + 0.2°2θ; h) 2θ values of about 4.2, 10.2, 15.7, and 16.5 + 0.2°2θ; i) 2θ values including at least or selected from about 4.2, 10.2, 15.7, and 16.5 + 0.2°2θ; j) 2θ values of about 10.2, 15.7, and 16.5 + 0.2°2θ; k) 2θ values including at least or selected from about 10.2, 15.7, and 16.5 + 0.2°2θ; l) 2θ values of about 4.2, 10.2, 15.1, 15.7, 16.5, 17.2, 18.1, 20.9, 21.9, and 23.4 + 0.2°2θ; m) 2θ values including at least or selected from about 4.2, 10.2, 15.1, 15.7, 16.5, 17.2, 18.1, 20.9, 21.9, and 23.4 + 0.2°2θ; n) 2θ values of about 10.2, 15.1, 15.7, 16.5, 17.2, 18.1, 20.6, 20.9, 21.9, and 23.4 + 0.2°2θ; o) 2θ values including at least or selected from about 10.2, 15.1, 15.7, 16.5, 17.2, 18.1, 20.6, 20.9, 21.9, and 23.4 + 0.2°2θ; 38 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT p) 2θ values of about 10.2, 15.7, 16.5, and 20.9 + 0.2°2θ; q) 2θ values including at least or selected from about 10.2, 15.7, 16.5, and 20.9 + 0.2°2θ; r) 2θ values of about 10.2, 15.7, 16.5, and 23.4 + 0.2°2θ; s) 2θ values including at least or selected from about 10.2, 15.7, 16.5, and 23.4 + 0.2°2θ; t) 2θ values of about 10.2, 15.7, 16.5, and 18.1 + 0.2°2θ; u) 2θ values including at least or selected from about 10.2, 15.7, 16.5, and 18.1 + 0.2°2θ; v) 2θ values of about 10.2, 15.7, 16.5, and 17.2 + 0.2°2θ; and w) 2θ values including at least or selected from about 10.2, 15.7, 16.5, and 17.2 + 0.2°2θ.

[0213] In one or more embodiments, Free Base Form H is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with two endotherm maxima between about 170°C and about 195°C and between about 230°C and about 265°C. or with two endotherm maxima between about 174°C and about 194°C and between about 231°C and about 261°C. In one or more embodiments, Free Base Form H is characterized by a differential thermal analysis (DTA) thermogram having two endotherms with endotherm maxima at about 185°C and about 245°C. In one or more embodiments, Free Base Form H is characterized by DTA thermogram substantially similar to that set forth in FIG.27.

[0214] In one or more embodiments, Free Base Form H is characterized by a weight loss in the range of about 5% to about 10% when heated from about 40°C to about 305°C in a thermogravimetric analysis (TGA). In one or more embodiments, Free Base Form H is characterized by a weight loss of about 8.77% when heated from about 44°C to about 302°C in a TGA. In one or more embodiments, Free Base Form H is characterized by a TGA substantially similar to that set forth in FIG.27.

[0215] Free Base Form H can be synthesized as described in Synthetic Example 9. In one or more embodiments, Free Base Form H is synthesized by mixing free base compound of Formula (I) in an aprotic solvent and evaporating. In one or more embodiments, the solvent is dimethylsulfoxide.

[0216] After mixing, dimethylsulfoxide was evaporated under vacuum at about 50°C and a solid was formed. The solid was dried to afford Free Base Form H.

[0217] In one or more embodiments, Free Base Form H is synthesized by a method comprising: 39 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT a) mixing free base compound of Formula (I) in dimethylsulfoxide; b) evaporating dimethylsulfoxide under vacuum at about 50°C; and c) isolating the solid to afford Free Base Form H.

[0218] Free Base Form J

[0219] In one or more embodiments, provided herein is a free base of a compound of Formula (I). In one or more embodiments, the free base of the compound of Formula (I) is Free Base Form J.

[0220] In one or more embodiments, Free Base Form J is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 28. In one or more embodiments, Free Base Form J is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 29. In one or more embodiments, Free Base Form J is characterized by an XRPD pattern comprising: a) 2θ values of about 4.6, 9.9, 14.2, 15.7, and 17.0 + 0.2°2θ; b) 2θ values of about 4.6, 9.9, 14.2, 15.7, 17.0, 19.6, and 20.3 + 0.2°2θ; c) 2θ values including at least or selected from about 4.6, 6.9, 9.9, 12.1, 14.2, 14.9, 15.7, 17.0, 17.8, 18.4, 18.8, 19.6, 20.3, 22.0, 22.9, 24.7 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 4.6, 9.9, 14.2, 15.7, 17.0, and 19.6 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 4.6, 9.9, 14.2, 15.7, 17.0, 17.8, 18.4, 19.6, 20.3, 22.0, and 22.9 + 0.2°2θ; f) 2θ values of about 4.6, 9.9, 14.2, 15.7, 17.0, 17.8, 18.4, 19.6, and 20.3 + 0.2°2θ; g) 2θ values including at least or selected from about 4.6, 9.9, 14.2, 15.7, 17.0, 17.8, 18.4, 19.6, and 20.3 + 0.2°2θ; h) 2θ values of about 4.6, 14.2, 15.7, and 17.0 + 0.2°2θ; i) 2θ values including at least or selected from about 4.6, 14.2, 15.7, and 17.0 + 0.2°2θ; j) 2θ values of about 4.6, 14.2, and 15.7 + 0.2°2θ; k) 2θ values including at least or selected from about 4.6, 14.2, and 15.7 + 0.2°2θ; l) 2θ values of about 4.6, 9.9, 14.2, 15.7, 17.0, 18.4, 19.6, 20.3, and 22.9 + 0.2°2θ; m) 2θ values including at least or selected from about 4.6, 9.9, 14.2, 15.7, 17.0, 18.4, 19.6, 20.3, and 22.9 + 0.2°2θ; 40 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT n) 2θ values of about 14.2, 15.7, 17.0, 17.8, 18.4, 19.6, 20.3, 22.0, and 22.9 + 0.2°2θ; o) 2θ values including at least or selected from about 14.2, 15.7, 17.0, 17.8, 18.4, 19.6, 20.3, 22.0, and 22.9 + 0.2°2θ; p) 2θ values of about 4.6, 9.9, 14.2, and 15.7 + 0.2°2θ; q) 2θ values including at least or selected from about 4.6, 9.9, 14.2, and 15.7 + 0.2°2θ; r) 2θ values of about 4.6, 14.2, 15.7, and 19.6 + 0.2°2θ; s) 2θ values including at least or selected from about 4.6, 14.2, 15.7, and 19.6 + 0.2°2θ; t) 2θ values of about 4.6, 14.2, 15.7, and 20.3 + 0.2°2θ; u) 2θ values including at least or selected from about 4.6, 14.2, 15.7, and 20.3 + 0.2°2θ; v) 2θ values of about 4.6, 14.2, 15.7, and 18.4 + 0.2°2θ; and w) 2θ values including at least or selected from about 4.6, 14.2, 15.7, and 18.4 + 0.2°2θ.

[0221] In one or more embodiments, Free Base Form J is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with an endotherm maxima between about 190°C and about 215°C. In one or more embodiments, Free Base Form J is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at about 192°C and about 214°C. In one or more embodiments, Free Base Form J is characterized by DTA thermogram substantially similar to that set forth in FIG.30.

[0222] In one or more embodiments, Free Base Form J is characterized by a weight loss in the range of about 5% to about 10% when heated from about 50°C to about 300°C in a thermogravimetric analysis (TGA). In one or more embodiments, Free Base Form J is characterized by a weight loss of about 7.80% when heated from about 54°C to about 299°C in a TGA. In one or more embodiments, Free Base Form J is characterized by a TGA substantially similar to that set forth in FIG.30.

[0223] Free Base Form J can be synthesized as described in Synthetic Example 10. In one or more embodiments, Free Base Form J is synthesized by mixing free base compound of Formula (I) in an aprotic solvent and evaporating. In one or more embodiments, the solvent is anisole. In one or more embodiments, Free Base Form J is synthesized by conversion of Free Base Form F stored under ambient conditions (including a temperature of from 15°C to 30°C).

[0224] When evaporating, after mixing, anisole was evaporated at ambient temperature (of from 15°C to 30°C) and a solid was formed. The solid was dried to afford Free Base Form J. 41 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0225] When converting, Free Base Form F was stored under ambient conditions (including a temperature of from 15°C to 30°C) for 4-7 days and a solid was formed. The solid was dried to afford Free Base Form J.

[0226] In one or more embodiments, Free Base Form J is synthesized by a method comprising: a1) mixing free base compound of Formula (I) in anisole; b1) evaporating anisole at ambient temperature; and c1) isolating the solid to afford Free Base Form J; or a2) obtaining Free Base Form F and storing under ambient conditions (including a temperature of from 15°C to 30°C) for 4-7 days; b2) isolating solid to afford Free Base Form J.

[0228] Additional salt forms

[0229] Also provided herein is a salt form of a compound of Formula (I) selected from the group consisting of a fumarate salt, a maleate salt, and a p-toluenesulfonic acid (PTSA) salt.

[0230] In one or more embodiments, provided herein is a salt form of a compound of Formula (I) selected from the group consisting of a hydrochloric acid salt (HCl salt), a sulfuric acid salt, a methanesulfonic acid salt, a phosphoric acid salt, a tartaric acid salt, a citric acid salt, a hippuric acid salt, and a gluconic acid salt.

[0231] In one or more embodiments, provided herein is a salt form of a compound of Formula (I) selected from the group consisting of Formula (I-A), Formula (I-B), and Formula (I-C):42 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0232] The salt forms of a compound of Formula (I) described herein can be in a form that is at least 90% free of the opposite compound of Formula (I) enantiomer (excluding the weight of the salt). In one or more embodiments, the salt form of a compound of Formula (I) is at least 95%, 98%, 99%, or even 100% free of the opposite compound of Formula (I) enantiomer (excluding the weight of the salt).

[0233] For example, in one or more embodiments, the compound of Formula (I-A) is at least 90%, 95%, 98%, 99%, or even 100% free of the opposite compound of Formula (I-A) (excluding the weight of the salt). For example, in one or more embodiments, the compound of Formula (I-B) is at least 90%, 95%, 98%, 99%, or even 100% free of the opposite compound of Formula (I-B) (excluding the weight of the salt). For example, in one or more embodiments, the compound of Formula (I-C) is at least 90%, 95%, 98%, 99%, or even 100% free of the opposite compound of Formula (I-C) (excluding the weight of the salt). 43 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0234] Fumarate Salt Form A

[0235] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a fumarate salt. In one or more embodiments, the fumarate salt is Fumarate Salt Form A.

[0236] In one or more embodiments, Fumarate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.32. In one or more embodiments, Fumarate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 30. In one or more embodiments, Fumarate Salt Form A is characterized by an XRPD pattern comprising: a) 2θ values of about 4.58, 14.18, 16.04, 18.00, 18.48, 19.18, 19.64, 21.16, 22.56, 25.22, and 25.58 + 0.2°2θ; b) 2θ values of about 4.58, 9.82, 14.18, 15.52, 16.04, 18.00, 18.48, 19.18, 19.64, 21.16, 22.56, 24.64, 25.22, and 25.58 + 0.2°2θ; c) 2θ values including at least or selected from about 4.58, 6.84, 9.82, 10.64, 11.38, 11.72, 13.62, 14.18, 14.72, 15.52, 16.04, 16.76, 17.54, 18.00, 18.48, 19.18, 19.64, 20.7021.16, 22.56, 23.36, 24.06, 24.64, 25.22, 25.58, 26.06, 27.36, 27.98, 28.72, 29.18, 29.68, 30.30, 31.08, 31.58, 32.22, and 33.76 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 4.58, 14.18, 15.52, 16.04, 16.76, 17.54, 18.00, 18.48, 19.18, 19.64, 21.16, 22.56, 24.06, 24.64, 25.22, 25.58 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 4.58, 9.82, 14.18, 15.52, 16.04, 16.76, 17.54, 18.00, 18.48, 19.18, 19.64, 20.70, 21.16, 22.56, 23.36, 24.06, 24.64, 25.22, 25.58, 26.06, 27.36, 28.72, 29.18, 29.68 + 0.2°2θ; f) 2θ values of about 14.18, 16.04, 18.00, 18.48, 19.18, 21.16, and 22.56 + 0.2°2θ; g) 2θ values including at least or selected from about 14.18, 16.04, 18.00, 18.48, 19.18, 21.16, and 22.56 + 0.2°2θ; h) 2θ values of about 18.00, 18.48, 19.18, 22.56 + 0.2°2θ; i) 2θ values including at least or selected from about 18.00, 18.48, 19.18, 22.56 + 0.2°2θ; j) 2θ values of about 18.00, 18.48, 22.56 + 0.2°2θ; k) 2θ values including at least or selected from about 18.00, 18.48, 22.56 + 0.2°2θ; 44 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT l) 2θ values of about 14.18, 16.04, 18.00, 18.48, 19.18, 19.64, 21.16, 22.56, 25.22, 25.58 + 0.2°2θ; m) 2θ values including at least or selected from about 14.18, 16.04, 18.00, 18.48, 19.18, 19.64, 21.16, 22.56, 25.22, 25.58 + 0.2°2θ; n) 2θ values of about 14.18, 16.04, 18.00, 18.48, 19.18, 19.64, 21.16, and 22.56 + 0.2°2θ; o) 2θ values including at least or selected from about 14.18, 16.04, 18.00, 18.48, 19.18, 19.64, 21.16, and 22.56 + 0.2°2θ; p) 2θ values of about 14.18, 18.00, 18.48, and 22.56 + 0.2°2θ; q) 2θ values including at least or selected from about 14.18, 18.00, 18.48, and 22.56 + 0.2°2θ; r) 2θ values of about 16.04, 18.00, 18.48, and 22.56 + 0.2°2θ; s) 2θ values including at least or selected from about 16.04, 18.00, 18.48, and 22.56 + 0.2°2θ; t) 2θ values of about 18.00, 18.48, 19.18, and 22.56 + 0.2°2θ; u) 2θ values including at least or selected from about 18.00, 18.48, 19.18, and 22.56 + 0.2°2θ; v) 2θ values of about 18.00, 18.48, 21.16, and 22.56 + 0.2°2θ; and w) 2θ values including at least or selected from about 18.00, 18.48, 21.16, and 22.56 ± 0.2°2θ.

[0237] In one or more embodiments, Fumarate Salt Form A is characterized by a differential scanning calorimetry (DSC) thermogram having one endotherm with an endotherm maxima between about 240°C and about 250°C. In one or more embodiments, Fumarate Salt Form A is characterized by a differential scanning calorimetry (DSC) thermogram having one endotherm with an endotherm maxima at about 245°C. In one or more embodiments, Fumarate Salt Form A is characterized by a DSC thermogram substantially similar to that set forth in FIG.37.

[0238] In one or more embodiments, Fumarate Salt Form A is characterized by a weight loss in the range of about 0.1% to about 5% when heated from about 25°C to about 125°C, and in the range of about 10% to about 15% when heated from about 125°C to about 275°C in a thermogravimetric analysis (TGA). In one or more embodiments, Fumarate Salt Form A is characterized by a weight loss of about 1.7% when heated from about 25°C to about 125°C in a TGA, and from about 10.0% to about 12.3% when heated from about 125°C to about 275°C. In one or more embodiments, Fumarate Salt Form A is characterized by a TGA substantially similar to that set forth in FIG.37.

[0239] A DVS analysis of Fumarate Salt Form A is shown in FIG.38. 45 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0240] Fumarate Salt Form A can be synthesized as described in Synthetic Example 11. In one or more embodiments, Fumarate Salt Form A is synthesized by mixing free base compound of Formula (I) and fumaric acid in a solvent. Compound of Formula (I) can be synthesized as described in Synthetic Example A, in its free form (which is called a free base or free base starting material). In one or more embodiments, the solvent is a protic solvent. In one or more embodiments, the solvent is an aprotic solvent. In one or more embodiments, the solvent is selected from the group consisting of methanol, ethanol, isopropanol, formic acid, acetic acid, acetone, and DCM. In one or more embodiments, the mixture comprises water. In one or more embodiments, the mixture does not comprise water. After stirring, for instance overnight or a week and under heat, the precipitate is centrifuged, decanted, and dried to afford Fumarate Salt Form A.

[0241] In one or more embodiments, Fumarate Salt Form A is synthesized by a method comprising: a) mixing free base compound of Formula (I) and fumaric acid in methanol and water; b) stirring and heating to afford a precipitate; and c) isolating the precipitate to afford Fumaric Salt Form A.

[0242] In one or more embodiments, the mixture is allowed to stir and heat for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b).

[0243] In one or more embodiments, an amorphous solid dispersion (ASD) prepared from Fumarate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.77. In one or more embodiments, an amorphous solid dispersion (ASD) prepared from Fumarate Salt Form A is characterized by a differential scanning calorimetry (DSC) pattern substantially similar to that set forth in FIG.78. In one or more embodiments, when a compound of Formula (I) (e.g., Fumarate Salt Form A) is converted and presented in the amorphous solid dispersion, the form is amorphous.

[0244] Fumarate Salt Amorphous Form

[0246] In one or more embodiments, provided herein is a salt a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a fumarate salt. In one or more embodiments, the salt of the compound of Formula (I) is Fumarate Salt Amorphous Form. In one or more embodiments, the Fumarate Salt Amorphous Form is a hydrate. 46 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0247] In one or more embodiments, Fumarate Salt Amorphous Form is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.39. In one or more embodiments, Fumarate Salt Amorphous Form is shown to be amorphous by XRPD.

[0248] In one or more embodiments, Fumarate Salt Amorphous Form is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with an endotherm maxima between about 75°C and about 190°C. In one or more embodiments, Fumarate Salt Amorphous Form is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima between about 77°C and about 184°C. In one or more embodiments, Fumarate Salt Amorphous Form is characterized by DTA thermogram substantially similar to that set forth in FIG.41.

[0249] In one or more embodiments, Fumarate Salt Amorphous Form is characterized by a weight loss in the range of about 1% to about 10% when heated from about 35°C to about 180°C in a thermogravimetric analysis (TGA). In one or more embodiments, Fumarate Salt Amorphous Form is characterized by a weight loss of about 4.66% when heated from about 37°C to about 179°C in a TGA. In one or more embodiments, Fumarate Salt Amorphous Form is characterized by a TGA substantially similar to that set forth in FIG.41.

[0250] Fumarate Salt Amorphous Form can be synthesized as described in Synthetic Example 12. In one or more embodiments, Fumarate Salt Amorphous Form is synthesized by heating and lyophilizing (freeze drying) a solution of free base compound of Formula (I) (Fumarate Salt Form A). In one or more embodiments, the solution includes acetonitrile and water. In one or more embodiments, the heating is at 80°C. In one or more embodiments, the lyophilizing (freeze drying) is in liquid nitrogen.

[0251] In one or more embodiments, Fumarate Salt Amorphous Form is synthesized by a method comprising: a) mixing Fumarate Salt Form A in acetonitrile / water (1:3) to form a suspension; b) heating the suspension to 80°C to afford a solution; and c) removing from heat and freezing in liquid nitrogen, lyophilizing (freeze drying) for 24 hours.

[0252] In one or more embodiments, Fumarate Salt Amorphous Form is characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with an endotherm 47 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT maxima between about 30°C and about 130°C. In one or more embodiments, Fumarate Salt Amorphous Form is characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with endotherm maxima at about 77°C. In one or more embodiments, Fumarate Salt Amorphous Form is characterized by DSC thermogram substantially similar to that set forth in FIG.42.

[0253] A DVS analysis of Fumarate Salt Amorphous Form is shown in FIG.44.

[0254] Fumarate Salt Form B

[0255] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a hemi-fumarate salt. In one or more embodiments, the hemi-fumarate salt is Fumarate Salt Form B.

[0256] In one or more embodiments, Fumarate Salt Form B is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 45 (2ndfrom bottom). In one or more embodiments, Fumarate Salt Form B (hemi-fumarate) is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 31. In one or more embodiments, Fumarate Salt Form B (hemi-fumarate) is characterized by an XRPD pattern comprising: a) 2θ values of about 6.60, 7.54, 7.67, 8.57, 16.42, 18.18, and 21.56 + 0.2°2θ; b) 2θ values of about 6.02, 6.60, 7.54, 7.67, 8.57, 11.74, 14.97, 16.42, 17.19, 18.18, 18.49, and 21.56 + 0.2°2θ; c) 2θ values including at least or selected from about 4.54, 6.02, 6.60, 7.15, 7.54, 7.67, 8.57, 8.88, 10.44, 10.82, 11.74, 12.04, 12.42, 12.71, 13.63, 13.95, 14.35, 14.97, 15.17, 15.90, 16.42, 17.19, 17.83, 18.18, 18.49, 18.96, 19.86, 20.09, 20.43, 20.80, 21.56, 22.09, 22.76, 23.21, 23.74, 24.78, 25.35, 26.52, 27.31, 28.53, 30.47, 31.29, 31.89, 33.51, 35.56, and 38.03 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 6.02, 6.60, 7.54, 7.67, 8.57, 11.74, 14.97, 16.42, 17.19, 18.18, 18.49, 21.56, 23.21 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 6.02, 6.60, 7.15, 7.54, 7.67, 8.57, 11.74, 14.97, 16.42, 17.19, 18.18, 18.49, 18.96, 19.89, 21.56, 22.09, 23.21 + 0.2°2θ; f) 2θ values of about 6.02, 6.60, 7.54, 7.67, 16.42, 18.18, and 21.56 + 0.2°2θ; 48 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT g) 2θ values including at least or selected from about 2θ values of about 6.02, 6.60, 7.54, 7.67, 16.42, 18.49, and 21.56 + 0.2°2θ; h) 2θ values of about 6.60, 7.54, 7.67, 16.42, and 21.56 + 0.2°2θ; i) 2θ values including at least or selected from about 7.54, 7.67, 16.42, and 21.56 + 0.2°2θ; j) 2θ values of about 6.60, 7.67, 16.42, and 21.56; and k) 2θ values including at least or selected from about 7.67, 16.42, and 21.56 + 0.2°2θ.

[0257] Fumarate Salt Form B can be synthesized as described in Synthetic Example 13.

[0258] In one or more embodiments, Fumarate Salt Form B is synthesized by a method comprising: a) mixing Fumarate Salt Amorphous Form (hemi-fumarate salt, a compound of Formula (I)) with methanol; b) stirring to form a slurry; and c) isolating the precipitate to afford Fumarate Salt Form B.

[0259] In one or more embodiments, Fumarate Salt Form B (hemi-fumarate salt) is synthesized by a method comprising: a) mixing Free Base Form A (a compound of Formula (I)) with methanol and 0.5 mol. equivalents of fumaric acid; b) stirring to form a slurry; and c) isolating the precipitate to afford Fumarate Salt Form B.

[0260] In one or more embodiments, the mixture is allowed to stir and heat for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b).

[0261] Fumarate Salt Form C

[0262] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a hemi-fumarate salt. In one or more embodiments, the hemi-fumarate salt is Fumarate Salt Form C.

[0263] In one or more embodiments, Fumarate Salt Form C is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 47 (2ndfrom bottom). In one or more embodiments, Fumarate Salt Form C (hemi-fumarate) is characterized by 49 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 32. In one or more embodiments, Fumarate Salt Form C (hemi-fumarate) is characterized by an XRPD pattern comprising: a) 2θ values of about 6.14, 7.69, 8.08, 8.18, 12.14, 15.44, 20.89, 21.13, and 24.03 + 0.2°2θ; b) 2θ values of about 6.14, 8.44, 7.69, 8.08, 8.18, 11.37, 12.14, 13.53, 15.44, 19.28, 20.47, 20.89, 21.13, 23.59, and 24.03 + 0.2°2θ; c) 2θ values including at least or selected from about 4.89, 6.14, 6.38, 7.69, 8.08, 8.18, 8.44, 9.51, 11.37, 12.14, 12.86, 13.53, 14.21, 14.37, 15.44, 16.23, 16.42, 16.61, 16.68, 16.95, 17.51, 17.67, 18.01, 18.35, 18.51, 19.16, 19.28, 19.71, 20.47, 20.89, 21.13, 21.96, 22.30, 22.84, 23.04, 23.59, 23.74, 24.03, 24.43, 24.65, 24.93, 25.25, 25.61, 25.91, 26.14, 26.99, 27.46, 28.49, 28.78, 29.18, 30.14, 30.47, 30.91, 31.18, 31.68, 32.14, 32.59, 32.95, 33.77, 34.86, 35.30, 36.27, 38.05, 39.50 and + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 6.14, 8.44, 7.69, 8.08, 8.18, 11.37, 12.14, 13.53, 15.44, 19.28, 20.47, 20.89, 21.13, 23.59, and 24.03 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 6.14, 8.44, 7.69, 8.08, 8.18, 11.37, 12.14, 13.53, 15.44, 16.23, 17.67, 18.01, 18.35, 18.51, 19.16, 19.28, 20.47, 20.89, 21.13, 23.59, 23.74, 24.03, 24.65, and 25.91 + 0.2°2θ; f) 2θ values of about 6.14, 7.69, 8.08, 15.44, and 21.13 + 0.2°2θ; g) 2θ values including at least or selected from about 2θ values of about 6.14, 7.69, 8.08, 12.14, 15.44, and 21.13 + 0.2°2θ; h) 2θ values of about 6.14, 7.69, 8.08, 15.44, 20.89, and 21.13 + 0.2°2θ; i) 2θ values including at least or selected from about 6.14, 7.69, 8.08, 15.44, 20.47, and 21.13 + 0.2°2θ; j) 2θ values of about 6.14, 7.69, 8.08, and 21.13; and k) 2θ values including at least or selected from about 6.14, 7.69, 15.44, and 21.13 + 0.2°2θ.

[0264] Fumarate Salt Form C can be synthesized as described in Synthetic Example 14.

[0265] In one or more embodiments, Fumarate Salt Form C (hemi-fumarate salt) is synthesized by a method comprising: a) mixing Free Base Form A (a compound of Formula (I)) with 0.5 mol. equivalent of fumaric acid in methanol / water; 50 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT b) stirring; and c) isolating the precipitate to afford Fumarate Salt Form C.

[0266] In one or more embodiments, Fumarate Salt Form C (hemi-fumarate salt) is synthesized by a method comprising: a) mixing Fumarate Salt Form B (hemi-fumarate salt, a compound of Formula (I)) in methanol / water; b) stirring; and c) isolating the precipitate to afford Fumarate Salt Form C.

[0267] In one or more embodiments, the methanol / water in step (a) is in a ratio of from about 99 / 1 to about 50 / 50, such as from 99 / 1 to 60 / 40, from 99 / 1 to 70 / 30, from 99 / 1 to 80 / 20, from 90 / 10 to 50 / 50, from 90 / 10 to 60 / 40, from 90 / 10 to 70 / 30, or from 90 / 10 to 80 / 20. In one or more embodiments, the methanol / water in step (a) is in a ratio of 84 / 16.

[0268] In one or more embodiments, the mixture is allowed to stir and heat for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b).

[0269] Fumarate Salt Form D

[0270] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a mono-fumarate salt. In one or more embodiments, the mono-fumarate salt is Fumarate Salt Form D.

[0271] In one or more embodiments, Fumarate Salt Form D is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.49.

[0272] In one or more embodiments, Fumarate Salt Form D is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with an endotherm maxima between about 220°C and about 250°C. In one or more embodiments, Fumarate Salt Form D is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at about 222°C and about 243°C. In one or more embodiments, Fumarate Salt Form D is characterized by DTA thermogram substantially similar to that set forth in FIG.50.

[0273] In one or more embodiments, Fumarate Salt Form D is characterized by a weight loss in the range of about 30% to about 40% when heated from about 30°C to about 300°C in a 51 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT thermogravimetric analysis (TGA). In one or more embodiments, Fumarate Salt Form D is characterized by a weight loss of about 34.0% when heated from about 32°C to about 295°C in a TGA. In one or more embodiments, Fumarate Salt Form D is characterized by a TGA substantially similar to that set forth in FIG.50.

[0274] Fumarate Salt Form D can be synthesized as described in Synthetic Example 15.

[0275] In one or more embodiments, Fumarate Salt Form D is synthesized by a method comprising: a) mixing Fumarate Salt Amorphous Form (a compound of Formula (I)) in DMSO or DMSO / water; b) stirring and temperature cycling; and c) isolating the precipitate to afford Fumarate Salt Form D.

[0276] In one or more embodiments, the DMSO / water in step (a) is in a ratio of from about 70 / 30 to about 95 / 5, such as from about 75 / 25 to about 90 / 10, or from about 80 / 20 to about 90 / 10, or about 85 / 15. In one or more embodiments, the DMSO / water in step (a) is in a ratio of 86 / 14.

[0277] In one or more embodiments, the mixture is allowed to stir and heat for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b).

[0278] In one or more embodiments, the temperature cycling is between 5°C to 100°C and back to 5°C in step (b).

[0279] Fumarate Salt Form E

[0280] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a mono-fumarate salt. In one or more embodiments, the mono-fumarate salt is Fumarate Salt Form E.

[0281] In one or more embodiments, Fumarate Salt Form E is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.51.

[0282] Fumarate Salt Form E can be synthesized as described in Synthetic Example 16.

[0283] In one or more embodiments, Fumarate Salt Form E is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with an endotherm maxima between 52 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT about 200°C and about 240°C. In one or more embodiments, Fumarate Salt Form E is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at about 206°C and about 238°C. In one or more embodiments, Fumarate Salt Form E is characterized by DTA thermogram substantially similar to that set forth in FIG.52.

[0284] In one or more embodiments, Fumarate Salt Form E is characterized by a weight loss in the range of about 5% to about 15% when heated from about 40°C to about 215°C in a thermogravimetric analysis (TGA). In one or more embodiments, Fumarate Salt Form E is characterized by a weight loss of about 9.08% when heated from about 41°C to about 213°C in a TGA. In one or more embodiments, Fumarate Salt Form E is characterized by a TGA substantially similar to that set forth in FIG.52.

[0285] In one or more embodiments, Fumarate Salt Form E is synthesized by a method comprising: a) mixing Fumarate Salt Amorphous Form (a compound of Formula (I)) in dimethylacetamide; b) stirring to form a slurry; c) isolating the precipitate to afford Fumarate Salt Form E.

[0286] In one or more embodiments, the mixture is allowed to stir and heat for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b).

[0287] Maleate Salt Form A (Maleate Form 1 or Maleate Salt Form 1)

[0288] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a maleate salt. In one or more embodiments, the maleate salt is Maleate Salt Form A.

[0289] In one or more embodiments, Maleate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 55. In one or more embodiments, Maleate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 33. In one or more embodiments, Maleate Salt Form A is characterized by an XRPD pattern comprising: a) 2θ values of about 14.20, 16.48, 18.28, 19.46, and 21.74 + 0.2°2θ; 53 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT b) 2θ values of about 4.66, 9.28, 14.20, 16.48, 18.28, 18.92, 19.46, 21.44, 21.74, 22.74, 23.22, and 24.82 + 0.2°2θ; c) 2θ values including at least or selected from about 4.66, 9.28, 11.78, 14.20, 14.84, 15.64, 16.02, 16.48, 17.26, 17.60, 18.28, 18.92, 19.46, 20.42, 21.44, 21.74, 22.74, 23.22, 23.70, 24.82, 25.36, 26.04, 26.60, 26.80, 28.02, 28.40, 29.16, 30.04, 30.96, 31.58, 33.50, 35.46, and 35.82 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 14.20, 16.48, 18.28, 18.92, 19.46, 21.44, 21.74, 22.74, 23.22, and 24.82 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 4.66, 9.28, 14.20, 14.84, 15.64, 16.02, 16.48, 17.26, 17.60, 18.28, 18.92, 19.46, 20.42, 21.44, 21.74, 22.74, 23.22, 23.70, 24.82, 25.36, and 26.04 + 0.2°2θ; f) 2θ values of about 14.20, 16.48, 18.28, 18.92, 19.46, 21.74, 23.22, and 24.82 + 0.2°2θ; g) 2θ values including at least or selected from about 14.20, 16.48, 18.28, 18.92, 19.46, 21.74, 23.22, and 24.82 + 0.2°2θ; h) 2θ values of about 14.20, 16.48, 18.28, and 19.46 + 0.2°2θ; i) 2θ values including at least or selected from about 14.20, 16.48, 18.28, and 19.46 + 0.2°2θ; j) 2θ values of about 16.48, 18.28, and 19.46 + 0.2°2θ; k) 2θ values including at least or selected from about 16.48, 18.28, and 19.46 + 0.2°2θ; l) 2θ values of about 14.20, 16.48, 18.28, 18.92, 19.46, 21.44, 21.74, 23.22, and 24.82 + 0.2°2θ; m) 2θ values including at least or selected from about 14.20, 16.48, 18.28, 18.92, 19.46, 21.44, 21.74, 23.22, and 24.82 + 0.2°2θ; n) 2θ values of about 14.20, 16.48, 18.28, 18.92, 19.46, 21.44, and 21.74 + 0.2°2θ; o) 2θ values including at least or selected from about 14.20, 16.48, 18.28, 18.92, 19.46, 21.44, and 21.74 + 0.2°2θ; p) 2θ values of about 16.48, 18.28, 18.92, and 19.46 + 0.2°2θ; q) 2θ values including at least or selected from about 16.48, 18.28, 18.92, and 19.46 + 0.2°2θ; r) 2θ values of about 16.48, 18.28, 19.46, and 21.74 + 0.2°2θ; s) 2θ values including at least or selected from about 16.48, 18.28, 19.46, and 21.74 + 0.2°2θ; t) 2θ values of about 16.48, 18.28, 19.46, and 23.22 + 0.2°2θ; u) 2θ values including at least or selected from about 16.48, 18.28, 19.46, and 23.22 + 0.2°2θ; 54 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT v) 2θ values of about 16.48, 18.28, 19.46, and 24.82 + 0.2°2θ; and w) 2θ values including at least or selected from about 16.48, 18.28, 19.46, and 24.82 ± 0.2°2θ.

[0290] In one or more embodiments, Maleate Salt Form A is characterized by a differential scanning calorimetry (DSC) thermogram having one endotherm with an endotherm maxima between about 225°C and about 235°C. In one or more embodiments, Maleate Salt Form A is characterized by a differential scanning calorimetry (DSC) thermogram having one endotherm with an endotherm maxima at about 229°C. In one or more embodiments, Maleate Salt Form A is characterized by a DSC thermogram substantially similar to that set forth in FIG.56.

[0291] In one or more embodiments, Maleate Salt Form A is characterized by a weight loss in the range of about 0.1% to about 5% when heated from about 25°C to about 175°C, and in the range of about 5% to about 10% when heated from about 175°C to about 250°C in a thermogravimetric analysis (TGA). In one or more embodiments, Maleate Salt Form A is characterized by a weight loss of about 2.3% when heated from about 25°C to about 175°C in a TGA, and about 9.0% when heated from about 175°C to about 250°C. In one or more embodiments, Maleate Salt Form A is characterized by a TGA substantially similar to that set forth in FIG.56.

[0292] Maleate Salt Form A can be synthesized as described in Synthetic Example 17. In one or more embodiments, Maleate Salt Form A is synthesized by mixing free base compound of Formula (I) with maleic acid in an aprotic solvent (wet). In one or more embodiments, the solvent is selected from the group consisting of tetrahydrofuran, acetone, ethyl acetate, diethyl ether, toluene, hexane, dichloromethane, methyl ethyl ketone, dimethylsulfoxide, and dimethylformamide. In one or more embodiments, the mixture comprises tetrahydrofuran. In one or more embodiments, the mixture does not comprise water. After stirring, for instance overnight or a week, the precipitate is centrifuged, decanted, and dried to afford Maleate Salt Form A.

[0293] In one or more embodiments, Maleate Salt Form A is synthesized by a method comprising: a) mixing free base compound of Formula (I) and maleic acid in tetrahydrofuran; b) stirring to afford a precipitate; c) isolating the precipitate to afford Maleate Salt Form A. 55 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0294] In one or more embodiments, the mixture is allowed to stir for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b).

[0295] Tosylate Salt Form A (Tosylate Form 1 or Tosylate Salt Form 1)

[0296] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a tosylate salt. In one or more embodiments, the tosylate salt is Tosylate Salt Form A.

[0297] In one or more embodiments, Tosylate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.57. In one or more embodiments, Tosylate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 34. In one or more embodiments, Tosylate Salt Form A is characterized by an XRPD pattern comprising: a) 2θ values of about 15.76, 19.34, 20.96, 22.86, and 24.02 + 0.2°2θ; b) 2θ values of about 9.94, 10.24, 15.76, 16.74, 17.54, 19.34, 20.32, 20.96, 21.84, 22.86, 24.02, and 25.32 + 0.2°2θ; c) 2θ values including at least or selected from about 4.14, 8.20, 9.94, 10.24, 10.62, 11.40, 12.84, 13.96, 14.64, 15.14, 15.76, 16.74, 17.54, 19.34, 20.32, 20.96, 21.84, 22.86, 24.02, 24.64, 25.32, 26.84, 28.38, 28.78, 29.64, 30.68, 32.14, and 36.66 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 9.94, 10.24, 14.64, 15.14, 15.76, 16.74, 17.54, 19.34, 20.32, 20.96, 21.84, 22.86, 24.02, 24.64, and 25.32 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 9.94, 10.24, 12.84, 14.64, 15.14, 15.76, 16.74, 17.54, 19.34, 20.32, 20.96, 21.84, 22.86, 24.02, 24.64, 25.32, and 26.84 + 0.2°2θ; f) 2θ values of about 15.76, 17.54, 19.34, 20.32, 20.96, 21.84, 22.86, 24.02, and 25.32 + 0.2°2θ; g) 2θ values including at least or selected from about 15.76, 17.54, 19.34, 20.32, 20.96, 21.84, 22.86, 24.02, and 25.32 + 0.2°2θ; h) 2θ values of about 15.76, 19.34, 20.96, and 22.86 + 0.2°2θ; i) 2θ values including at least or selected from about 15.76, 19.34, 20.96, and 22.86 + 0.2°2θ; j) 2θ values of about 15.76, 20.96, and 22.86 + 0.2°2θ; 56 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT k) 2θ values including at least or selected from about 15.76, 20.96, and 22.86 + 0.2°2θ; l) 2θ values of about 15.76, 17.54, 19.34, 20.32, 20.96, 21.84, 22.86, and 24.02 + 0.2°2θ; m) 2θ values including at least or selected from about 15.76, 17.54, 19.34, 20.32, 20.96, 21.84, 22.86, and 24.02 + 0.2°2θ; n) 2θ values of about 15.76, 19.34, 20.32, 20.96, 21.84, 22.86, and 24.02 + 0.2°2θ; o) 2θ values including at least or selected from about 15.76, 19.34, 20.32, 20.96, 21.84, 22.86, and 24.02 + 0.2°2θ; p) 2θ values of about 15.76, 20.96, 22.86, and 24.02 + 0.2°2θ; q) 2θ values including at least or selected from about 15.76, 20.96, 22.86, and 24.02 + 0.2°2θ; r) 2θ values of about 15.76, 17.54, 20.96, and 22.86 + 0.2°2θ; s) 2θ values including at least or selected from about 15.76, 17.54, 20.96, and 22.86 + 0.2°2θ; t) 2θ values of about 15.76, 20.32, 20.96, and 22.86 + 0.2°2θ; u) 2θ values including at least or selected from about 15.76, 20.32, 20.96, and 22.86 + 0.2°2θ; v) 2θ values of about 15.76, 20.96, 21.84, and 22.86 + 0.2°2θ; and w) 2θ values including at least or selected from about 15.76, 20.96, 21.84, and 22.86 ± 0.2°2θ.

[0298] Tosylate Salt Form A can be synthesized as described in Synthetic Example 18. In one or more embodiments, Tosylate Salt Form A is synthesized by mixing free base compound of Formula (I) with p-toluenesulfonic acid in an aprotic solvent (wet). In one or more embodiments, the solvent is selected from the group consisting of tetrahydrofuran, acetone, ethyl acetate, diethyl ether, toluene, hexane, dichloromethane, methyl ethyl ketone, dimethyl sulfoxide, and dimethylformamide. In one or more embodiments, the mixture comprises tetrahydrofuran. In one or more embodiments, the mixture does not comprise water. After stirring, for instance overnight or a week, the precipitate is centrifuged, decanted, and dried to afford Tosylate Salt Form A.

[0299] In one or more embodiments, Tosylate Salt Form A is synthesized by a method comprising: a) mixing free base compound of Formula (I) and p-toluenesulfonic acid in tetrahydrofuran; b) stirring to afford a precipitate; and c) isolating the precipitate to afford Tosylate Salt Form A.

[0300] In one or more embodiments, the mixture is allowed to stir for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b). 57 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0301] Tosylate Salt Form B (Tosylate Form 2 or Tosylate Salt Form 2)

[0302] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a tosylate salt. In one or more embodiments, the tosylate salt is Tosylate Salt Form B.

[0303] In one or more embodiments, Tosylate Salt Form B is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.58. In one or more embodiments, Tosylate Salt Form B is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks substantially similar to those set forth in Table 35. In one or more embodiments, Tosylate Salt Form B is characterized by an XRPD pattern comprising: a) 2θ values of about 18.40, 19.12, 19.68, and 22.08 + 0.2°2θ; b) 2θ values of about 9.00, 10.20, 10.54, 18.00, 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, 22.58, 22.90, and 26.38 + 0.2°2θ; c) 2θ values including at least or selected from about 9.00, 9.64, 9.90, 10.20, 10.54, 11.36, 11.86, 12.58, 12.80, 13.10, 13.42, 13.78, 14.12, 14.64, 15.06, 15.32, 15.72, 16.56, 17.50, 18.00, 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, 22.58, 22.90, 23.42, 24.08, 24.60, 25.28, 26.38, 26.86, 27.24, and 27.64 + 0.2°2θ; d) at least two, three, four, or five 2θ values selected from about 15.72, 16.56, 17.50, 18.40, 19.12, 19.68, and 22.08 + 0.2°2θ; e) at least six, seven, or eight 2θ values selected from about 10.20, 10.54, 15.72, 16.56, 17.50, 18.00, 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, 22.58, 22.90, 23.42, 24.08, 25.28, and 26.38 + 0.2°2θ; f) 2θ values of about 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, 22.58, and 22.90 + 0.2°2θ; g) 2θ values including at least or selected from about 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, 22.58, and 22.90 + 0.2°2θ; h) 2θ values of about 18.40, 19.12, 19.68, and 22.08 + 0.2°2θ; i) 2θ values including at least or selected from about 18.40, 19.12, 19.68, and 22.08 + 0.2°2θ; j) 2θ values of about 19.12, 19.68, and 22.08 + 0.2°2θ; k) 2θ values including at least or selected from about 19.12, 19.68, and 22.08 + 0.2°2θ; 58 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT l) 2θ values of about 18.00, 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, 22.58, and 22.90 + 0.2°2θ; m) 2θ values including at least or selected from about 18.00, 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, 22.58, and 22.90 + 0.2°2θ; n) 2θ values of about 18.00, 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, and 22.58 + 0.2°2θ; o) 2θ values including at least or selected from about 18.00, 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, and 22.58 + 0.2°2θ; p) 2θ values of about 19.12, 19.68, 20.38, and 22.08 + 0.2°2θ; q) 2θ values including at least or selected from about 19.12, 19.68, 20.38, and 22.08 + 0.2°2θ; r) 2θ values of about 19.12, 19.68, 20.88, and 22.08 + 0.2°2θ; s) 2θ values including at least or selected from about 19.12, 19.68, 20.88, and 22.08 + 0.2°2θ; t) 2θ values of about 19.12, 19.68, 21.86, and 22.08 + 0.2°2θ; u) 2θ values including at least or selected from about 19.12, 19.68, 21.86, and 22.08 + 0.2°2θ; v) 2θ values of about 19.12, 19.68, 22.08, and 22.36 + 0.2°2θ; and w) 2θ values including at least or selected from about 19.12, 19.68, 22.08, and 22.36 ± 0.2°2θ.

[0304] Tosylate Salt Form B can be synthesized as described in Synthetic Example 19. In one or more embodiments, Tosylate Salt Form B is synthesized by mixing free base compound of Formula (I) and p-toluenesulfonic acid in a protic solvent. In one or more embodiments, the solvent is a polar protic solvent. In one or more embodiments, the solvent is selected from the group consisting of methanol, ethanol, isopropanol, formic acid, and acetic acid. In one or more embodiments, the mixture comprises water. In one or more embodiments, the mixture does not comprise water. After stirring, for instance overnight or a week and under heat, the precipitate is centrifuged, decanted, and dried to afford Tosylate Salt Form B.

[0305] In one or more embodiments, Tosylate Salt Form B is synthesized by a method comprising: a) mixing free base compound of Formula (I) and p-toluenesulfonic acid in methanol and water; b) stirring and heating to afford a precipitate; c) isolating the precipitate to afford Tosylate Salt Form B. 59 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0306] In one or more embodiments, the mixture is allowed to stir and heat for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b).

[0307] Besylate Salt Form A

[0308] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt is a besylate salt. In one or more embodiments, the besylate salt is Besylate Salt Form A.

[0309] In one or more embodiments, Besylate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.59 (2ndfrom top).

[0310] Besylate Salt Form A can be synthesized as described in Synthetic Example 20.

[0311] In one or more embodiments, Besylate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having two endotherms with a first endotherm maxima between about 85°C and about 160°C, and a second endotherm maxima between about 205°C and about 255°C. In one or more embodiments, Besylate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having two endotherms with a first endotherm maxima at about 87°C and about 155°C, and a second endotherm maxima at about 208°C and about 205°C. In one or more embodiments, Besylate Salt Form A is characterized by DTA thermogram substantially similar to that set forth in FIG.60.

[0312] In one or more embodiments, Besylate Salt Form A is characterized by a weight loss in the range of about 0.1% to about 5% when heated from about 30°C to about 90°C, and a weight loss in the range of about 30% to about 40% when heated from about 85°C to about 160°C in a thermogravimetric analysis (TGA). In one or more embodiments, Besylate Salt Form A is characterized by a weight loss of about 1.12% when heated from about 31°C to about 88°C, and a weight loss of about 34.2% when heated from about 88°C to about 155°C in a TGA. In one or more embodiments, Besylate Salt Form A is characterized by a TGA substantially similar to that set forth in FIG.60.

[0313] In one or more embodiments, Besylate Salt Form A is synthesized by a method comprising: 60 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT a) mixing Free Base Form A (a compound of Formula (I)) in tetrahydrofuran / water and 1 mol. equivalent of benzenesulfonic acid; b) stirring and temperature cycling; c) isolating the precipitate to afford Besylate Salt Form A.

[0314] In one or more embodiments, the tetrahydrofuran / water in step (a) is in a ratio of from about 1:1 to about 10:1, such as from 1:1 to 9:1, from 1:1 to 8:1, from 1:1 to 7:1, from 1:1 to 6:1, from 1:1 to 5:1, from 1:1 to 4:1, or from 1:1 to 3:1. In one or more embodiments, the tetrahydrofuran / water in step (a) is in a ratio of 2:1 (12 vols).

[0315] In one or more embodiments, the mixture is allowed to stir and temperature cycle for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b). In one or more embodiments, the mixture is allowed to stir and temperature cycle for 75-80 hours.

[0316] In one or more embodiments, the temperature cycling is between ambient temperature (of from 15°C to 30°C) to 50°C and back to ambient temperature in step (b). In one or more embodiments, the temperature cycling is between ambient temperature to 50°C at 60 hours, returned to ambient temperature, and stirred for another 18 hours.

[0317] In one or more embodiments, the isolating is by centrifugation in step (c).

[0318] Cyclamate Salt Form A

[0319] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a cyclamate salt. In one or more embodiments, the cyclamate salt is Cyclamate Salt Form A.

[0320] In one or more embodiments, Cyclamate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.61.

[0321] Cyclamate Salt Form A can be synthesized as described in Synthetic Example 21.

[0322] In one or more embodiments, Cyclamate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having two endotherms with a first endotherm maxima between about 220°C and about 245°C, and a second endotherm maxima between about 275°C to about 305°C. In one or more embodiments, Cyclamate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at 61 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT about 222°C and about 240°C, and at about 278°C and about 300°C. In one or more embodiments, Cyclamate Salt Form A is characterized by DTA thermogram substantially similar to that set forth in FIG.62.

[0323] In one or more embodiments, Cyclamate Salt Form A is characterized by a weight loss in the range of about 1% to about 5% when heated from about 30°C to about 235°C in a thermogravimetric analysis (TGA). In one or more embodiments, Cyclamate Salt Form A is characterized by a weight loss of about 1.72% when heated from about 31°C to about 229°C in a TGA. In one or more embodiments, Cyclamate Salt Form A is characterized by a TGA substantially similar to that set forth in FIG.62.

[0324] In one or more embodiments, Cyclamate Salt Form A is synthesized by a method comprising: a) mixing Free Base Form A (a compound of Formula (I)) and cyclamic acid (1 mol. equivalent) in THF; b) stirring and temperature cycling; c) isolating the precipitate to afford Cyclamate Salt Form A; optionally drying under vacuum for 1 hour to afford Cyclamate Salt Form A.

[0325] In one or more embodiments, the mixture is allowed to stir and temperature cycle for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b). In one or more embodiments, the mixture is allowed to stir and temperature cycle for 75-80 hours.

[0326] In one or more embodiments, the temperature cycling is between ambient temperature (of from 15°C to 30°C) to 40°C and back to 5°C in step (b). In one or more embodiments, the temperature cycling is between ambient temperature to 40°C at 60 hours, then cooled to 5°C and stirred at this temperature for another 18 hours.

[0327] In one or more embodiments, the isolating is by centrifugation in step (c).

[0328] Malate Salt Form A

[0329] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a malate salt. In one or more embodiments, the malate salt is Malate Salt Form A. 62 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0330] In one or more embodiments, Malate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.63.

[0331] Malate Salt Form A can be synthesized as described in Synthetic Example 22.

[0332] In one or more embodiments, Malate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with two endotherm maximas between about 60°C and about 130°C, and between about 220°C and about 260°C. In one or more embodiments, Malate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having two endotherms with endotherm maxima at about 64°C and about 124°C, and about 222°C and about 254°C. In one or more embodiments, Malate Salt Form A is characterized by DTA thermogram substantially similar to that set forth in FIG.64.

[0333] In one or more embodiments, Malate Salt Form A is characterized by a weight loss in the range of about 1% to about 10% when heated from about 30°C to about 225°C in a thermogravimetric analysis (TGA). In one or more embodiments, Malate Salt Form A is characterized by a weight loss of about 4.73% when heated from about 30°C to about 223°C in a TGA. In one or more embodiments, Malate Salt Form A is characterized by a TGA substantially similar to that set forth in FIG.64.

[0334] In one or more embodiments, Malate Salt Form A is synthesized by a method comprising: a) mixing Free Base Form A (a compound of Formula (I)) and malic acid (1 mol. equivalent) in tetrahydrofuran; b) stirring and temperature cycling; c) isolating the precipitate to afford Malate Salt Form A; optionally drying under vacuum for 1 hour to afford Malate Salt Form A.

[0335] In one or more embodiments, the mixture is allowed to stir and temperature cycle for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b). In one or more embodiments, the mixture is allowed to stir and temperature cycle for 75-80 hours.

[0336] In one or more embodiments, the temperature cycling is between ambient temperature (of from 15°C to 30°C) to 40°C and back to 5°C in step (b). In one or more embodiments, the 63 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT temperature cycling is between ambient temperature to 40°C at 60 hours, then cooled to 5°C and stirred at this temperature for another 18 hours.

[0337] In one or more embodiments, the isolating is by centrifugation in step (c).

[0338] Malonate Salt Form A

[0339] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a malonate salt. In one or more embodiments, the malonate salt is Malonate Salt Form A.

[0340] In one or more embodiments, Malonate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.65.

[0341] Malonate Salt Form A can be synthesized as described in Synthetic Example 23.

[0342] In one or more embodiments, Malonate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with an endotherm maxima between about 140°C and about 190°C. In one or more embodiments, Malonate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at about 143°C and about 185°C. In one or more embodiments, Malonate Salt Form A is characterized by DTA thermogram substantially similar to that set forth in FIG.66.

[0343] In one or more embodiments, Malonate Salt Form A is characterized by a weight loss in the range of about 1% to about 10% when heated from about 30°C to about 140°C, about 1% to about 10% when heated from about 135°C to about 180°C, and about 1% to about 10% when heated from about 180°C to about 305°C in a thermogravimetric analysis (TGA). In one or more embodiments, Malonate Salt Form A is characterized by a weight loss of about 2.43% when heated from about 31°C to about 137°C, 6.30% when heated from about 138°C to about 180°C, and 4.48% when heated from about 181°C to about 298°C in a TGA. In one or more embodiments, Malonate Salt Form A is characterized by a TGA substantially similar to that set forth in FIG.66.

[0344] In one or more embodiments, Malonate Salt Form A is synthesized by a method comprising: a) mixing Free Base Form A (a compound of Formula (I)) with malonic acid (1 mol. equivalent) in THF / water; b) stirring and temperature cycling; 64 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT c) isolating the precipitate as an amorphous solid; d) mixing the amorphous solid with acetone (15-20 vols) to form a slurry; e) temperature cycling; f) isolating the solid to afford Malonate Salt Form A.

[0345] In one or more embodiments, the tetrahydrofuran / water in step (a) is in a ratio of from about 1:1 to about 10:1, such as from 1:1 to 9:1, from 1:1 to 8:1, from 1:1 to 7:1, from 1:1 to 6:1, from 1:1 to 5:1, from 1:1 to 4:1, or from 1:1 to 3:1. In one or more embodiments, the tetrahydrofuran / water in step (a) is in a ratio of 2:1 (12 vols).

[0346] In one or more embodiments, the mixture is allowed to stir and temperature cycle for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b) and (e). In one or more embodiments, the mixture is allowed to stir and temperature cycle for 75- 80 hours in step (b). In one or more embodiments, the mixture is allowed to stir and temperature cycle for 45-55 hours in step (e).

[0347] In one or more embodiments, the temperature cycling is between ambient temperature (of from 15°C to 30°C) to 50°C and back to ambient temperature in step (b). In one or more embodiments, the temperature cycling is between ambient temperature to 50°C at 60 hours, then cooled to ambient and stirred at this temperature for another 18 hours.

[0348] In one or more embodiments, the temperature cycling is between ambient temperature (of from 15°C to 30°C) to 40°C and back to ambient temperature in step (e). In one or more embodiments, the temperature cycling is between ambient temperature to 40°C at 48 hours, then cooled to ambient temperature in step (e).

[0349] In one or more embodiments, the isolating is by centrifugation in steps (c) and (f).

[0350] Napsylate Salt Form A

[0351] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a napsylate salt. In one or more embodiments, the napsylate salt is Napsylate Salt Form A.

[0352] In one or more embodiments, Napsylate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.67. 65 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0353] Napsylate Salt Form A can be synthesized as described in Synthetic Example 24.

[0354] In one or more embodiments, Napsylate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with an endotherm maxima between about 240°C and about 280°C. In one or more embodiments, Napsylate Salt Form A is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at about 247°C and about 277°C. In one or more embodiments, Napsylate Salt Form A is characterized by DTA thermogram substantially similar to that set forth in FIG.68.

[0355] In one or more embodiments, Napsylate Salt Form A is characterized by a weight loss in the range of about 1% to about 5% when heated from about 30°C to about 255°C in a thermogravimetric analysis (TGA). In one or more embodiments, Napsylate Salt Form A is characterized by a weight loss of about 2.78% when heated from about 31°C to about 251°C in a TGA. In one or more embodiments, Napsylate Salt Form A is characterized by a TGA substantially similar to that set forth in FIG.68.

[0356] In one or more embodiments, Napsylate Salt Form A is synthesized by a method comprising: a) mixing Free Base Form A (a compound of Formula (I)) and naphthalene-2-sulfonic acid (1 mol. equivalent) in THF; b) stirring and temperature cycling; c) isolating the precipitate to afford Napsylate Salt Form A.

[0357] In one or more embodiments, the mixture is allowed to stir and temperature cycle for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b). In one or more embodiments, the mixture is allowed to stir and temperature cycle for 75-80 hours.

[0358] In one or more embodiments, the temperature cycling is between ambient temperature (of from 15°C to 30°C) to 40°C and back to 5°C in step (b). In one or more embodiments, the temperature cycling is between ambient temperature to 40°C at 60 hours, then cooled to 5°C and stirred at this temperature for another 18 hours.

[0359] In one or more embodiments, the isolating is by centrifugation in step (c).

[0360] Napsylate Salt Form B, Napsylate Salt Form C, and Napsylate Salt Form D 66 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0361] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a napsylate salt. In one or more embodiments, the napsylate salt is Napsylate Salt Form B. In one or more embodiments, the napsylate salt is Napsylate Salt Form C. In one or more embodiments, the napsylate salt is Napsylate Salt Form D.

[0362] In one or more embodiments, Napsylate Salt Form B is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.69 (2ndfrom top). In one or more embodiments, Napsylate Salt Form C is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.69 (2ndfrom bottom). In one or more embodiments, Napsylate Salt Form D is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.69 (bottom) and FIG.70.

[0363] Napsylate Salt Form B can be synthesized as described in Synthetic Example 25. Napsylate Salt Form C can be synthesized as described in Synthetic Example 26. Napsylate Salt Form D can be synthesized as described in Synthetic Example 27.

[0364] In one or more embodiments, Napsylate Salt Form D is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with an endotherm maxima between about 75°C and about 140°C. In one or more embodiments, Napsylate Salt Form D is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at about 79°C and about 138°C. In one or more embodiments, Napsylate Salt Form D is characterized by DTA thermogram substantially similar to that set forth in FIG.71.

[0365] In one or more embodiments, Napsylate Salt Form D is characterized by a weight loss in the range of about 1% to about 5% when heated from about 25°C to about 85°C, a range of about 20% to about 30% when heated from about 85°C to about 125°C, and a range of about 0.1% to 5% when heated from about 150°C to about 180°C in a thermogravimetric analysis (TGA). In one or more embodiments, Napsylate Salt Form D is characterized by a weight loss of about 1.97% when heated from about 30°C to about 83°C, a range of about 25% when heated from about 86°C to about 124°C, and a range of about 0.9% when heated from about 151°C to about 175°C in a TGA. In one or more embodiments, Napsylate Salt Form D is characterized by a TGA substantially similar to that set forth in FIG.71. 67 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0366] In one or more embodiments, Napsylate Salt Form B is synthesized by a method comprising: a) mixing Free Base Form A (a compound of Formula (I)) with naphthalene-2-sulfonic acid (1 mol. equivalent) in THF / water (12 vols); b) stirring and temperature cycling; c) isolating the precipitate to afford Napsylate Salt Form B.

[0367] In one or more embodiments, the mixture is allowed to stir and temperature cycle for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b). In one or more embodiments, the mixture is allowed to stir and temperature cycle for 75-80 hours.

[0368] In one or more embodiments, the temperature cycling is between ambient temperature (of from 15°C to 30°C) to 50°C and back to ambient temperature in step (b). In one or more embodiments, the temperature cycling is between ambient temperature to 50°C at 60 hours, then cooled to ambient temperature and stirred at this temperature for another 18 hours.

[0369] In one or more embodiments, the isolating is by centrifugation in step (c).

[0370] In one or more embodiments, Napsylate Salt Form C is synthesized by a method comprising storing Napsylate Salt Form B under ambient conditions (including a temperature of from 15°C to 30°C) to convert to Napsylate Salt Form C.

[0371] In one or more embodiments, Napsylate Salt Form D is synthesized by a method comprising drying Napsylate Salt Form B under vacuum for 1 hour to convert to Napsylate Salt Form D.

[0372] Succinate Salt Forms A and B

[0373] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a succinate salt. In one or more embodiments, the succinate salt is Succinate Salt Form A. In one or more embodiments, the succinate salt is Succinate Salt Form B.

[0374] In one or more embodiments, Succinate Salt Form A is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.72 (2ndfrom top, and bottom) and FIG.73. 68 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0375] Succinate Salt Form A can be synthesized as described in Synthetic Example 28.

[0376] In one or more embodiments, Succinate Salt Form B is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG. 72 (2ndfrom bottom).

[0377] Succinate Salt Form B can be synthesized as described in Synthetic Example 29.

[0378] In one or more embodiments, Succinate Salt Form B is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with two endotherm maxima, the first endotherm maxima between about 75°C and about 125°C, and between about 200°C and about 230°C. In one or more embodiments, Succinate Salt Form B is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with endotherm maxima at about 77°C and about 122°C, and at about 202°C and about 226°C. In one or more embodiments, Succinate Salt Form B is characterized by DTA thermogram substantially similar to that set forth in FIG.74.

[0379] In one or more embodiments, Succinate Salt Form B is characterized by a weight loss in the range of about 1% to about 5% when heated from about 30°C to about 215°C in a thermogravimetric analysis (TGA). In one or more embodiments, Succinate Salt Form B is characterized by a weight loss of about 1.55% when heated from about 34°C to about 214°C in a TGA. In one or more embodiments, Succinate Salt Form B is characterized by a TGA substantially similar to that set forth in FIG.74.

[0380] In one or more embodiments, Succinate Salt Form A and Succinate Salt Form B are synthesized by a method comprising: a) mixing Free Base Form A (a compound of Formula (I)) with succinic acid (1 mol. equivalent) in THF; b) stirring and temperature cycling; c) isolating the precipitate to afford Succinate Salt Form A; d) drying the precipitate under vacuum 1 hour to afford Succinate Salt Form B.

[0381] In one or more embodiments, the mixture is allowed to stir and temperature cycle for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b). In one or more embodiments, the mixture is allowed to stir and temperature cycle for 75-80 hours. 69 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0382] In one or more embodiments, the temperature cycling is between ambient temperature (of from 15°C to 30°C) to 40°C and back to 5°C in step (b). In one or more embodiments, the temperature cycling is between ambient temperature to 40°C at 60 hours, then cooled to 5°C and stirred at this temperature for another 18 hours.

[0383] In one or more embodiments, the isolating is by centrifugation in step (c).

[0384] Succinate Salt Form C

[0385] In one or more embodiments, provided herein is a salt of a compound of Formula (I). In one or more embodiments, the salt of the compound of Formula (I) is a succinate salt. In one or more embodiments, the succinate salt is Succinate Salt Form C.

[0386] In one or more embodiments, Succinate Salt Form C is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that set forth in FIG.75.

[0387] Succinate Salt Form C can be synthesized as described in Synthetic Example 30.

[0388] In one or more embodiments, Succinate Salt Form C is characterized by a differential thermal analysis (DTA) thermogram having an endotherm with two endotherms, the first endotherm maxima between about 80°C and about 155°C, and the second endotherm maxima between about 200°C and about 235°C. In one or more embodiments, Succinate Salt Form C is characterized by a differential thermal analysis (DTA) thermogram having two endotherms, the first endotherm maxima at about 83°C and about 151°C, and the second endotherm maxima at about 203°C to about 227°C. In one or more embodiments, Succinate Salt Form C is characterized by DTA thermogram substantially similar to that set forth in FIG.76.

[0389] In one or more embodiments, Succinate Salt Form C is characterized by a weight loss in the range of about 20% to about 30% when heated from about 70°C to about 155°C in a thermogravimetric analysis (TGA). In one or more embodiments, Succinate Salt Form C is characterized by a weight loss of about 23.6% when heated from about 74°C to about 153°C in a TGA. In one or more embodiments, Succinate Salt Form C is characterized by a TGA substantially similar to that set forth in FIG.76.

[0390] In one or more embodiments, Succinate Salt Form C is synthesized by a method comprising: 70 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT a) mixing Free Base Form A (a compound of Formula (I)) with succinic acid (1 mol. equivalent) in THF / water (12 vols); b) stirring and temperature cycling; c) isolating the precipitate to afford Succinate Salt Form C.

[0391] In one or more embodiments, the mixture is allowed to stir and temperature cycle for at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 24 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, or at least 6 days in step (b). In one or more embodiments, the mixture is allowed to stir and temperature cycle for 75-80 hours.

[0392] In one or more embodiments, the temperature cycling is between ambient temperature (of from 15°C to 30°C) to 50°C and back to ambient temperature in step (b). In one or more embodiments, the temperature cycling is between ambient temperature to 50°C at 60 hours, then cooled to ambient temperature and stirred at this temperature for another 18 hours.

[0393] In one or more embodiments, the isolating is by centrifugation in step (c).

[0394] Pharmaceutical Compositions

[0395] The compounds described herein can be formulated into pharmaceutical compositions that further comprise a pharmaceutically acceptable carrier, diluent, adjuvant, or vehicle. In one or more embodiments, this disclosure provides a pharmaceutical composition comprising a compound described above, and a pharmaceutically acceptable carrier, diluent, adjuvant, or vehicle. In one or more embodiments, this disclosure is a pharmaceutical composition comprising an effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, adjuvant, or vehicle. Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients, or carriers suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practices.

[0396] According to one or more embodiments, the description provides a composition comprising a compound herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0397] Pharmaceutical compositions of this description comprise a therapeutically effective amount of a salt or free base compound of Formula (I), Free Base Form A, Free Base Amorphous 71 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Form, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, Free Base Form J, Fumarate Salt Form A, Fumarate Salt Amorphous Form, Fumarate Salt Form B, Fumarate Salt Form C, Fumarate Salt Form D, Fumarate Salt Form E, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Besylate Salt Form A, Cyclamate Salt Form A, Malate Salt Form A, Malonate Salt Form A, Napsylate Salt Form A, Napsylate Salt Form B, Napsylate Salt Form C, Napsylate Salt Form D, Succinate Salt Form A, Succinate Salt Form B, and Succinate Salt Form C.

[0398] Pharmaceutical compositions of this description comprise a therapeutically effective amount of a salt or free base compound of Formula (I), Fumarate Salt Form A, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Free Base Form A, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, Free Base Form J, Fumarate Salt Amorphous Form, and / or Free Base Amorphous Form.

[0399] Pharmaceutical compositions of this description comprise a therapeutically effective amount of a salt or free base compound of Formula (I), Fumarate Salt Form A, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Free Base Form A, Free Base Form B, Free Base Form C, and / or Free Base Form D.

[0400] A “therapeutically effective amount” is an amount that is (a) effective to measurably degrade BTK (or reduce the amount of BTK) in a biological sample or in a patient; or (b) effective in treating and / or ameliorating a disease, disorder, or condition that is mediated by BTK.

[0401] The term “patient,” as used herein, means an animal, alternatively a mammal, and alternatively a human.

[0402] A pharmaceutically acceptable carrier may contain inert ingredients that do not unduly inhibit the biological activity of the compounds. The pharmaceutically acceptable carriers should be biocompatible, for example, non-toxic, non-inflammatory, non-immunogenic, or devoid of other undesired reactions or side-effects upon the administration to a subject. Standard pharmaceutical formulation techniques can be employed.

[0403] The pharmaceutically acceptable carrier, adjuvant, or vehicle, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, 72 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds described herein, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, the use of such conventional carrier medium is contemplated to be within the scope of this description. As used herein, the phrase “side effects” encompasses unwanted and adverse effects of a therapy (e.g., a prophylactic or therapeutic agent). Side effects are always unwanted, but unwanted effects are not necessarily adverse. An adverse effect from a therapy (e.g., prophylactic or therapeutic agent) might be harmful, uncomfortable, or risky. Side effects include, but are not limited to, fever, chills, lethargy, gastrointestinal toxicities (including gastric and intestinal ulcerations and erosions), nausea, vomiting, neurotoxicities, nephrotoxicities, renal toxicities (including such conditions as papillary necrosis and chronic interstitial nephritis), hepatic toxicities (including elevated serum liver enzyme levels), myelotoxicities (including leukopenia, myelosuppression, thrombocytopenia and anemia), dry mouth, metallic taste, prolongation of gestation, weakness, somnolence, pain (including muscle pain, bone pain, and headache), hair loss, asthenia, dizziness, extra-pyramidal symptoms, akathisia, cardiovascular disturbances, and sexual dysfunction.

[0404] In one or more embodiments, an amorphous solid dispersion includes a pharmaceutically acceptable carrier, adjuvant, or vehicle. In one or more embodiments, an amorphous solid dispersion comprises a dispersion aid. In one or more embodiments, the dispersion aid is a polymer. In one or more embodiments, the dispersion aid is a polymer selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), an anionic copolymer consisting of methacrylic acid / ethyl acrylate, or a random copolymer of N- vinyl pyrrolidone and vinyl acetate (PVP / VA). In one or more embodiments, the HPMCAS is type L (HPCMAS-L), type M (HPMCAS-M), or type H (HPMCAS-H). In one or more embodiments, the HPMCAS is type L (HPCMAS-L) or type H (HPMCAS-H). In one or more embodiments, the anionic copolymer consisting of methacrylic acid / ethyl acrylate is Eudragit L100. In one or more embodiments, the random copolymer of N-vinyl pyrrolidone and vinyl is a 6:4 linear random copolymer of N-vinyl pyrrolidone and vinyl acetate (PVP-VA64). 73 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0405] Some examples of materials that can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as tween 80, phosphates, glycine, sorbic acid, or potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, or zinc salts), colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, methylcellulose, hydroxypropyl methylcellulose, wool fat, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring, and perfuming agents. Preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

[0406] As used herein, the term “measurably degrade,” means a measurable reduction in (a) BTK activity, between a sample comprising a compound of this description and a BTK and an equivalent sample comprising a BTK in the absence of said compound; or (b) the concentration of the BTK in a sample over time.

[0407] Administration

[0408] The compositions of this disclosure may be administered orally. The pharmaceutically acceptable compositions of this description may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions, or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When an aqueous suspension is for oral 74 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT use, the active ingredient is combined with emulsifying and suspending agents. If desired, sweetening, flavoring, or coloring agents also may be added.

[0409] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds herein, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions also can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0410] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound herein is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, one or more silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form also may comprise buffering agents.

[0411] Solid compositions of a similar type also may be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. Solid dosage forms optionally may contain opacifying agents. These solid dosage forms also can be of a composition such that they 75 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT release the active ingredient(s) only, for example, in a part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type also may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.

[0412] The active compounds herein also can be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms also may comprise, as is normal practice, additional substances other than inert diluents, for example, tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms also may comprise buffering agents. They may optionally contain opacifying agents and also can be of a composition such that they release the active ingredient(s) only, for example, in a part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0413] The compounds of the description are formulated in dosage unit form for ease of administration and uniformity of dosage. As used herein, the phrase “dosage unit form” refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of this disclosure will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disease, disorder, or condition being treated and the severity of the disease, disorder, or condition; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. 76 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0414] The amount of the compounds of this disclosure that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration, and other factors. The compositions should be formulated so that a dosage of between 0.01 - 100 mg / kg body weight / day of the compound or inhibitor can be administered to a patient receiving these compositions.

[0415] Depending upon the particular disease, disorder, or condition to be treated or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, also may be present in the compositions of this disclosure. As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, disorder, or condition, are known as “appropriate for the disease, disorder, or condition being treated.”

[0416] For example, chemotherapeutic agents or other anti-proliferative agents may be combined with the compounds of this disclosure to treat proliferative diseases and cancer. Examples of known chemotherapeutic agents include, but are not limited to, PI3K inhibitors (e.g., idelalisib and copanlisib), BCL-2 inhibitors (e.g., venetoclax), BTK inhibitors (e.g., ibrutinib and acalabrutinib), etoposide, CD20 antibodies (e.g., rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab), aletuzumab, bendamustine, cladribine, doxorubicin, chlorambucil, prednisone, midostaurin, lenalidomide, pomalidomide, checkpoint inhibitors (e.g., ipilimumab, nivolumab, pembolizumab, atezolizumab, avelumab, durvalumab), engineered cell therapy (e.g., CAR-T therapy - Kymriah®, Yescarta®), Gleevec™, adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum derivatives.

[0417] And, in some instances, radiation therapy is administered during the treatment course wherein a compound of this disclosure (or a pharmaceutically acceptable salt thereof) is administered to a patient in need thereof.

[0418] Other examples of agents with which the compounds or inhibitors of this disclosure also may be combined include, without limitation, treatments for Alzheimer's Disease such as Aricept®and Excelon®; treatments for Parkinson's Disease such as L-DOPA / carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex®and Rebif®), Copaxone®, and mitoxantrone; treatments for asthma such as albuterol and Singulair®; agents for 77 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.

[0419] The amount of additional therapeutic agent present in the compositions of this disclosure will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. The amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.

[0420] Methods of Treatment

[0421] In one or more embodiments, a form of compound of Formula (I) provided herein, including salt forms and crystalline forms thereof and the Fumarate Salt Form A, Maleate Salt Form A, Tosylate Salt Form A, and Tosylate Salt Form B, is used to treat a disease, disorder, or condition caused by oxidative stress and / or inflammation useful for degrading BTK in biological samples or in patients via a ubiquitin proteolytic pathway.

[0422] In one or more embodiments, a form of compound of Formula (I) provided herein, including free bases and crystalline forms thereof and the Free Base Form A, Free Base Form B, Free Base Form C, and Free Base Form D, is used to treat a disease, disorder, or condition caused by oxidative stress and / or inflammation useful for degrading BTK in biological samples or in patients via a ubiquitin proteolytic pathway.

[0423] In one or more embodiments, a form of compound of Formula (I) provided herein, including free bases and crystalline forms thereof and the Free Base Form A, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, 78 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Free Base Form H, and Free Base Form J, is used to treat a disease, disorder, or condition caused by oxidative stress and / or inflammation useful for degrading BTK in biological samples or in patients via a ubiquitin proteolytic pathway.

[0424] In one or more embodiments, a form of compound of Formula (I) provided herein, including free bases and crystalline forms thereof and the Free Base Form A, Free Base Amorphous Form, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, Free Base Form J, Fumarate Salt Form A, Fumarate Salt Amorphous Form, Fumarate Salt Form B, Fumarate Salt Form C, Fumarate Salt Form D, Fumarate Salt Form E, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Besylate Salt Form A, Cyclamate Salt Form A, Malate Salt Form A, Malonate Salt Form A, Napsylate Salt Form A, Napsylate Salt Form B, Napsylate Salt Form C, Napsylate Salt Form D, Succinate Salt Form A, Succinate Salt Form B, and Succinate Salt Form C, is used to treat a disease, disorder, or condition caused by oxidative stress and / or inflammation useful for degrading BTK in biological samples or in patients via a ubiquitin proteolytic pathway.

[0425] In one or more embodiments, a compound of Formula (I) provided herein, including amorphous forms thereof and the Fumarate Salt Amorphous Form and Free Base Amorphous Form, is used to treat a disease, disorder, or condition caused by oxidative stress and / or inflammation useful for degrading BTK in biological samples or in patients via a ubiquitin proteolytic pathway.

[0426] The forms of compounds of the present disclosure are useful for degrading BTK in biological samples or in patients via a ubiquitin proteolytic pathway. Thus, an embodiment of the present disclosure provides a method of treating a BTK-mediated disease, disorder, or condition. As used herein, the term “BTK-mediated disease, disorder, or condition” means any disease, disorder, or other deleterious condition in which a BTK is known to play a role. In some instances, a BTK-mediated disease, disorder, or condition is a proliferative disorder or an autoimmune disorder. Examples of proliferative disorders include cancer.

[0427] The term “cancer” includes, but is not limited to, the following cancers: epidermoid Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), yxo a, rhabdomyoma, fibroma, lipoma, and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, 79 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal, rectum; Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses ), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull ( osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus ( endometrial carcinoma), cervix ( cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma 80 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT (malignant lymphoma) hairy cell; lymphoid disorders (e.g., mantle cell lymphoma, Waldenstrom’s macroglobulinemia, Marginal zone lymphoma, and Follicular lymphoma); Skin: malilymphgnant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, undifferentiated thyroid cancer, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; and Adrenal glands: neuroblastoma.

[0428] Examples of autoimmune diseases, disorders, or conditions include uticaria, graft-versus-host disease, pemphigus vulgaris, achalasia, Addison’s disease, Adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, axonal and neuronal neuropathy (AMAN), Balo disease, Behcet’s disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease (CD), Celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA), cicatricial pemphigoid, Cogan’s syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST syndrome, Crohn’s disease, dermatitis herpetiformis, dermatomyositis, Devic’s disease (neuromyelitis optica), discoid lupus, Dressler’s syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, goodpasture’s syndrome, granulomatosis with polyangiitis, Graves’ disease, Guillain-Barre syndrome, Hashimoto’s thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), herpes gestationis or pemphigoid gestationis (PG), hidradenitis suppurativa (HS) (Acne Inversa), hypogammalglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura (ITP), inclusion body myositis (IBM), interstitial cystitis (IC), juvenile arthritis, juvenile diabetes (Type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert- Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous 81 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT conjunctivitis, linear IgA disease (LAD), lupus, lyme disease chronic, Meniere’s disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, Multifocal Motor Neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, pars planitis (peripheral uveitis), Parsonnage-Tumer syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndromes type I, II, III, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRC A), pyoderma gangrenosum, Raynaud’s phenomenon, reactive Arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjogren’s syndrome, sperm and testicular autoimmunity, stiff person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac’s syndrome, sympathetic ophthalmia (SO), Takayasu’s arteritis, temporal arteritis (giant cell arteritis), thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome (THS), transverse myelitis, Type 1 diabetes, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, Vogt-Koyanagi-Harada Disease, and Wegener's granulomatosis (or Granulomatosis with Polyangiitis (GPA)).

[0429] In one or more embodiments, the disease, disorder, or condition is diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), including those with secondary CNS involvement in any disease, disorder, or condition listed, or primary central nervous system lymphoma (PCNSL).

[0430] In one or more embodiments, DLBCL is non-GCM DLBCL: non-Germinal center (non-GCB) B-cell like subtype DLBCL. In one or more embodiments, the MCL is non-GCB MCL.

[0431] In one or more embodiments, the disease, disorder, or condition includes secondary CNS involvement in the disease, disorder, or condition. 82 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0432] In one or more embodiments, the disease, disorder, or condition is in a patient (or adult patient) with relapsed / refractory (R / R) B cell malignancy who has received at least 2 prior lines of therapy and for whom no other therapies are known to provide clinical benefit. EXAMPLES

[0433] Methods

[0434] For Fumarate Salt Form A, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Free Base Form A, Free Base Form B, Free Base Form C, and Free Base Form D: XRPD analyses were performed using a Panalytical Empyrean diffractometer equipped with a Cu X-ray tube and a PIXcel 1D-Medipix3 detector system. The samples were analyzed at ambient temperature (of from 15°C to 30°C) in transmission mode on a 48 well plate and held between mylar polymer film. The Almac default XRPD program was used (range 4-40°2θ, step size 0.01313 °, counting time 24 sec, ~6 min run time). Diffraction peaks were detected using the peak picking tool of HighScore Plus v4.9 software and fitted using the “default profile fit” routine of HighScore Plus v4.9 software. A typical variability of ± 0.2 °2θ in peak positions (USP-941) applies to this data. XRPD peak positions were determined using Panalytical X'Pert HighScore Plus software V4.9c with default peak picking and fitting parameters. Peak positions were added for a few small peaks that were not found using the default peak search. Peak positions can be difficult to determine for small intensity peaks, peaks with an unusual profile shape, broad peaks (disorder) or peaks that were poorly resolved.

[0435] Powder samples for XRPD analysis were prepared in a low background silicon holder using light manual pressure to keep the sample surfaces flat and level with the reference surface of the sample holder. Each sample was analysed from 2 to 40 °2θ using a continuous scan of 6 °2θ per minute with an effective step size of 0.02 °2θ.

[0436] For Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, and Free Base Form J: two different instruments were used for characterizing the materials by XRPD. Samples were analysed dry with a Malvern Panalytical Xpert Pro diffractometer, except for Free Base Form F. Free Base Form F was analysed using a Malvern Panalytical Empyrean diffractometer. Free Base Form F was characterised by XRPD as it was a wet sample, which converted on drying at ambient conditions (including a temperature of from 15°C to 30°C) to Free Base Form J. 83 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0437] XRPD patterns of Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, and Free Base Form J were collected with a Malvern Panalytical Xpert Pro diffractometer equipped with a Cu X-ray tube and a PIXcel detector system. The isothermal samples were analysed in transmission mode and held on low density PVC films. The Almac default program was used (range 3-40°2θ, step size 0.013°, counting time 99 seconds, about 22 minutes runtime.

[0438] XRPD patterns of Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, and Free Base Form J were collected with a Malvern Panalytical Empyrean diffractometer equipped with a Cu X-ray tube as described previously, and a Malvern Panalytical PIXcel1Ddetector with Medipix3. Powder samples for XRPD analysis were analysed at ambient temperature in transmission mode on a 96 well plate and held on mylar polymer film. The default XRPD program was used (range 4-40°2θ, step size 0.01313°, counting time 24 sec, ~5 min run time).

[0439] Diffraction peaks were detected using the peak picking tool of HighScore Plus v4.9 software and fitted using the “default profile fit” routine of HighScore Plus v4.9 software. A typical variability of ± 0.1°2θ in peak positions (USP-941) applies to this data for Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, and Free Base Form J.

[0440] For Fumarate Salt Amorphous Form and Free Base Amorphous Form: X-ray powder diffraction (XRPD) patterns were collected with were collected with a Malvern Panalytical Empyrean diffractometer equipped with a Cu X-ray tube as described previously, and a Malvern Panalytical PIXcel1Ddetector with Medipix3. The samples for XRPD analysis were analysed at ambient temperature in transmission mode on a 48 well plate and held on mylar polymer film. The default XRPD program was used (range 4-40°2θ, step size 0.01313°, counting time 24 sec, ~5 min run time).

[0441] For Fumarate Salt Form A, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Free Base Form A, Free Base Form B, Free Base Form C, and Free Base Form D: differential scanning calorimetry (DSC) analyses were performed using a TA Instruments Q2500 Discovery Series instrument. The instrument temperature calibration was performed using indium. The DSC cell was kept under a nitrogen purge of ~50 mL per minute during each analysis. The sample was placed in a standard, crimped, aluminum pan and was heated from approximately 25°C to 350°C at a rate of 10 °C per minute. 84 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0442] For Fumarate Salt Form A, Maleate Salt Form A, Tosylate Salt Form A, Tosylate Salt Form B, Free Base Form A, Free Base Form B, Free Base Form C, and Free Base Form D: thermogravimetric analysis (TGA) was performed using a TA Instruments Q5500 Discovery Series instrument. The instrument balance was calibrated using class M weights and the temperature calibration was performed using alumel. The nitrogen purge was ~40 mL per minute at the balance and ~60 mL per minute at the furnace. Each sample was placed into a pre-tared platinum pan and heated from approximately 25°C to 350°C at a rate of 10°C per minute.

[0443] For Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, and Free Base Form J: Thermogravimetric analyses were carried out on a Mettler Toledo TGA / DSC1 STARe. Samples were placed in an aluminium sample pan, accurately weighed and pin hole lid crimped into position before inserting into the TG furnace. Under a stream of nitrogen at a rate of 10 °C / minute, the heat flow signal was stabilised for one minute at 30 °C, prior to heating to 300 °C. DTA signal is calibrated against indium and zinc standards..

[0444] For Fumarate Salt Amorphous Form and Free Base Amorphous Form: thermogravimetric analysis and differential thermal analysis (TGA / DTA) was performed using a Mettler Toledo TGA / DSC1 STARe. Samples were placed on an aluminum sample pan, accurately weighed as previously described in the preceding paragraph, and inserted into the TG furnace. Under a stream of nitrogen at a rate of 10°C / minute, the heat flow signal was stabilized for 1 minute at 30°C, prior to heating to 300°C. The DTA signal was calibrated against indium and zinc standards.

[0445] For Fumarate Salt Amorphous Form and Free Base Amorphous Form: differential scanning calorimetry (DSC) analyses were performed using a Perkin Elmer DSC8500. The samples were accurately weighed and were placed in aluminium pans, covered with lid, and crimped (closed but not gas tight). Each sample was heated under nitrogen at a rate of 10°C / minute to a maximum of 240°C for Fumarate Salt Amorphous Form and 300°C for Free Base Amorphous Form. Indium and Zinc metals were used as the calibration standard. Temperatures were reported at the transition onset to the nearest 0.01 degree.

[0446] In one or more examples, Karl Fischer titrations (water content analyses) for Free base(s) were carried out using a Mettler Toledo model D03080 drying oven interfaced to a Mettler-Toledo C20 Coulometric KF titrator. The titrator was equipped a DM143-SC sensor and filled with 85 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT HYDRANAL®-Coulomat AD fritless methanol solution. The oven and titrator were calibrated using Apura®Water Standard Oven 1%. For each measurement, the sample was accurately weighed into an aluminum weigh boat and placed into the oven. The sample was titrated using a maximum starting drift of 25 µg / min, a 120 second mix time, and a 35% stirring speed. The oven was purged with nitrogen at a flow rate of 40 mL / min and the temperature was set to 150°C. Duplicate analyses were performed per sample.

[0447] In another one or more examples, Karl Fischer titrations (water content analysis) for fumarate salt(s) (e.g., Fumarate Salt Form A) were carried out using a Mettler-Toledo C20 Coulometric KF titrator. The instrument was calibrated using a Hydranal water standard containing 1% water. The titrant was a Hydranal methanol solution.

[0448] For Fumarate Salt Form A, Dynamic vapor sorption (DVS) analysis was carried out using a TA Instruments Q5000 Dynamic Vapor Sorption analyser. The instrument was calibrated with standard weights and a sodium bromide standard for humidity. Approximately 10-25 mg of sample was loaded into a metal coated quartz pan for analysis. The sample was analysed at 25°C with a maximum equilibration time of one hour in 10% relative humidity (RH) steps from 5 to 95% RH (adsorption cycle) and from 95 to 5% RH (desorption cycle). The movement from one step to the next occurred either after satisfying the equilibrium criterion of 0.01% weight change, or when the equilibrium criterion was not met after one hour. The percent weight change values were then calculated.

[0449] For Fumarate Salt Amorphous Form and Free Base Amorphous Form: Dynamic Vapour Sorption (DVS) was performed using a SMS DVS Intrinsic Vapour Sorption Balance. Approximately 19.75 mg of Free Base Amorphous Form and 15.47 mg of Fumarate Salt Amorphous Form, respectively, were placed into an aluminium balance pan, loaded into the vapour sorption balance and held at 25°C ± 0.1°C. The sample was subjected to a step profile in 10% increments from 40-90% relative humidity (RH), followed by desorption from 90-0%RH and a second sorption cycle from 0-90%RH, a second desorption from 90-0% and finished by a last sorption step from 0-40% relative humidity (RH). The equilibrium criterion was set as ∂m / ∂t = 0.002% / min with a minimum of 60 minutes and a maximum of 5 hours for each increment. The weight change during the sorption cycle was monitored, allowing for the hygroscopic nature of the sample to be determined. The data collection interval was in seconds. 86 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0450] Optical microscopy samples were observed under a Leica DM 2500 P compound microscope. Images were captured using a QImaging MicroPublisher 3.3 RTV camera. Images were collected at 10× magnification.

[0451] The1H NMR spectra were acquired on a Bruker Avance II 400 MHz or 500 MHzspectrometer. Sampleswere prepared by dissolving material in DMSO-d6. The solutions were filtered and placed into individual 5 mm NMR tubes for subsequent spectral acquisition. The temperature controlled (295 K)1H NMR spectra were acquired on the Bruker Avance II 400 utilized a 5 mm cryoprobe operating at an observing frequency of 400.18 MHz.

[0452] Fourier transform infrared spectroscopy (FT-IR) analyses were performed on a Nicolet 6700 FT-IR system. Samples were analysed using a Nicolet SMART iTR attenuated total reflectance device.

[0453] Fourier transform Raman spectroscopy were performed on a Nicolet model 6700 spectrometer interfaced to a Nexus Raman accessory module. This instrument isconfigured witha Nd:YAG laser operating at 1024 nm, a CaF2 beamsplitter, and an indiumgallium arsenidedetector. OMNIC 8.1 software was used for control of data acquisition and processing of the spectra. Samples were packed into a 3-inch glass NMR tube for analysis.

[0454] Example 1: Free base compound of Formula (I), starting material characterization and studies

[0455] Polymorph screening of compounds of Formula (I) were conducted. Compounds in these studies included four polymorphic salt forms of compounds of Formula (I): fumarate, maleate, and two tosylate salts. Compounds in these studies also included four polymorphic free bases of compounds of Formula (I): Free Base Forms A, B, C, and D.

[0456] The free base compound of Formula (I) was used as a starting material. The compound of Formula (I) (MW 806.973 g / mol) is a chimeric targeting molecule that has two ligands connected by a linker. The pKa (base) of the free base compound of Formula (I) is about 6.5; permeability is 2.3 / 16.3 or 9.6 / 6.2 (with and without Aloe vera, respectively), and kinetic solubility at pH 7.4 is 10 µM.

[0457] Solubilities of the compound of Formula (I), free base, in a few solvents were estimated. The experiments were carried out by adding the test solvent in aliquots to weighed portions of 87 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT solid. Whether dissolution had occurred was judged by visual inspection after addition of each solvent aliquot. The results are shown in Tables 1 and 2. Solubility numbers were calculated by dividing the weight of the sample by total amount of solvent used to dissolve the sample. The actual solubilities may be greater than the numbers calculated because of the use of solvent aliquots that were too large or because of slow dissolution rates. The solubility number is expressed as “less than” if dissolution did not occur during the experiment. The solubility number is expressed as “greater than or equal to” if dissolution occurred on addition of the first solvent aliquot. Table 1. Solubilities of Compounds of Formula (I), free base, in selected solvents Solvent Solubility (mg / mL)Table 2. Solubilities and water activity of compounds of Formula (I), free base, in aqueous binary mixtures Solvent mixture Water activity, awSolubility (mg / mL)88 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Solvent mixture Water activity, awSolubility (mg / mL) 14-dioxane / H2O (60 / 40) 10 2 at 60°C

[0458] 2: Salt screening

[0459] The free base compound of Formula (I) was mixed with different acids (counterions) under various conditions to generate crystalline salts. Samples generated and analysed are listed in Table 3. Experiments were performed using 1 mol. equivalent of acid, except sulfuric (0.5 mol eq.). Table 3. Samples generated and analysed Base Conditions XRPD pattern89 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Base Conditions XRPD pattern l DCM 15°C t lli k b d [two non-crystalline or low crystalline salts were identified: two tosylate salt forms. Poorly crystalline material was obtained from experiments involving p-toluenesulfonic acid. Overlay plots of the XRPD patterns are shown in FIGS.1 and 2.

[0461] All samples having a unique XRPD pattern were characterized further. The results are summarized in Table 4. 90 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Table 4. Characterization of unique phases Salt Test Results a. b.. overnight in the given solvent. The slurry was then centrifuged, mother liquor decanted, and the solids allowed to air dry

[0462] Example 3: Scale up of fumarate salt (Fumarate Salt Form A)

[0463] The fumarate salt (Fumarate Salt Form A) was made at a larger scale for further characterization. The experiments are summarized in Table 5. Table 5. Scale up of fumarate salt (Fumarate Salt Form A) Experimental Details XRPD Results91 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Experimental Details XRPD Results d b filt ti ty [ andwas characterized. The data is summarized in Table 6. The thermal data was consistent with the previous lot (small scale) of fumarate salt (Fumarate Salt Form A) that was characterized, showing a weight loss of 1.7% below 125°C followed by melting around 240°C. The weight loss in the TGA suggests the material is solvated, and approximately 0.5 moles of water were observed by Karl Fischer analysis. This suggests that the fumarate salt (Fumarate Salt Form A) may be a hydrate. The fumarate salt (Fumarate Salt Form A) was moderately hygroscopic, showing a weight gain of approximately 4% up to 95% RH. The absorbed water was lost on the desorption step and the resulting material was unchanged by XRPD. Table 6. Characterization of fumarate salt (Fumarate Salt Form A) Test Results

[0465] ExamForm A)

[0466] A polymorph screen of the compound of Formula (I) as a fumarate salt was conducted. The fumarate salt (Fumarate Salt Form A) polymorph screen experiments used wet solvents (class 2 or 3 solvents, e.g., wet DCM, wet EtOAc), and aqueous binary systems with high water activities (aw). Fumarate Salt Form A was prepared at approximately 800 mg scale and characterized by DSC, TGA, Karl Fisher, DVS analysis, FT-IR, Raman, and1H NMR. 92 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0467] The free base compound of Formula (I) was combined with fumaric acid under various conditions to generate a crystalline fumarate salt (Fumarate Salt Form A). Samples generated and analysed from this polymorph screening via salt formation in situ are listed in Table 7. Table 7. Samples generated and analysed (Fumarate Salt Form A) Method Solvent Conditions XRPD Pattern93 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Method Solvent Conditions XRPD Pattern 8°C slurr 5hrTable 7, continued. Samples generated and analysed (Fumarate Salt Form A) Method Solvent Conditions XRPD Pattern94 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Method Solvent Conditions XRPD Pattern

[0468] The “Form A” or “A” (or Fumarate Salt Form A) designation regarding XRPD pattern of Fumarate Salt Form A is used herein to describe XRPD patterns that exhibited a higher degree of crystallinity; “low crystallinity” was used to describe XRPD patterns showing a higher degree of disorder. Form A (higher crystallinity) in these studies also exhibited crystalline disorder by XRPD, as evident by some diffuse scattering (amorphous halo) and peak broadening at higher 95 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT angles (top pattern, FIG.31). XRPD patterns showing a varying degree of crystallinity in Form A are compared in an overlay plot (FIG.31).

[0469] Initial polymorph screening was conducted by salt formation in situ (Table 7). The fumarate salt (Fumarate Salt Form A) was found to be soluble in aqueous solvents with high water activities; however, oily or glassy materials resulted from evaporation or cooling in those solvent systems. A crystalline fumarate salt (Fumarate Salt Form A) was obtained by slurry in various organic solvents and aqueous solvent systems (Table 7). A higher crystallinity Fumarate Salt Form A was obtained in wet EtOAc and solvent systems with high water activities (Table 7).

[0470] Based on XRPD analysis, crystalline Fumarate Salt Form A appeared to be stable upon preparing a slurry in aqueous binary mixtures with high water activities (50°C for 1 week). The slurries in non-aqueous and some of the low water activity solvents (e.g., dioxane / water 95:5, aw0.4) resulted in disordered / low crystalline materials.

[0471] Fumarate Salt Form A (crystalline compound of Formula (I), fumarate salt) was prepared by obtaining a slurry of the free base and fumaric acid in 90:10 acetone / water, at approximately 45°C. A detailed procedure to prepare the salt at approximately 800-mg scale is described herein.

[0472] Initial physical stability evaluation of Fumarate Salt Form A was conducted at various relative humidity conditions and room temperature for approximately 1 week. While no changes were observed by XPRD analysis, the water content in the samples varied from approximately 0.6 moles at 0% relative humidity (RH) to 2.1 moles at 97% RH. The water content was found to be unchanged in the relative humidity range from 40 to 75%RH. This observation was consistent with a lower water uptake observed for that RH range by DVS analysis (FIG.38).

[0473] Solubilities of Fumarate Salt Form A are shown in Tables 8 and 9, in selected solvents and aqueous binary mixtures. Table 8. Solubilities of Fumarate Salt Form A in selected solvents Solvent Solubility (mg / mL)96 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Solvent Solubility (mg / mL) 14-dioxane 1 at 60°C Table 9. Solubiliti resSolvent mixture Water activity, awSolubility (mg / mL)

[00474] Regarding the use of crystalline Fumarate Salt Form A in polymorph screens, crystalline Fumarate Salt Form A as a starting material was mixed with different solvents under various conditions in attempts to generate polymorphs. Samples generated and analyzed are listed in Table 10. Table 10. Samples Generated and analysed: Fumarate Salt Form A as starting material Method Solvent Conditions XRPD Pattern97 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Method Solvent Conditions XRPD Pattern d d [0reens, a non-crystalline Fumarate Salt Form A was generated by freeze-drying a solution in 60:40 dioxane / water (Table 7). The non-crystalline fumarate salt (Fumarate Salt Form A) remained unchanged by XRPD analysis at 40°C / 75%RH for 2 days. The non-crystalline Fumarate Salt Form A was used as starting material in additional polymorph screen experiments shown in Table 11. Samples generated and analyzed are listed in Table 11. Higher crystallinity Fumarate Salt Form A was obtained by stressing the non-crystalline material under acetone / water 90:10 and wet EtOAc vapor, i.e., higher water activity conditions. Table 11. Samples generated and analysed: non-crystalline material with Fumarate Salt Form A as starting material Method Solvent Conditions XRPD Pattern98 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Method Solvent Conditions XRPD Pattern °

[0476] In sum, polymorph screens showed that Fumarate Salt Form A exhibited a varying degree of crystallinity, and non-crystalline materials were observed in the polymorph screen. 99 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0477] Characterization of compound of Formula (I), fumarate salt (Fumarate Salt Form A) The compound of Formula (I), fumarate salt (Fumarate Salt Form A), was prepared at approximately 800-mg scale by elevated temperature slurry (45°C) in acetone / water (9:1) (Table 12). The material was characterized by various analytical techniques as summarized in Table 13. Table 12. Preparation of compounds of Formula (I), fumarate salt (Fumarate Salt Form A) Method Solvent Conditions XRPD Pattern Tabl SaltForm A) Salt Analysis Results100 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Salt Analysis Results Consistent with 1:1 salt trace acetone [0047 with some disorder and was consistent with Fumarate Salt Form A observed in the polymorph screen study and a previously conducted salt screen. The proton NMR (1H NMR) spectrum confirmed a 1:1 salt stoichiometry with a trace amount of acetone present (0.04 moles). Fumarate Salt Form A exhibited some peak shifting (XRPD) at higher angles after 2-day vacuum drying, as shown in FIG.33, likely indicating variable solvent content.

[0479] By thermal analysis, Fumarate Salt Form A showed initial dissolving / dehydrating based on a small, broad endotherm at approximately 47°C; the corresponding weight loss in TGA (approximately 1.7%) was consistent with the water content found by Karl Fischer analysis (1.5%). An additional weight loss of approximately 0.5% was observed in the range between 100 to 200°C. A probable melt (sharp, intense endotherm) was observed at approximately 244°C, immediately followed by decomposition.

[0480] By DVS analysis, the fumarate salt (Fumarate Salt Form A) was moderately hygroscopic and exhibited approximately 3% water uptake between 5-95% RH. Approximately 1% of water (or one third of the total uptake) was absorbed over each of the following relative humidity ranges: 5 to 35%; 35 to 85%; and 85 to 95% RH. The desorption curve showed a continuous weight loss from 95 to 5% RH; all of the absorbed water was lost during desorption. A hysteresis was not observed, indicating no stable hydrate was formed; however, based on continuous sorption / desorption, a variable hydrate system is possible. The XRPD pattern of post- DVS material was consistent with Fumarate Salt Form A exhibiting some peak shifting at higher angles (degrees 2Theta or °2θ).

[0481] FT-IR and Raman spectra of the fumarate salt (Fumarate Salt Form A) are included in FIGS.5 and 6, respectively.

[0482] Initial physical stability evaluation of compound of Formula (I), fumarate salt (Fumarate Salt Form A)

[0483] For initial physical stability evaluation, Fumarate Salt Form A was stored at various relative humidity conditions and room temperature for approximately 1 week (Table 14). 101 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Subsamples of Fumarate Salt Form A (approximately 90 mg) were weighed and placed inside relative humidity (RH) jars; after 1 week the samples were analyzed by XRPD and Karl Fisher analysis; the results are summarized in Table 14. Table 14. Physical stability of compound of Formula (I), fumarate salt (Fumarate Salt Form A) Starting Form Conditions XRPD Result* KF-Oven %Water (moles) [00 own inTables 15 and 16, in selected solvents and aqueous binary mixtures. Table 15. Solubilities of Fumarate Salt Form A in selected solvents Solvent Solubility (mg / mL)102 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Table 16. Solubilities of Fumarate Salt Form A in aqueous binary mixtures Solvent mixture Water activity, aw Solubility (mg / mL) acetone / H2O (70 / 30) 085 6a[004, erial and samples after stressing at various relative humidities (FIG.36). XRPD data in these studies were acquired at approximately 26-30% RH (laboratory RH).

[0486] Based on Karl Fisher data, the water content varied from approximately 0.6 moles at 0%RH to 2.1 moles at 97%RH; some of which may be due to surface water. In the relative humidity range from 40-75%RH, the water content was found to be unchanged (approximately 0.9 moles). This observation was consistent with a lower water uptake (approximately 0.5%) observed for that RH range by DVS analysis.

[0487] In sum, the polymorph screen revealed that Fumarate Salt Form A may have a varying degree of crystallinity depending on how it (the polymorph, etc.) is prepared, from non-crystalline to highly crystalline.

[0488] Acid selection

[0489] At least 11 different acids were used in the salt screen (Table 17). Table 17. Acids (counterions) used in salt screen Acid MW (g / mol) pKa Stahl Class103 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Acid MW (g / mol) pKa Stahl Class h h i 98 196 1

[0490] and D)

[0491] These studies characterized the compound of Formula (I) free base (starting material), and screened and characterized polymorphs of the free base compound of Formula (I).

[0492] Characterization data of the free base of the compound of Formula (I) are previously described. The free base compound of Formula (I) starting material was the same free base used in the, e.g., fumarate salt screen. The free base compound of Formula (I) was crystalline, although the XRPD pattern exhibited some disorder. The TGA results showed a 3.5% weight loss which corresponds to 1.6 moles of water; so, the free base compound of Formula (I) starting material may be a hydrate. No organic solvents were observed in the1HNMR. The free base compound of Formula (I) starting material was moderately hygroscopic, exhibiting a weight gain of approximately 7% up to 95% relative humidity (DVS). The water absorbed during the experiment was lost on the desorption test, and the resulting material was unchanged by XRPD. DSC displayed the following thermograms: Endo 63.7, 99.9, 213.0, and 231.4°C.

[0493] Polymorph screening

[0494] The free base compound of Formula (I) was mixed with solvents under various conditions in attempts to generate crystalline material. Samples generated and analysed are listed in Table 18. Table 18. Samples generated and analysed (free base of compound of Formula (I)) Method Solvent Conditions XRPD Pattern104 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Method Solvent Conditions XRPD Pattern ° °Formula (I)) Method Solvent Conditions XRPD Pattern105 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Method Solvent Conditions XRPD Pattern F B F A106 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Table 18, continued. Samples generated and analysed (free base of compound of Formula (I)) Method Solvent Conditions XRPD Pattern [0 orms“A”, “B”, “C”, and “D”. An overlay plot of the XRPD patterns is shown in FIG. 10. Free Base Form A was the form most often seen in the screen. Free Base Form D was obtained as disordered (poorly crystalline) material.

[0496] The new forms were characterized by DSC and TGA. The results are summarized in Table 19. Table 19. Characterization of Free Base Forms B, C, and D Free Base Form Test Resultthe specified temperature and held at that temperature for approximately 1 minute. The material was then recovered from the TGA and analyzed by XRPD. The results are summarized in Table 20. Table 20. Heat stress of Free Base Forms A, B, C, and D Free Base Form Test Result107 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Free Base Form Test Result Free Base Form A

[0498] Synthetic Example A. Synthesis of compound of Formula (I) (starting material, free form, or free base compound of Formula (I)) Scheme A1. Synthetic step A1Table A1. Material usage, step A1Compound MW Amount Equiv.

[0499] Step A1 was performed in a reaction kettle, 44.0 L of DMF was added at 20°C. Compound A (13.0 kg, 1.73 equiv., TFA) was added at 25°C. The mixture was cooled to 0°C. 108 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT DIEA (22.0 L, 5.00 equiv.) was added drop-wise at 0~5°C over approximately 1 hr. The mixture was stirred at 0°C for 0.5 hr. Compound B (4.40 kg, 1.00 equiv.) in dimethyl formamide (10.0 L) was added drop-wise over approximately 1 hr. The mixture was heated to 15°C and stirred for 1.5 hrs. TLC showed that compound B was consumed.

[0500] The mixture was poured into saturated NH4Cl solution, extracted with ethyl acetate, the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to give crude product C.

[0501] Ethyl acetate was added to crude product C (16.2 kg, 1.00 equiv.), heated to 80°C and stirred for 1 hr. Petroleum ether (20.0 L) was added to the mixture and stirred at 80°C for 0.5 hr, then cooled to 25°C and stirred for 8 hrs. The mixture was filtered. The filter cake was dried under vacuum to give the crude product C (10.5 kg, 1.00 equiv.).

[0502] A mixture of crude product C (10.3 kg, 1.00 equiv.) in dimethyl formamide (3.50 L) was stirred at 70°C. After dissolved clarification, to the mixture was added methyl tert-butyl ether (21.0 L) slowly at 70°C. The mixture was cooled to 25°C and stirred for 12 hrs. The mixture was filtered to give a crude product. The crude product was purified by triturated with methyl tert-butyl ether (40.0 L) at 50°C for 1 hr. After cooling to 25°C, the mixture was filtered. The filter cake was dried by vacuum drier to give the product C (7.84 kg).

[0503] Characterization of product C from Step A1. LCMS: Rt = 1.909 min, m / z = 321.1 (M+H)+. HPLC: Rt = 7.807 mins, under 220 nm.1H NMR: (400 MHz, CDCl3) δ 8.06 (s, 1H), 4.40 (s, 2H), 3.80 - 3.73 (m, 1H), 3.42 - 3.30 (m, 4H), 3.18 - 3.12 (m, 1H), 3.02 - 2.95 (m, 1H), 2.81 (s, 3H), 2.05 - 1.92 (m, 2H), 1.84 - 1.75 (m, 1H), 1.72 -1.64 (m, 1H). 109 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Scheme A2. Synthetic step A2 TableCompound MW Amount Equiv. C 320.78 19.5 kg 1.0

[0504] For step A2, A reactor was prepared as follows. Nitrogen was charged into a reactor, then 2-MeTHF (179 kg) was charged into the reactor via SS charging device, with SS diaphragm pump. Refluxed at 70-90°C for 1 to 3 h. Lowered temperature to 20-40°C. Removed material from reactor, vacuumed and charged reactor with nitrogen.

[0505] The materials were charged as follows.2-MeTHF (138 kg) was charged via a charging device. Compound C (19.5 kg), Compound C-1 (16.9 kg), and K2CO3 were charged (16.8 kg) into the reactor via a flexible isolator. The reactor was purged / charged with vacuum and nitrogen. Next, 2-MeTHF (54 kg) was charged into the reactor via charging device (SS diaphragm pump and spray ball). The reactor temperature was adjusted to 15-25°C under nitrogen; bubbling with nitrogen continued for 0.5 to 1 hr. Palladium (II) acetate (0.149 kg) and BINAP (0.38 kg) were charged into the reactor. The reactor was purged and charged again with 2-MeTHF (38 kg). The reactor was purged / charged with vacuum and nitrogen and temperature was adjusted to 15-25°C under 110 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT nitrogen. Next, the reaction was stirred in the reactor at 20-25°C for 0.5-1.0 h under nitrogen; the temperature was raised to 40-60°C, and then 70-80°C and held at this temperature while stirred for 12-16 h under nitrogen. The reactor temperature was adjusted to 35 to 45°C under nitrogen. An aliquot was removed and tested; the reaction was deemed complete.

[0506] To workup, the reactor temperature was lowered to 20-30°C over 1.5 hours and then charged with water (104 kg) in portions over 1 hr via peristaltic pump under nitrogen, then stirred for 1-2 hours. Next, MTBE (145 kg) was charged into the reactor in portions over 0.5 to 1 hr at 20-30°C, and stirred for 1-2 hours under nitrogen at the same temperature. An aliquot was removed, and the residual crude D was confirmed to be present. To isolate compound D, the crude product was transferred to a centrifuge bag in portions, centrifuged, and then dried overnight under vacuum at 45-55°C to obtain compound D (17.90 kg). Scheme A3. Synthetic step A3Compound MW Amount Equiv. D 7 22 k 1

[0507] For step A3, the reactor was prepared by charging EtOH (60 kg), heated, distilled, refluxed, cleared, and charged with nitrogen and purged. Next, compound D (22.8 kg), DMSO (50 kg), and EtOH (108 kg) were charged into a reactor, adjusted to 20-30°C under nitrogen. NaOH (3.45 kg) was charged, and the mixture was stirred for 1 hr. Temperature was adjusted to 40°C for 1 hr, 50°C for 1 hr, 60°C for 1 hr, and 70°C for 6-8 hrs. Next, the temperature was 111 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT adjusted to 45-50°C to remove a sample for testing, and back to 70°C for 2-5 hours. This process was repeated until the reaction was found to be complete.

[0508] For workup, water (183 kg) was charged, and the temperature was lowered to 0-10°C, with stirring for 1 hr. The temperature was adjusted to 20-30°C for 2-6 hours and the contents of the reactor were transferred to centrifuge bags and centrifuged. The material was dried under vacuum for 18-24 hours at 50-60°C to obtain compound E (21.80kg). Scheme A4. Synthetic step A4Compound MW Amount Equiv. E 57872 218 k 10

[0509] For step A4, 3M HCl IPAc solution was prepared by charging IPAc (88 kg) into the reactor, the temperature was adjusted to -10 to 10°C under nitrogen, and then the reactor was scrubbed, and pH was confirmed. HCl gas (12.5 kg) was added to the reactor at -10 to 10°C, and stirred at -10 to 10°C for 10-20 minutes under nitrogen.3M HCl / IPA was obtained (100.1 kg).

[0510] The reactor was purged and charged, then compound E was charged (21.8 kg) into the reactor, followed by nitrogen, then the IPAc (88 kg) was charged to the reactor, and temperature was adjusted to 20-30°C. Next, 3M HCl IPAc (97 kg) was charged in the reactor slowly at 20-30°C under nitrogen, and stirring continue for 3-6 hr. Crude product F was obtained and confirmed by 112 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT analysis. The crude was centrifuged in centrifuge bags, processed, and dried to obtain product F (17.76 kg). Scheme B1: Synthetic step B1 Table B1. MaterialCompound MW Amount Equiv. M N lt 30011 235 k 10

[0511] For step B1, compound M (2350 g, 1.0 equiv.) and DMF (35.2 L) were added to a 50 L jacketed reactor at 15~25 °C under N2protection. DIPEA (2528.5 g, 2.5 equiv.) was added. Cooled to 0~5oC. HATU (4463.4 g, 1.5 equiv.) was added in portions at 0~5oC. Stirred at 0~5oC for an extra 1 h. Compound N (1472.3 g, 0.9 equiv.) was added in portions at 0~5oC over 30 min. 113 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Stirred at 15~25°C for extra 16 h.

[0512] The reaction mixture was poured into KH2PO4 aq. (5325 g, 5 eq., in 94.5 L H2O) at 0~10 ℃ with stirring (pH=6~7). Next, the mixture was stirred at 0~10 °C for extra 1 h, filtered, and the cake washed with H2O (5 L x 3). This was combined with the crude solid from another batch with similar result (2350 g x 1). The batch mixture was added to water (15 L) at 15~20oC for 1 h to form another slurry. The slurry was filtered, and cake was washed with H2O (2 L x 2). The cake was dried under N2 flow for 16 h to obtain 7900 g of Compound O. Purity was confirmed by HPLC, and1H NMR: consistent and clean. B2step B2 Compound MW Amount Equiv.114 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0513] For step B2, compound O (1316 g, 1.0 equiv.) and THF (7.6 L) were added into 50 L jacketed reactor at 25~30oC. DI water (26 L) was added. 3 M aq. HCl (1700 mL; 425 mL 12M aq. HCl+1275 mL DI H2O) was added. The mixture was heated to 50~55oC and stirred for 2 h. The pH was adjusted to 7-8 by addition of K2HPO4(1800 g, 5.26 eq.) portion-wise into the reaction mixture at 15~20oC. Next, DCM / iPrOH (10 / 1, 7.5 L) was added. The mixture was separated, and the aqueous phase was back extracted with DCM / iPrOH (10 / 1, 3.5 L x 2). The organic phase was dried over Na2SO4, filtered, and concentrated via rotary evaporation to afford 676 g of crude product P. These above steps were repeated with the crude to increase conversion.

[0514] 7 batches were combined (about 6 kg); heptane (21.4 L) was added to the final precipitate and stirred at 25~30oC for 1h. After filtering, the filter cake was washed with heptane and dried under air for 24h to obtain 5300 g of product P. LC-MS: [M+H]+=345.5; [M+NH4+H]+=363.5.1HNMR: Consistent and clean (with 0.122 wt% DCM; 0.209 wt% THF; 0.174 wt% iPrOH; heptanes-ND). ROA: -26.859° (1.0133 g / 100 mL, MeCN). Scheme C1. Synthetic step C1, reductive amination to form Free Base Form A (shown as Q in scheme C1)115 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCTCompound MW Amount Equiv. F (amine) 478.60 1.50 kg* (1.58 kg) Limiting reagent * “

[0515] For step C1, a 100 L reactor was charged with DMSO (7.68 kg), DCM (0.98 kg), compound F (amine, 1.58 kg), compound P (aldehyde, 1.30 kg, 1.20 equiv.), and again with DMSO (7.45 kg) and DCM (0.99 kg). The suspension was stirred for 1 h and charged with AcOH (189 g, 1.0 equiv.). Next, the solution was charged with NaBH(OAc)3 (1.66 kg, 2.5 equiv.) in one equal portions at T < 30 ºC. Stirring continued at 15 – 25 ºC for 4 to 24 h. When the product Q was obtained, the wet cake was blown dry under nitrogen for 1 hour, and dried at ambient temperature under vacuum. Product Q (2.35 kg) was confirmed by HPLC.

[0516] Alternatively for step C1, in a round bottom flask, compound F (30.5 g) was charged with dimethylsulfoxide (DMSO, 153 mL, 5 vol), acetic acid (AcOH, 1.9 g, 0.5 eq), and the line was washed with DMSO (3 mL, 0.1 vol). The slurry was stirred for not less than (NLT) 1 hour at 25 °C. A solution of compound P (24.6 g, 1.20 eq) in DMSO (153 mL, 5 vol) was prepared at 25 °C. The solutions were stirred for not less than 1 hour. Visual inspection ensured that the 116 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT mixture was fully dissolved. Compound P was charged in DMSO solution to reaction at 25 °C. The line was washed with DMSO (30 mL, 1 vol). The slurry was stirred for 1 hour at 25 °C. A solution of sodium triacetoxyborohydride (STAB, 20.2 g, 1.5 eq) in DMSO (183 mL, 6 vol) was prepared at 25 °C. The solution was stirred for not less than 10 minutes. The sodium triacetoxyborohydride was fully solubilized in DMSO solution, and was charged to the reaction mixture at 20-30 °C. The line was washed with DMSO (91 mL, 3 vol). The slurry was stirred for not less than 12 hours at 25 °C.

[0517] In a second reactor, water (426 mL, 14 V) and THF (61 mL, 2 vol) were charged and the temperature was adjusted to 25 ºC. The reaction mixture was dosed over a water / THF mixture in not less than 1 hour. The internal temperature was controlled at 20-35 C. The line was washed with DMSO (30 mL, 1 vol). The mixture was stirred at 25 ºC for not less than 2 hours, but for not more than 4 hours. Solid crystallization was observed toward the end of the addition or within few minutes from the end of addition; the aging time was required to crystallize the product before pH adjustment.

[0518] The pH was adjusted to 6.5 – 7.0 (or between 6.5 to 7.0) using NaOH (aq. 2N, ~ 1.2 vol) at 25 ºC. The pH was be measured on the supernatant and not on the entire mixture. The mixture was stirred at room temperature for not less than 15 min at 25 ºC and the pH was confirmed in the range of 6.5 – 7.0. The slurry was aged for 2-20 hours at 20 – 25 ºC. The slurry was filtered. The wet cake was washed with a mixture of THF / H2O 1 / 4 (5 vol). The wet cake was washed with a mixture of tetrahydrofuran / water 1 / 4 (5 vol). The wet cake was washed with water (5 vol); and again with water (5 vol). The wet cake was washed with ethanol (5 vol) by reslurry. The wet cake was blown dry under nitrogen and vacuum for not less than 1 hour. The wet cake was dried at 25 ºC under vacuum for not less than 23 hours. Product Q as Free Base Form A was obtained in about 85% molar yield and close to or above 99.0% a / a purity.

[0519] Synthetic Example 1. Synthesis and characterization of Free Base Form A

[0520] The compound of Formula (I) (16.7 mg, free base) was placed into a 20 mL glass vial. A magnetic stir bar was added, and the vial was placed on a hotplate set to 60°C with stirring on. Tetrahydrofuran (2 mL) was slowly added until the solid dissolved. Methyl ethyl ketone (10 mL) was then slowly added until the solution became turbid. The head was turned off and the sample was cooled to room temperature. No solid was observed the next day and an additional 5 mL of 117 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT methyl ethyl ketone was added. Minimal solids were observed after 6 days and the sample was placed in a freezer at -15°C. Minimal solids were observed after 2 days in the freezer and the sample was removed from the freezer, uncapped, and placed in a fume hood to allow the solvent to evaporate. The resulting solid was analysed by XRPD. Scheme 1. Synthesis of Free Base Form A1) add 2 mL tetrahydrofuran (THF) at 60°C, with stirring 2) add 10 mL of methyl ethyl ketone (MEK), at 60°C, with stirring until turbid, cool to room temperature (RT) Free Base Form Await 6 days, place in freezer at -15°C 4) let sit in freezer at -15°C for 2 days, remove from freezer, uncap, place in fume hood to evaporate solvent, analyze with XRPD

[0521] The XRPD pattern of Free Base Form A is shown in FIG. 1. Table 21 is a list of the XRPD peaks for the Free Base Form A. Table 21. Peaks of the XRPD pattern of Free Base Form A ˚2θ d value (or d space, Å) Intensity (%) 4.96 ± 0.20 17.8158 74.5236 7.44 ± 0.20 11.8818 22.7838 9.42 ± 0.20 9.3883 13.4217 9.92 ± 0.20 8.9162 24.9793 11.42 ± 0.20 7.7483 13.3941 118 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 12.42 ± 0.20 7.1266 14.1259 14.00 ± 0.20 6.3256 41.3146 14.26 ± 0.20 6.2109 84.2999 14.86 ± 0.20 5.9614 21.7758 15.86 ± 0.20 5.5877 59.8730 16.24 ± 0.20 5.4578 31.8835 17.00 ± 0.20 5.2155 38.0006 18.04 ± 0.20 4.9171 36.8268 18.90 ± 0.20 4.6953 55.3714 19.98 ± 0.20 4.4438 100.0000 20.82 ± 0.20 4.2664 33.2643 22.12 ± 0.20 4.0185 55.4681 23.06 ± 0.20 3.8568 29.3289 23.68 ± 0.20 3.7572 41.0108 25.00 ± 0.20 3.5617 56.0204 26.36 ± 0.20 3.3810 15.3549 27.32 ± 0.20 3.2643 17.2880 28.50 ± 0.20 3.1318 17.3847 30.06 ± 0.20 2.9727 14.3331 31.88 ± 0.20 2.8070 12.6208 32.32 ± 0.20 2.7698 10.2458

[0522] The thermograms for Free Base Form A are provided in FIG.2. The TGA (right side y-axis) showed 3.455% weight loss up to 75°C. As shown in FIG.2 (left side y-axis), four DSC endotherms in the TGA exhibited peak maxima of 63.73°C, 99.88°C, 212.98°C, and 231.37°C.

[0523] A DVS analysis of Free Base Form A is shown in FIG.3.

[0524] Synthetic Example 2. Synthesis and characterization of Free Base Amorphous Form

[0525] Free Base Amorphous Form was prepared by melt / quench of Free Base Form A (a compound of Formula (I)) (25-50 mg). An amber glass sample vial was flushed with nitrogen, and Free Base Form A was weighted into the vial. The vial was placed on a hot plate and heated to 260°C. After 45-60 seconds, when the material appeared fully molten, the vial was removed from the hot plate and quenched in liquid nitrogen. The material obtained was a light brown solid (glassy appearance). The resulting solid was analysed by XRPD analysis,1H NMR spectroscopy, and TGA-DSC, and DVS analysis. 119 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0526] Scheme 2. Synthesis of Free Base Amorphous Form 1) obtain 20 to 50 mg of Free Base Form A 2) heat to 260°C to obtain a melt Free Base Amorphous Formquench the melt in liquid nitrogen, analyze with XRPD

[0527] The XRPD pattern of Free Base Amorphous Form is shown in FIG. 4. Free Base Amorphous Form was analysed by XRPD and was shown to be amorphous, with an XRPD pattern as expected from an amorphous solid (FIG.4).

[0528] The1H NMR spectrum (500 MHz, DMSO-d6) of Free Base Amorphous Form is shown in FIG.5. Analysis by1H-NMR spectroscopy (FIG.5) conformed to the molecular structure with no degradation observed.

[0529] The thermograms for Free Base Amorphous Form are provided in FIG. 6. The TGA (right side y-axis) showed 0.5% weight loss between 36°C and 184°C. As shown in FIG.6 (left side y-axis), a DTA endotherm in the TGA exhibited peak onset at 145.17°C (in the DTA signal).

[0530] The DSC thermogram for Free Base Amorphous Form is provided in FIG.7. The DSC thermogram (FIG.7) concurred with the thermal behaviour seen by TGA / DTA with an initial broad endotherm between 30 and 100°C likely due to dehydration, which was followed by a possible glass transition at 148.15°C.

[0531] Free Base Amorphous Form was physically stable to stressing at 40°C / 75% relative humidity (RH) for 7 days (FIG.8, top), and to the DVS cycling experiment (FIG.8, bottom). DVS showed that Free Base Amorphous Form was hygroscopic with an average weight gain between 40-80% relative humidity (RH) of 3.2% (FIG.9).

[0532] Synthetic Example 3. Synthesis and characterization of Free Base Form B

[0533] The compound of Formula (I) (20.0 mg, Free Base Form A) was placed into a 1-dram glass vial and of dimethyl sulfoxide (0.5 mL) was added. A magnetic stir bar was added, and the vial was placed on a stir plate at room temperature with stirring turned on. The slurry was stirred 120 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT for 7 days at room temperature. The vial was centrifuged, the mother liquor was decanted, and the solid was air dried at room temperature. The resulting solid was analysed by XRPD analysis. Scheme 3. Synthesis of Free Base Form B1) add 0.5 mL of dimethylsulfoxide (DMSO), stir at RT for 7 days Free Base Form B 2) decant motheranalyze with XRPD

[0534] The XRPD pattern of Free Base Form B is shown in FIG.11. Table 22 is a list of the XRPD peaks for the Free Base Form B. Table 22. Peaks of the XRPD pattern of Free Base Form B ˚2θ d value (or d space, Å) Intensity (%) 3.76 ± 0.20 23.4985 39.1387 7.48 ± 0.20 11.8184 29.6874 10.20 ± 0.20 8.6721 34.1923 10.70 ± 0.20 8.2680 10.4604 11.18 ± 0.20 7.9140 11.5055 11.46 ± 0.20 7.7213 11.4695 12.50 ± 0.20 7.0811 9.5684 13.68 ± 0.20 6.4729 24.3626 14.92 ± 0.20 5.9376 27.4980 15.80 ± 0.20 5.6088 47.8782 16.04 ± 0.20 5.5254 45.9231 16.14 ± 0.20 5.4914 46.0492 16.46 ± 0.20 5.3854 97.3331 16.98 ± 0.20 5.2216 32.8498 17.38 ± 0.20 5.1023 21.5064 121 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 17.70 ± 0.20 5.0108 31.0569 17.98 ± 0.20 4.9334 68.1413 18.28 ± 0.20 4.8531 41.3821 18.56 ± 0.20 4.7805 28.9035 19.30 ± 0.20 4.5988 12.9471 19.58 ± 0.20 4.5337 31.4353 20.10 ± 0.20 4.4176 39.6973 20.44 ± 0.20 4.3449 39.3459 20.82 ± 0.20 4.2664 17.7674 21.22 ± 0.20 4.1869 86.8186 21.42 ± 0.20 4.1482 34.5166 21.70 ± 0.20 4.0953 100.0000 21.96 ± 0.20 4.0474 53.9148 22.18 ± 0.20 4.0078 35.5618 22.42 ± 0.20 3.9654 20.6145 22.92 ± 0.20 3.8800 96.8376 23.78 ± 0.20 3.7416 21.6686 24.00 ± 0.20 3.7078 16.1636 24.46 ± 0.20 3.6391 57.1493 24.70 ± 0.20 3.6043 54.4554 25.08 ± 0.20 3.5506 12.1813 25.36 ± 0.20 3.5120 10.2982 25.78 ± 0.20 3.4557 22.8579 25.94 ± 0.20 3.4348 26.6510 26.38 ± 0.20 3.3785 19.4612 26.94 ± 0.20 3.3095 11.3253 27.50 ± 0.20 3.2434 17.1547 27.68 ± 0.20 3.227 16.4970 28.16 ± 0.20 3.1688 25.1104 29.06 ± 0.20 3.0727 14.6680 29.48 ± 0.20 3.0299 9.9919 30.00 ± 0.20 2.9785 19.5964 30.48 ± 0.20 2.9327 14.7040 30.86 ± 0.20 2.8975 12.8570 31.24 ± 0.20 2.8631 11.6137 31.72 ± 0.20 2.8208 14.3526 32.36 ± 0.20 2.7665 9.9468 33.24 ± 0.20 2.6952 9.7036 33.60 ± 0.20 2.6672 10.2892 34.28 ± 0.20 2.6158 8.2530 34.82 ± 0.20 2.5765 7.4601 35.78 ± 0.20 2.5095 9.7937 36.38 ± 0.20 2.4695 7.6674 36.90 ± 0.20 2.4359 10.0910 38.52 ± 0.20 2.3371 10.0279 39.40 ± 0.20 2.2869 9.9198 122 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0535] The thermograms for Free Base Form B are provided in FIG.12. The TGA (right side y-axis) showed 13.40% weight loss up to 175°C. As shown in FIG.12, three DSC endotherms in the TGA exhibited peak maxima of 123.92°C, 225.75°C, and 236.42°C.

[0536] Synthetic Example 4. Synthesis and characterization of Free Base Form C

[0537] The compound of Formula (I) (16.1 mg, Free Base Form A) was placed into a 1-dram glass vial and N,N-dimethylformamide (0.5 mL) was added. A magnetic stir bar was added, and the vial was placed on a stir plate at room temperature with stirring turned on. The slurry was stirred for 7 days. The vial was centrifuged, the mother liquor was decanted, and the solid was air dried at room temperature. The resulting solid was analysed by XRPD analysis. Scheme 4. Synthesis of Free Base Form C1) add 0.5 mL of N,N-dimethylformamide (DMF), stir at RT for 7 days Free Base Form Canalyze with XRPD

[0538] The XRPD pattern of Free Base Form C is shown in FIG.13. Table 23 is a list of the XRPD peaks for the Free Base Form C. Table 23. Peaks of the XRPD pattern of Free Base Form C ˚2θ d value (or d space, Å) Intensity (%) 3.18 ± 0.20 27.7830 33.4736 5.80 ± 0.20 15.2373 55.5606 123 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 6.40 ± 0.20 13.8101 78.1324 7.30 ± 0.20 12.1094 14.5327 8.40 ± 0.20 10.5259 72.2151 9.44 ± 0.20 9.3685 11.7157 10.96 ± 0.20 8.0724 33.3272 11.18 ± 0.20 7.9140 32.9980 12.30 ± 0.20 7.1958 42.6194 12.76 ± 0.20 6.9374 71.4103 13.68 ± 0.20 6.4729 13.4169 14.54 ± 0.20 6.0919 13.1974 15.18 ± 0.20 5.8365 53.5943 15.72 ± 0.20 5.6372 24.1540 16.16 ± 0.20 5.4847 17.7428 16.76 ± 0.20 5.2896 100.0000 17.06 ± 0.20 5.1973 50.5213 17.34 ± 0.20 5.1140 61.3042 17.98 ± 0.20 4.9334 92.7931 18.44 ± 0.20 4.8113 46.5155 18.82 ± 0.20 4.7150 27.9038 19.68 ± 0.20 4.5109 52.6797 20.02 ± 0.20 4.4350 40.5433 20.58 ± 0.20 4.3156 63.5358 21.16 ± 0.20 4.1986 37.3605 21.76 ± 0.20 4.0842 30.7664 22.46 ± 0.20 3.9584 30.3549 22.80 ± 0.20 3.9002 24.9497 23.28 ± 0.20 3.8208 50.1463 23.64 ± 0.20 3.7635 30.6201 24.20 ± 0.20 3.6776 34.8089 25.16 ± 0.20 3.5394 35.7600 25.48 ± 0.20 3.4957 26.2210 26.20 ± 0.20 3.4013 27.1630 26.46 ± 0.20 3.3684 22.6175 27.34 ± 0.20 3.2620 20.1939 27.98 ± 0.20 3.1888 17.9074 29.18 ± 0.20 3.0603 16.0691 30.40 ± 0.20 2.9402 14.9716 31.48 ± 0.20 2.8418 12.1547 32.06 ± 0.20 2.7917 12.0359 33.30 ± 0.20 2.6905 11.8529 33.70 ± 0.20 2.6595 11.8438 34.56 ± 0.20 2.5953 10.7554 36.84 ± 0.20 2.4397 9.3744 124 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0539] The thermograms for Free Base Form C are provided in FIG.14. The TGA (right side y-axis) showed 11.36% weight loss up to 205°C. As shown in FIG.14 (left side y-axis), two DSC endotherms in the TGA exhibited peak maxima of 63.89°C and 201.97°C.

[0540] Synthetic Example 5. Synthesis and characterization of Free Base Form D

[0541] The compound of Formula (I) (17.8 mg, Free Base Form A) was placed into a 20 mL glass vial and diethyl ether (15 mL) was added. A magnetic stir bar was added, and the vial was placed on a hotplate set to 40°C with stirring turned on. The slurry was stirred for 6 days at 40°C. The vial was centrifuged, the mother liquor was decanted, and the solid was air dried at room temperature. The resulting solid was analysed by XRPD analysis, TGA-DSC, and TGA / DTA.

[0542] Alternatively, Free Base Form D was prepared by temperature cycling Free Base Form A in acetonitrile or tetrahydrofuran. For example, Free Base Form D was prepared by temperature cycling Free Base Form A in acetonitrile between 20-79°C with two cycles of: heating at a rate of 0.5°C / min, and cooling at a rate of 0.2°C / min. Scheme 5. Synthesis of Free Base Form D1) add 15 mL of diethyl ether, stir at 40°C for 6 days Free Base Form Dair dry solid at RT, analyze with XRPD

[0543] The XRPD pattern of Free Base Form D is shown in FIG.15. Table 24 is a list of the XRPD peaks for the Free Base Form D. 125 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Table 24. Peaks of the XRPD pattern of Free Base Form D ˚2θ d value (or d space, Å) Intensity (%) 4.18 ± 0.20 21.1383 100.0000 5.98 ± 0.20 14.7791 20.1933 8.48 ± 0.20 10.4268 27.3173 9.54 ± 0.20 9.2705 19.3988 11.42 ± 0.20 7.7483 23.0800 12.68 ± 0.20 6.9810 16.1149 13.78 ± 0.20 6.4261 15.0821 15.48 ± 0.20 5.7240 24.5233 17.20 ± 0.20 5.1553 58.3289 17.52 ± 0.20 5.0619 53.4560 18.06 ± 0.20 4.9117 42.0816 18.74 ± 0.20 4.7350 38.7050 19.32 ± 0.20 4.5941 52.7145 19.64 ± 0.20 4.5200 55.3099 20.26 ± 0.20 4.3830 27.4894 21.62 ± 0.20 4.1103 32.5344 22.44 ± 0.20 3.9619 22.3252 23.12 ± 0.20 3.8469 19.3194 24.84 ± 0.20 3.5843 46.3586 27.78 ± 0.20 3.2113 26.9597 30.74 ± 0.20 2.9085 10.0636 31.68 ± 0.20 2.8243 10.4608 32.68 ± 0.20 2.7401 9.6266 35.84 ± 0.20 2.5055 9.4544 36.84 ± 0.20 2.4397 9.5339

[0544] The thermograms for Free Base Form D are provided in FIG.16 (TGA-DSC) and FIG. 17 (TGA / DTA). The TGA (right side y-axis) showed 1.944% weight loss up to 80°C. As shown in FIG.16 (left side y-axis), three DSC endotherms in the TGA exhibited peak maxima of 56.73°C, 162.07°C, and 176.92°C. As shown in FIG.17, the TGA (right side y-axis) showed 2.97% weight loss between 43°C and 193°C. As shown in FIG.17 (left side y-axis), one DTA endotherm in the TGA exhibited a peak onset at 173.68°C (in the DTA signal).

[0545] Synthetic Example 6. Synthesis and characterization of Free Base Form E

[0546] Compound of Formula (I) (Free Base Form A) was temperature cycled in ethanol, ethyl acetate, methanol, 2-methyl-THF, or isopropanol solvent systems to prepare Free Base Form E; or Free Base Form E was prepared by evaporation of dioxane from the compound of Formula (I) (Free Base Form A). 126 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0547] The samples analysed here were prepared by temperature cycling Formula (I) (Free Base Form A) in ethanol between 20°C to 75°C, with two temperature cycles. The two temperature cycles were as follows: heat at a rate of 0.5°C / min (heating rate) from 20°C to 75°C, and cool at a rate of 0.2°C / min (cooling rate) from 75°C to 20°C; repeat the same heating and cooling temperature cycle. The resulting solid was analysed by XRPD analysis,1H NMR spectroscopy, and TGA / DTA. Scheme 6. Synthesis of Free Base Form E1a) add ethanol, ethyl acetate, methanol, 2-methyl-THF, or isopropanol 2a) heat at a rate of 0.5°C / min from 20°C to 75°C 3a) cool at a rate of 0.2°C / min from 75°C to 20°C Free Base Form E 4a) heat at a rate of 0.5°C / min from 20°C to 75°C 5a) cool at a rate of 0.2°C / min from 75°C to 20°C air dry solid at RT, analyze with XRPD or 1b) add dioxane, evaporate under ambient temperature and pressure, analyze with XRPD Free Base Form E

[0548] The XRPD pattern of Free Base Form E is shown in FIG.18. Table 25 is a list of the XRPD peaks for the Free Base Form E. 127 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Table 25. Peaks of the XRPD pattern of Free Base Form E ˚2θ Intensity (%) 4.6 ± 0.20 100.00 6.9 ± 0.20 18.95 9.4 ± 0.20 18.79 12.3 ± 0.20 4.47 14.6 ± 0.20 46.08 15.7 ± 0.20 28.46 17.4 ± 0.20 45.58 18.6 ± 0.20 11.45 19.2 ± 0.20 10.32 20.0 ± 0.20 31.7 22.1 ± 0.20 27.92 24.5 ± 0.20 37.85

[0549] The1H NMR spectrum (500 MHz, DMSO-d6) of Free Base Form E is shown in FIG. 19. An ethanol peak is shown in the1H NMR at 1.06 ppm, with an integration of 1.22 (ethanol in sample was further confirmed by TGA / DTA analysis).

[0550] The thermograms for Free Base Form E are provided in FIG.20. The TGA (right side y-axis) showed 2.42% weight loss between 44°C and 150°C. As shown in FIG.20 (left side y- axis), a DTA endotherm in the TGA exhibited peak onset at 169.9°C (in the DTA signal).

[0551] Free Base Form E was physically stable to stressing at 40°C / 75% relative humidity (RH) for 7 days (stability study).

[0552] In one or more embodiments, Free Base Form E is an isostructural solvate (dioxane, ethanol, ethyl acetate, methanol, 2-methyl-THF, or isopropanol).

[0553] Synthetic Example 7. Synthesis and characterization of Free Base Form F

[0554] The compound of Formula (I) (Free Base Form A) was temperature cycled in toluene solvent system to prepare Free Base Form F.

[0555] The samples analysed here were prepared by temperature cycling Formula (I) (Free Base Form A) in toluene between 20°C to 100°C, with two temperature cycles. The two temperature cycles were as follows: heat at a rate of 0.5°C / min (heating rate) from 20°C to 100°C, and cool at a rate of 0.2°C / min (cooling rate) from 100°C to 20°C; repeat the same heating and cooling temperature cycle. The resulting solid was analysed by XRPD analysis. 128 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Scheme 7. Synthesis of Free Base Form F1) add toluene 2) heat at a rate of 0.5°C / min from 20°C to 100°C 3) cool at a rate of 0.2°C / min from 100°C to 20°C Free Base Form F 4) heat at a rate of 0.5°C / min from 20°C to 100°C 5) cool at a rate of 0.2°C / min from 100°C to 20°C air dry solid at RT, analyze with XRPD

[0556] The XRPD pattern of Free Base Form F is shown in FIG.21. Table 26 is a list of the XRPD peaks for the Free Base Form F. Table 26. Peaks of the XRPD pattern of Free Base Form F ˚2θ Intensity (%) 4.3 ± 0.20 100.00 6.6 ± 0.20 7.75 8.8 ± 0.20 2.9 9.5 ± 0.20 20.37 9.9 ± 0.20 2.46 10.1 ± 0.20 2.94 11.0 ± 0.20 3.95 11.9 ± 0.20 1.4 12.4 ± 0.20 4.14 13.2 ± 0.20 2.85 13.5 ± 0.20 5.28 14.0 ± 0.20 13.61 14.1 ± 0.20 7.61 14.2 ± 0.20 8.3 14.6 ± 0.20 5.24 14.8 ± 0.20 5.98 129 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 15.1 ± 0.20 5.71 15.6 ± 0.20 15.28 15.9 ± 0.20 3.64 16.4 ± 0.20 5.57 16.8 ± 0.20 17.87 17.4 ± 0.20 15.52 18.5 ± 0.20 33.75 18.9 ± 0.20 15.36 19.2 ± 0.20 12.71 19.6 ± 0.20 6.65 19.8 ± 0.20 18.88 20.6 ± 0.20 5.03 21.3 ± 0.20 10.54 21.6 ± 0.20 11.41 22.3 ± 0.20 7.46 22.9 ± 0.20 17.05 23.6 ± 0.20 2.33 24.2 ± 0.20 3.8 24.4 ± 0.20 11.43 24.9 ± 0.20 3.74 25.7 ± 0.20 5.99 25.9 ± 0.20 3.33 26.6 ± 0.20 2.32 27.0 ± 0.20 1.95 27.5 ± 0.20 1.92 28.4 ± 0.20 3.67 29.4 ± 0.20 2.66 30.0 ± 0.20 0.92 30.6 ± 0.20 1.64 31.7 ± 0.20 1.02

[0557] Free Base Form F was not physically stable to stressing at 40°C / 75% relative humidity (RH) for 7 days or to ambient conditions (stability studies) including a temperature of from 15°C to 30°C.

[0558] In one or more embodiments, Free Base Form F is a toluene solvate, which converts to Free Base Form J, to be described.

[0559] Synthetic Example 8. Synthesis and characterization of Free Base Form G

[0560] Free Base Form G was prepared by evaporation from a solution of the compound of Formula (I) (Free Base Form A) in dimethylacetamide (evaporation under vacuum at about 50°C). The resulting solid was analysed by XRPD analysis,1H NMR spectroscopy, and TGA / DTA. 130 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Scheme 8. Synthesis of Free Base Form G1) add dimethylacetamide Free Base Form G 2) evaporate under vacuum at about 50°C,

[0561] The XRPD pattern of Free Base Form G is shown in FIG.22. Table 27 is a list of the XRPD peaks for the Free Base Form G. Table 27. Peaks of the XRPD pattern of Free Base Form G ˚2θ Intensity (%) 3.9 ± 0.20 41.22 7.8 ± 0.20 54.89 10.1 ± 0.20 49.48 10.6 ± 0.20 21.21 11.1 ± 0.20 32.19 12.4 ± 0.20 25.87 13.2 ± 0.20 30.34 15.1 ± 0.20 32.67 15.4 ± 0.20 36.89 15.7 ± 0.20 14.16 16.0 ± 0.20 51.21 16.4 ± 0.20 28.9 16.5 ± 0.20 100 17.2 ± 0.20 37.47 17.6 ± 0.20 36.4 18.2 ± 0.20 73.05 19.1 ± 0.20 7.93 19.3 ± 0.20 40.69 19.7 ± 0.20 12.85 20.5 ± 0.20 30.69 131 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 21.4 ± 0.20 26.27 21.6 ± 0.20 42.47 21.9 ± 0.20 95.3 22.9 ± 0.20 16.41 23.5 ± 0.20 41.87 24.9 ± 0.20 38.78 25.5 ± 0.20 48.21 26.5 ± 0.20 5.94 28.1 ± 0.20 21.33 29.0 ± 0.20 7.78 30.3 ± 0.20 7.81 30.8 ± 0.20 5.57

[0562] The1H NMR spectrum (500 MHz, DMSO-d6) of Free Base Form G is shown in FIG.23. A dimethylacetamide peak is shown in the1H NMR at 1.96 ppm, with an integration of 3.10 (dimethylacetamide in sample was further confirmed by TGA / DTA analysis).

[0563] The thermograms for Free Base Form G are provided in FIG.24. The TGA (right side y-axis) showed 9% weight loss between 40°C and 300°C. As shown in FIG.24 (left side y-axis), two DTA endotherms in the TGA exhibited peak onsets at 131.94°C and 214.27°C (in the DTA signal).

[0564] Free Base Form G was not physically stable to stressing at 40°C / 75% relative humidity (RH) for 7 days (stability study).

[0565] In one or more embodiments, Free Base Form G is a dimethylacetamide solvate.

[0566] Synthetic Example 9. Synthesis and characterization of Free Base Form H

[0567] Free Base Form H was prepared by evaporation from a solution of the compound of Formula (I) (Free Base Form A) in dimethylsulfoxide (evaporation under vacuum at about 50°C). The resulting solid was analysed by XRPD analysis,1H NMR spectroscopy, and TGA / DTA. 132 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Scheme 9. Synthesis of Free Base Form H1) add dimethylsulfoxide (DMSO) Free Base Form H 2) evaporate under vacuum at about 50°C,

[0568] The XRPD pattern of Free Base Form H is shown in FIG.25. Table 28 is a list of the XRPD peaks for the Free Base Form H. Table 28. Peaks of the XRPD pattern of Free Base Form H ˚2θ Intensity (%) 4.2 ± 0.20 63.25 6.4 ± 0.20 7.67 8.4 ± 0.20 15.69 10.2 ± 0.20 71.27 15.1 ± 0.20 29.44 15.7 ± 0.20 100 16.5 ± 0.20 64.37 16.9 ± 0.20 13.52 17.2 ± 0.20 25.98 18.1 ± 0.20 33.07 19.0 ± 0.20 11.85 20.6 ± 0.20 25.13 20.9 ± 0.20 43.32 21.9 ± 0.20 20.55 23.4 ± 0.20 34.68 25.6 ± 0.20 9.82 26.4 ± 0.20 2.99 27.0 ± 0.20 1.94 28.6 ± 0.20 6.91 28.8 ± 0.20 5.7 133 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 30.0 ± 0.20 6.14 39.7 ± 0.20 3.81

[0569] The1H NMR spectrum (500 MHz, DMSO-d6) of Free Base Form H is shown in FIG.26. A DMSO peak is shown in the1H NMR.

[0570] The thermograms for Free Base Form H are provided in FIG.27. The TGA (right side y-axis) showed 8.8% weight loss between 45°C and 301°C. As shown in FIG.27 (left side y-axis), two DTA endotherms in the TGA exhibited peak onsets at 175.7°C and 231.7°C (in the DTA signal).

[0571] Free Base Form H was physically stable to stressing at 40°C / 75% relative humidity (RH) for 7 days (stability study).

[0572] In one or more embodiments, Free Base Form H is a DMSO solvate.

[0573] Synthetic Example 10. Synthesis and characterization of Free Base Form J

[0574] Free Base Form J was prepared by evaporation from a solution of the compound of Formula (I) (Free Base Form A) in anisole (evaporation from anisole); or Free Base Form J was prepared by via conversion of Free Base Form F stored under ambient conditions (including a temperature of from 15°C to 30°C). The resulting solid was analysed by XRPD analysis,1H NMR spectroscopy, and TGA / DTA. Scheme 10. Synthesis of Free Base Form J134 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 1a) add anisole to Free Base Form A Free Base Form J 2a) evaporate at ambient temperature,analyze with XRPD or 1b) add Free Base Form F for conversion Free Base Form J 2b) store under ambient temperatureanalyze with XRPD

[0575] The XRPD pattern of Free Base Form J is shown in FIG. 28. Table 29 is a list of the XRPD peaks for the Free Base Form J. Table 29. Peaks of the XRPD pattern of Free Base Form J ˚2θ Intensity (%) 4.6 ± 0.20 100 6.9 ± 0.20 13.19 9.9 ± 0.20 32.14 12.1 ± 0.20 3.37 14.2 ± 0.20 38.18 14.9 ± 0.20 15.41 15.7 ± 0.20 46.1 17.0 ± 0.20 34.69 17.8 ± 0.20 24.4 18.4 ± 0.20 24.62 18.8 ± 0.20 12.13 19.6 ± 0.20 30.3 20.3 ± 0.20 26.6 22.0 ± 0.20 19.8 22.9 ± 0.20 21.25 24.7 ± 0.20 14.49

[0576] The1H NMR spectrum (500 MHz, DMSO-d6) of Free Base Form J is shown in FIG. 29.

[0577] The thermograms for Free Base Form J are provided in FIG.30. The TGA (right side yaxis) showed 7.8% weight loss between 53°C and 299°C. As shown in FIG.30 (left side y-axis), a DTA endotherm in the TGA exhibited peak onset at 205.5°C (in the DTA signal). 135 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0578] Free Base Form J was physically stable to stressing at 40°C / 75% relative humidity (RH) for 7 days (stability study).

[0579] In one or more embodiments, Free Base Form J is an isostructural solvate (toluene or anisole).

[0580] Synthetic Example 11. Synthesis and characterization of Fumarate Salt Form A Scheme S1. Synthetic step S1, salt formation (Fumarate Salt Form A)Compound MW Amount Equiv.136 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0581] For salt formation, a 100 L reactor was charged with EtOH (30.2 kg), water (4.24 kg), compound Q (2.35 kg), and fumaric acid (1.12 equiv., 0.378 kg). The mixture was stirred and warmed to 35 ± 5ºC, for 3 days. XRPD of the suspension was consistent with Fumarate Salt Form A. The heating was turned off and reaction mixture cooled to ambient, then the suspension was filtered and washed (EtOH / H2O, 9 / 1 volume ratio). The filter cake was blown dry under nitrogen for 1h. The product R was dried in a vacuum oven at about 35ºC until constant weight obtained. The solid was sieved with 20 mesh (830 µm) stainless steel sieve. Product R (2.4 kg) was obtained, and purity was confirmed by HPLC. The Fumarate Salt Form A was also obtained as follows.

[0582] Synthetic Example 11 (continued). Synthesis and characterization of Fumarate Salt Form A

[0583] The compound of Formula (I) (16.9 mg, free base) and fumaric acid (2.9 mg) were placed into a 1-dram glass vial. To the vial, 0.5 mL of 95:5 methanol:water (v:v) and a magnetic stir bar were added. The vial was placed on a hotplate set to 40°C with stirring turned on. The slurry was stirred and heated at 40°C for 7 days. The vial was centrifuged, the mother liquor was decanted, and the solid was air dried at room temperature. The resulting solid was analysed by XRPD. Scheme 11. Synthesis of Fumarate Salt Form A137 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 1) add A and B to 0.5 mL of 95:5 MeOH:H2O (v:v) stir at 40°C for 7 days Fumarate Salt Form A 2) centrifuge, decant mother liquor,analyze with XRPD

[0584] The XRPD pattern of Fumarate Salt Form A is shown in FIG.32. Table 30 is a list of the XRPD peaks for the Fumarate Salt Form A. Table 30. Peaks of the XRPD pattern of Fumarate Salt Form A ˚2θ d value (or d space, Å) Intensity (%) 4.58 ± 0.20 19.2930 44.0961 6.84 ± 0.20 12.9227 14.8329 9.82 ± 0.20 9.0068 27.3847 10.64 ± 0.20 8.3144 14.2596 11.38 ± 0.20 7.7754 18.1630 11.72 ± 0.20 7.5506 16.7846 13.62 ± 0.20 6.5012 17.6141 14.18 ± 0.20 6.2457 80.6416 14.72 ± 0.20 6.0178 16.4552 15.52 ± 0.20 5.7094 40.4123 16.04 ± 0.20 5.5254 87.9239 16.76 ± 0.20 5.2896 34.1059 17.54 ± 0.20 5.0561 35.7648 18.00 ± 0.20 4.9279 95.7917 18.48 ± 0.20 4.8010 99.6585 19.18 ± 0.20 4.6273 89.6926 19.64 ± 0.20 4.5200 64.1864 20.70 ± 0.20 4.2909 27.7141 21.16 ± 0.20 4.1986 80.5318 22.56 ± 0.20 3.9411 100.0000 23.36 ± 0.20 3.8079 25.2623 24.06 ± 0.20 3.6987 31.2759 24.64 ± 0.20 3.6129 41.1930 25.22 ± 0.20 3.5312 50.9149 25.58 ± 0.20 3.4823 53.7204 26.06 ± 0.20 3.4192 23.4447 27.36 ± 0.20 3.2596 24.7011 27.98 ± 0.20 3.1888 17.0285 28.72 ± 0.20 3.1083 24.1766 29.18 ± 0.20 3.0603 25.3354 29.68 ± 0.20 3.0099 23.0666 30.30 ± 0.20 2.9497 16.4674 31.08 ± 0.20 2.8774 17.0285 138 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 31.58 ± 0.20 2.8330 13.2837 32.22 ± 0.20 2.7782 15.0646 33.76 ± 0.20 2.6549 14.9183

[0585] The solution1H NMR spectrum for Fumarate Salt Form A was consistent with the chemical structure of the compound of Formula (I) and contained peaks attributed to fumaric acid.

[0586] The thermograms for Fumarate Salt Form A are provided in FIG.37. The TGA (right side y-axis) showed 1.715% weight loss up to 125°C and an additional 12.31% weight loss from 125°C to 275°C. As shown in FIG.37, a DSC endotherm in the TGA exhibited a peak maximum of 244.55°C.

[0587] A DVS analysis of Fumarate Salt Form A is shown in FIG.38.

[0588] Synthetic Example 12. Synthesis and characterization of Fumarate Salt Amorphous Form

[0589] Fumarate Salt Amorphous Form was prepared by lyophilisation of a suspension of Fumarate Salt Form A (a compound of Formula (I)) (15 mg / mL) in acetonitrile / water (1:3). The suspension was heated to 80°C to afford a (hot) solution. The hot solution was then frozen in liquid nitrogen and freeze dried (lyophilized, 24 hours) to afford Fumarate Salt Amorphous Form. The resulting solid was analysed by XRPD analysis,1H NMR spectroscopy, and TGA / DTA, DSC, and DVS analysis.

[0590] Scheme 12. Synthesis of Fumarate Salt Amorphous Form 1) mix 15 mg / mL of Fumarate Salt Form A in acetonitrile:water (1:3) to form a suspension 2) heat suspension to 80°C to afford a solution Fumarate Salt Amorphous Formanalyze with XRPD

[0591] The XRPD pattern of Fumarate Salt Amorphous Form is shown in FIG.39. Fumarate Salt Amorphous Form was analysed by XRPD and was shown to be amorphous, with an XRPD pattern as expected from an amorphous solid (FIG.39). 139 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0592] The1H NMR spectrum (500 MHz, DMSO-d6) of Fumarate Salt Amorphous Form is shown in FIG. 40. Analysis by1H-NMR spectroscopy (FIG. 40) conformed to the molecular structure and minimal residual acetonitrile content (max 0.07 mol. eq.).

[0593] The thermograms for Fumarate Salt Amorphous Form are provided in FIG. 41. The TGA (right side y-axis) showed 4.66% weight loss between about 35°C and about 180°C. As shown in FIG.41 (left side y-axis), a DTA endotherm in the TGA exhibited peak onset at 93.95°C (in the DTA signal). Decomposition of the Fumarate Salt Amorphous Form was observed at ~220°C.

[0594] The DSC thermogram for Free Base Amorphous Form is provided in FIG.42. The DSC thermogram (FIG.42) concurred with the thermal behaviour seen by TGA / DTA with an initial broad endotherm between 30 and 130°C likely due to dehydration, which was followed by a possible glass transition at 150.92°C.

[0595] Fumarate Salt Amorphous Form was physically stable to stressing at 40°C / 75% relative humidity (RH) for 7 days (FIG.43, top), and to the DVS cycling experiment (FIG.43, bottom). However, very small diffraction peaks seem to appear in both diffractograms. DVS showed that Fumarate Salt Amorphous Form was hygroscopic with an average weight gain between 40-80% relative humidity (RH) of 5.6% (FIG.44).

[0596] Synthetic Example 13. Synthesis and characterization of Fumarate Salt Form B

[0597] Fumarate Salt Form B was prepared by isolation from a slurry of Fumarate Salt Amorphous Form in methanol (MeOH). Alternatively, Fumarate Salt Form B was prepared by salt formation in methanol with Free Base Form A and 0.5 mol. equivalents of fumaric acid. The resulting solid was analysed by XRPD analysis and1H NMR spectroscopy.

[0598] Scheme 13. Synthesis of Fumarate Salt Form B 1A) mix Fumarate Salt Amorphous Form with MeOH to form a slurry; or Fumarate Salt Form B0.5 mol. equivalents of fumaric acid to form a slurry 140 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0599] The XRPD pattern of Fumarate Salt Forms A and B are shown in FIG. 45: Fumarate Salt Form A (top); Fumarate Salt Form A + Fumarate Salt Form B (2ndfrom top); Fumarate Salt Form B (2ndfrom bottom); and Fumarate Salt Form B after stressing for one week at 40°C and 75% relative humidity (bottom). Table 31 is a list of the XRPD peaks for the Fumarate Salt Form B. Table 31. Peaks of the XRPD pattern of Fumarate Salt Form B (hemi-fumarate salt) ˚2θ Intensity (%) 4.54 ± 0.20 1.31 6.02 ± 0.20 14.33 6.60 ± 0.20 23.34 7.15 ± 0.20 9.77 7.54 ± 0.20 25.61 7.67 ± 0.20 100.0 8.57 ± 0.20 15.20 8.88 ± 0.20 1.60 10.44 ± 0.20 5.87 10.82 ± 0.20 7.32 11.74 ± 0.20 12.08 12.04 ± 0.20 2.79 12.42 ± 0.20 2.17 12.71 ± 0.20 7.17 13.63 ± 0.20 5.11 13.95 ± 0.20 6.14 14.35 ± 0.20 3.76 14.97 ± 0.20 13.6 15.17 ± 0.20 4.09 15.90 ± 0.20 5.00 16.42 ± 0.20 29.47 17.19 ± 0.20 13.71 17.83 ± 0.20 6.78 18.18 ± 0.20 15.94 18.49 ± 0.20 13.49 18.96 ± 0.20 9.91 19.89 ± 0.20 9.80 20.09 ± 0.20 3.34 20.43 ± 0.20 2.14 20.80 ± 0.20 7.45 21.56 ± 0.20 71.79 22.09 ± 0.20 9.42 22.76 ± 0.20 4.86 23.21 ± 0.20 10.16 23.74 ± 0.20 7.85 141 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 24.78 ± 0.20 4.11 25.35 ± 0.20 2.98 26.52 ± 0.20 2.04 27.31 ± 0.20 4.97 28.53 ± 0.20 1.97 30.47 ± 0.20 1.17 31.29 ± 0.20 1.07 31.89 ± 0.20 1.69 33.51 ± 0.20 0.93 35.56 ± 0.20 0.79 38.03 ± 0.20 0.86

[0600] The1H NMR spectrum (500 MHz, DMSO-d6) of Fumarate Salt Form B is shown in FIG.46. Analysis by1H-NMR spectroscopy (FIG.46) conformed to the molecular structure and showed that Fumarate Salt Form B is a hemi-fumarate salt.

[0601] Synthetic Example 14. Synthesis and characterization of Fumarate Salt Form C

[0602] Fumarate Salt Form C was prepared by isolation from a salt formation with Fee Base Form A and 0.5 mol. equivalent of fumaric acid in methanol / water (84 / 16). Alternatively, Fumarate Salt Form C was prepared by temperature cycling between 5 °C and 60 °C Fumarate Salt Form B in methanol / water (84 / 16). The resulting solid was analysed by XRPD analysis and1H NMR spectroscopy.

[0603] Scheme 14. Synthesis of Fumarate Salt Form C 1A) mix Free Base Form A and 0.5 mol. equivalent of fumaric acid in methanol / water (84 / 16); or Fumarate Salt Form C

[0604] The XRPD pattern of Fumarate Salt Forms A and C are shown in FIG. 47: Fumarate Salt Form A (top); Fumarate Salt Form A + Fumarate Salt Form C (2ndfrom top); Fumarate Salt Form C (2ndfrom bottom); and Fumarate Salt Form C after stressing for one week at 40°C and 75% relative humidity (bottom). Table 32 is a list of the XRPD peaks for the Fumarate Salt Form C. 142 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Table 32. Peaks of the XRPD pattern of Fumarate Salt Form C (hemi-fumarate salt) ˚2θ Intensity (%) 4.89 ± 0.20 1.79 6.14 ± 0.20 44.78 6.38 ± 0.20 3.84 7.69 ± 0.20 40.03 8.08 ± 0.20 36.83 8.18 ± 0.20 21.28 8.44 ± 0.20 19.89 9.51 ± 0.20 2.1 11.37 ± 0.20 16.36 12.14 ± 0.20 28.25 12.86 ± 0.20 4.87 13.53 ± 0.20 16.16 14.21 ± 0.20 1.95 14.37 ± 0.20 3.67 15.44 ± 0.20 34.56 16.23 ± 0.20 10.7 16.42 ± 0.20 4.62 16.61 ± 0.20 3.54 16.80 ± 0.20 6.01 16.95 ± 0.20 5.26 17.51 ± 0.20 3.47 17.67 ± 0.20 11.47 18.01 ± 0.20 15.94 18.35 ± 0.20 12.16 18.51 ± 0.20 13.00 19.16 ± 0.20 13.28 19.28 ± 0.20 17.02 19.71 ± 0.20 2.60 20.47 ± 0.20 18.61 20.89 ± 0.20 20.81 21.13 ± 0.20 100.00 21.96 ± 0.20 3.89 22.30 ± 0.20 1.75 22.84 ± 0.20 2.26 23.04 ± 0.20 4.57 23.59 ± 0.20 19.13 23.74 ± 0.20 11.29 24.03 ± 0.20 22.12 24.43 ± 0.20 9.28 24.65 ± 0.20 13.49 24.93 ± 0.20 3.72 25.25 ± 0.20 7.64 25.61 ± 0.20 7.05 143 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 25.91 ± 0.20 10.65 26.14 ± 0.20 4.05 26.99 ± 0.20 3.63 27.46 ± 0.20 3.51 28.49 ± 0.20 2.08 28.78 ± 0.20 3.26 29.18 ± 0.20 2.76 30.14 ± 0.20 4.36 30.47 ± 0.20 3.66 30.91 ± 0.20 2.48 31.18 ± 0.20 2.00 31.68 ± 0.20 1.60 32.14 ± 0.20 1.67 32.59 ± 0.20 2.23 32.95 ± 0.20 1.53 33.77 ± 0.20 1.75 34.86 ± 0.20 2.02 35.30 ± 0.20 1.09 36.27 ± 0.20 1.77 38.05 ± 0.20 1.13 39.50 ± 0.20 0.61

[0605] The1H NMR spectrum (500 MHz, DMSO-d6) of Fumarate Salt Form C is shown in FIG.48. Analysis by1H-NMR spectroscopy (FIG.48) conformed to the molecular structure and showed that Fumarate Salt Form C is a hemi-fumarate salt.

[0606] Synthetic Example 15. Synthesis and characterization of Fumarate Salt Form D

[0607] Fumarate Salt Form D was prepared by temperature cycling Fumarate Salt Amorphous Form in DMSO or DMSO / water. The resulting solid was analysed by XRPD and TGA-DSC analysis. The analysis showed that Fumarate Salt Form D is a mono salt.

[0608] Scheme 15. Synthesis of Fumarate Salt Form D 1) mix Fumarate Salt Amorphous Form in DMSO or DMSO / water Fumarate Salt Form D

[0609] The XRPD pattern of Fumarate Salt Form D is shown in FIG.49. 144 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0610] The thermograms for Fumarate Salt Form D are provided in FIG.50. The TGA (right side y-axis) showed 34.0% weight loss from 32°C to 295°C. As shown in FIG.50 (left side y- axis), the DTA endotherm in the TGA exhibited a peak onset at 224.6°C (in the DTA signal).

[0611] Synthetic Example 16. Synthesis and characterization of Fumarate Salt Form E

[0612] Fumarate Salt Form E was prepared by isolation from a slurry of Fumarate Salt Amorphous Form in dimethylacetamide (DMAc). The resulting solid was analysed by XRPD and TGA-DSC analysis. The analysis showed that Fumarate Salt Form E is a mono salt.

[0613] Scheme 16. Synthesis of Fumarate Salt Form E 1) mix Fumarate Salt Amorphous Form with DMAc to form a slurry Fumarate Salt Form Eis shown in FIG.51.

[0615] The thermograms for Fumarate Salt Form E are provided in FIG.52. The TGA (right side y-axis) showed 9.08% weight loss from 41°C to 213°C. As shown in FIG. 52 (left side y- axis), the DTA endotherm in the TGA exhibited a peak onset at 215.8°C (in the DTA signal).

[0616] Synthetic Example 17. Synthesis and characterization of Maleate Salt Form A

[0617] The compound of Formula (I) (17.8 mg, free base) was dissolved in 2.0 mL of tetrahydrofuran. In a separate container, maleic acid (2.7 mg) was dissolved in 0.5 mL of tetrahydrofuran. The solutions were combined, and a precipitate was observed. A magnetic stir bar was added, and the vial was placed on a stir plate at room temperature with stirring turned on. The slurry was stirred for 6 days at room temperature. The vial was centrifuged, the mother liquor was decanted, and the solid was air dried at room temperature. The resulting solid was analysed by XRPD. 145 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0618] Scheme 17. Synthesis of Maleate Salt Form A1) add A in 2.0 mL THF, dissolve B in 0.5 mL THF combine A and B, stir at RT for 6 days Maleate Salt Form A 2) centrifuge, decant mother liquor,analyze with XRPD

[0619] The XRPD pattern of Maleate Salt Form A is shown in FIG. 55. Table 33 is a list of the XRPD peaks for the Maleate Salt Form A. Table 33. Peaks of the XRPD pattern of Maleate Salt Form A ˚2θ d value (or d space, Å) Intensity (%) 4.66 ± 0.20 18.9620 36.3655 9.28 ± 0.20 9.5297 24.5336 11.78 ± 0.20 7.5123 17.0300 14.20 ± 0.20 6.2370 53.7309 14.84 ± 0.20 5.9694 29.9413 15.64 ± 0.20 5.6658 30.6959 16.02 ± 0.20 5.5323 35.6110 16.48 ± 0.20 5.3789 57.9333 17.26 ± 0.20 5.1375 27.8453 17.60 ± 0.20 5.0390 31.3037 18.28 ± 0.20 4.8531 100.0000 18.92 ± 0.20 4.6903 51.8130 19.46 ± 0.20 4.5614 76.2838 20.42 ± 0.20 4.3491 20.1425 21.44 ± 0.20 4.1444 38.5768 21.74 ± 0.20 4.0879 56.5709 22.74 ± 0.20 3.9103 39.5515 146 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 23.22 ± 0.20 3.8306 48.6795 23.70 ± 0.20 3.7541 23.6324 24.82 ± 0.20 3.5872 45.1897 25.36 ± 0.20 3.5120 30.1719 26.04 ± 0.20 3.4218 26.6506 26.60 ± 0.20 3.3510 16.9147 26.80 ± 0.20 3.3265 16.9566 28.02 ± 0.20 3.1843 19.1469 28.40 ± 0.20 3.1426 17.3025 29.16 ± 0.20 3.0624 18.5077 30.04 ± 0.20 2.9747 12.6808 30.96 ± 0.20 2.8883 12.3873 31.58 ± 0.20 2.8330 13.1838 33.50 ± 0.20 2.6749 11.9681 35.46 ± 0.20 2.5314 10.2285 35.82 ± 0.20 2.5068 9.7883

[0620] The solution1H NMR spectrum for Maleate Salt Form A was consistent with the chemical structure of the compound of Formula (I) and contained peaks attributed to maleic acid.

[0621] The thermograms for Maleate Salt Form A are provided in FIG. 56. The TGA (right side y-axis) showed 2.289% weight loss up to 175°C and an additional 8.995% weight loss from 175°C to 250°C. As shown in FIG.56 (left side y-axis), a broad DSC endotherm exhibited a peak maximum of 228.92°C.

[0622] Synthetic Example 18. Synthesis and characterization of Tosylate Salt Form A

[0623] The compound of Formula (I) (16.9 mg, free base) was dissolved in 2.0 mL of tetrahydrofuran. p-Toluenesulfonic acid (4.0 mg, hydrate) was dissolved in 0.5 mL of tetrahydrofuran. The solutions were combined, and a precipitate was observed. A magnetic stir bar was added, and the vial was placed on a stir plate at room temperature with stirring turned on. The slurry was stirred for 6 days at room temperature. The vial was centrifuged, the mother liquor was decanted, and the solid was air dried at room temperature. The resulting solid was analysed by XRPD. 147 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0624] Scheme 18. Synthesis of Tosylate Salt Form A1) dissolve A in 2.0 mL THF, dissolve B in 0.5 mL THF combine A and B, stir at RT for 6 days Tosylate Salt Form A 2) centrifuge, decant mother liquor,analyze with XRPD

[0625] The XRPD pattern of Tosylate Salt Form A is shown in FIG.57. Table 34 is a list of the XRPD peaks for the Tosylate Salt Form A. Table 34. Peaks of the XRPD pattern of Tosylate Salt Form A ˚2θ d value (or d space, Å) Intensity (%) 4.14 ± 0.20 21.3425 25.2112 8.20 ± 0.20 10.7822 17.2525 9.94 ± 0.20 8.8983 39.1517 10.24 ± 0.20 8.6383 38.9659 10.62 ± 0.20 8.3301 26.1913 11.40 ± 0.20 7.7618 20.7503 12.84 ± 0.20 6.8944 32.1730 13.96 ± 0.20 6.3437 22.3217 14.64 ± 0.20 6.0505 36.3467 15.14 ± 0.20 5.8518 35.3329 15.76 ± 0.20 5.6230 84.4373 16.74 ± 0.20 5.2959 41.7709 17.54 ± 0.20 5.0561 48.9692 19.34 ± 0.20 4.5894 73.9777 20.32 ± 0.20 4.3702 56.2352 20.96 ± 0.20 4.2382 100.0000 21.84 ± 0.20 4.0694 57.4518 148 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 22.86 ± 0.20 3.8901 79.6553 24.02 ± 0.20 3.7048 72.3217 24.64 ± 0.20 3.6129 36.3129 25.32 ± 0.20 3.5174 46.5022 26.84 ± 0.20 3.3216 30.0101 28.38 ± 0.20 3.1448 23.2004 28.78 ± 0.20 3.1020 25.2957 29.64 ± 0.20 3.0139 27.6783 30.68 ± 0.20 2.9140 20.0743 32.14 ± 0.20 2.7849 17.2693 36.66 ± 0.20 2.4513 15.3937

[0626] The solution1H NMR spectrum for Tosylate Salt Form A was consistent with the chemical structure ofcompound of Formula (I) and contained peaks attributed to ptoluenesulfonic acid.

[0627] Synthetic Example 19. Synthesis and characterization of Tosylate Salt Form B

[0628] The compound of Formula (I) (19.1 mg, free base) and p-toluenesulfonic acid (5.0 mg, hydrate) were placed into a 1-dram glass vial. To the vial, 0.5 mL of 95:5 methanol:water (v:v) and a magnetic stir bar were added. The vial was placed on a hotplate set to 40°C with stirring turned on. The slurry was stirred for 7 days at 40°C. The vial was centrifuged, the mother liquor was decanted, and the solid was air dried at room temperature. The resulting solid was analysed by XRPD.

[0629] Scheme 19. Synthesis and Studies of Tosylate Salt Form B149 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 1) add A and B to 0.5 mL of 95:5 MeOH:H2O (v:v), stir at 40°C for 7 days Tosylate Salt Form B 2) centrifuge, decant mother liquor,analyze with XRPD

[0630] The XRPD pattern of Tosylate Salt Form B is shown in FIG.58. Table 35 is a list of the XRPD peaks for the Tosylate Salt Form B. Table 35. Peaks of the XRPD pattern of Tosylate Salt Form B ˚2θ d value (or d space, Å) Intensity (%) 9.00 ± 0.20 9.8255 41.8240 9.64 ± 0.20 9.1746 31.5519 9.90 ± 0.20 8.9342 32.2138 10.20 ± 0.20 8.6721 47.2665 10.54 ± 0.20 8.3931 52.1942 11.36 ± 0.20 7.7890 29.1983 11.86 ± 0.20 7.4618 30.7919 12.58 ± 0.20 7.0363 31.5028 12.80 ± 0.20 6.9158 29.9093 13.10 ± 0.20 6.7581 38.2937 13.42 ± 0.20 6.5977 35.2047 13.78 ± 0.20 6.4261 32.9983 14.12 ± 0.20 6.2721 38.0240 14.64 ± 0.20 6.0505 36.8473 15.06 ± 0.20 5.8827 39.7156 15.32 ± 0.20 5.7834 43.7362 15.72 ± 0.20 5.6372 50.0368 16.56 ± 0.20 5.3531 49.3748 17.50 ± 0.20 5.0676 52.1696 18.00 ± 0.20 4.9279 68.4236 18.40 ± 0.20 4.8217 83.8931 19.12 ± 0.20 4.6417 87.3008 19.68 ± 0.20 4.5109 100.0000 20.38 ± 0.20 4.3575 74.8958 20.88 ± 0.20 4.2543 79.6764 21.86 ± 0.20 4.0657 76.0481 22.08 ± 0.20 4.0257 86.1731 22.36 ± 0.20 3.9759 79.1370 22.58 ± 0.20 3.9377 72.6404 22.90 ± 0.20 3.8834 68.9385 23.42 ± 0.20 3.7983 65.9966 24.08 ± 0.20 3.6957 55.8961 24.60 ± 0.20 3.6187 43.4420 150 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT 25.28 ± 0.20 3.5229 49.5710 26.38 ± 0.20 3.3785 52.0961 26.86 ± 0.20 3.3192 42.3143 27.24 ± 0.20 3.2737 40.6227 27.64 ± 0.20 3.2272 42.1672 27.84 ± 0.20 3.2045 39.1027 28.26 ± 0.20 3.1578 33.8563 28.76 ± 0.20 3.1041 32.4099 29.62 ± 0.20 3.0159 30.1544 30.74 ± 0.20 2.9085 30.8654 32.06 ± 0.20 2.7917 26.5751 37.04 ± 0.20 2.4270 22.1868

[0631] The solution1H NMR spectrum for Tosylate Salt Form B was consistent with the chemical structure of the compound of Formula (I) and contained peaks attributed to ptoluenesulfonic acid.

[0632] Synthetic Example 20. Synthesis and characterization of Besylate Salt Form A

[0633] Besylate Salt Form A was prepared by a salt formation reaction with Free Base Form A in tetrahydrofuran / water (2:1, 12 vols) and 1 mol. equivalent of benzenesulfonic acid. The reaction mixture was stirred, and temperature cycled between ambient temperature (of from 15°C to 30°C) and 50°C for 60 hours before being returned to ambient temperature and stirred for another 18 hours. Besylate Salt Form A was obtained as a solid, isolated by centrifugation. The resulting solid was analysed by XRPD and TGA-DSC analysis. 151 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0634] Scheme 20. Synthesis of Besylate Salt Form A

[0635]

[0636] The thermograms for Besylate Salt Form A are provided in FIG. 60. The TGA (right side y-axis) showed 1.12% weight loss from 31°C to 88°C, and from 34.20% weight loss from 88°C to 155°C. As shown in FIG.60 (left side y-axis), the DTA endotherm in the TGA exhibited a peak onset at 99.13°C and 217.8°C (in the DTA signal).

[0637] Synthetic Example 21. Synthesis and characterization of Cyclamate Salt Form A

[0638] Cyclamate Salt Form A was prepared by a salt formation reaction with Free Base Form A and cyclamic acid (1 mol. equivalent) in THF. The reaction mixture was stirred at 40°C for 60 hours then cooled to 5°C and stirred at this lower temperature for 18h before the solids were isolated by centrifugation. The solids were dried under vacuum for 1 hour to afford Cyclamate Salt Form A. The resulting solid was analysed by XRPD and TGA-DSC analysis. 152 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0639] Scheme 21. Synthesis of Cyclamate Salt Form A

[0640]

[0641] The thermograms for Cyclamate Salt Form A are provided in FIG.62. The TGA (right side y-axis) showed 1.72% weight loss from 31°C to 229°C. As shown in FIG. 62 (left side y- axis), the DTA endotherm in the TGA exhibited peak onsets at 223.1°C and 284.2°C (in the DTA signal).

[0642] Synthetic Example 22. Synthesis and characterization of Malate Salt Form A

[0643] Malate Salt Form A was prepared by a salt formation reaction with Free Base Form A and malic acid (1 mol. eq.) in THF. The reaction mixture was stirred at 40°C for 60 hours then cooled to 5°C and stirred at this lower temperature for 18 hours before the solids were isolated by centrifugation. The solids were dried for 1 hour under vacuum to afford Malate Salt Form A. The resulting solid was analysed by XRPD and TGA-DSC analysis. 153 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0644] Scheme 22. Synthesis of Malate Salt Form A

[0645]

[0646] The thermograms for Malate Salt Form A are provided in FIG.64. The TGA (right side y-axis) showed 4.73% weight loss from 30°C to 223°C. As shown in FIG.64 (left side y-axis), the DTA endotherm in the TGA exhibited peak onsets at 87.2°C and 230.2°C (in the DTA signal).

[0647] Synthetic Example 23. Synthesis and characterization of Malonate Salt Form A

[0648] Malonate Salt Form A was prepared by salt formation with Free Base Form A in THF / water (2:1, 12 vols) using 1 mol. equivalent of malonic acid. The reaction mixture was stirred, and temperature cycled between ambient temperature (of from 15°C to 30°C) and 50°C for 60 hours before being returned to ambient temperature and stirred for a further 18 hours. Amorphous solids were isolated by centrifugation. These amorphous solids were mixed in acetone (15-20 vols) to form a slurry and heated at 40°C for a minimum of 48 hours before returning to ambient temperature. The solids were isolated by centrifugation and air dried for 1 hour before analysis to afford Malonate Salt Form A. The resulting solid was analysed by XRPD and TGA-DSC analysis. 154 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0649] Scheme 23. Synthesis of Malonate Salt Form A

[0650]

[0651] The thermograms for Malonate Salt Form A are provided in FIG.66. The TGA (right side y-axis) showed 2.43% weight loss from 31°C to 137°C, 6.30% weight loss from 138°C to 180°C, and 4.48% weight loss from 181°C to 298°C. As shown in FIG.66 (left side y-axis), the DTA endotherm in the TGA exhibited a peak onset at 159.3°C (in the DTA signal).

[0652] Synthetic Example 24. Synthesis and characterization of Napsylate Salt Form A

[0653] Napsylate Salt Form A was prepared by a salt formation reaction with Free Base Form A and naphthalene-2-sulfonic acid (1 mol. equivalent) in THF. The reaction mixture was stirred at 40°C for 60 hours then cooled to 5°C and stirred at this lower temperature for 18 hours before the solids were isolated by centrifugation to afford Napsylate Salt Form A. The resulting solid was analysed by XRPD and TGA-DSC analysis. 155 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0654] Scheme 24. Synthesis of Napsylate Salt Form A

[0655]

[0656] The thermograms for Napsylate Salt Form A are provided in FIG.68. The TGA (right side y-axis) showed 2.78% weight loss from 31°C to 251°C. As shown in FIG. 68 (left side y- axis), the DTA endotherm in the TGA exhibited a peak onset at 262.1°C (in the DTA signal).

[0657] Synthetic Examples 25-27. Synthesis and characterization of Napsylate Salt Form B (Synthetic Example 25), Napsylate Salt Form C (Synthetic Example 26), and Napsylate Salt Form D (Synthetic Example 27)

[0658] Napsylate Salt Form B was prepared by salt formation with Free Base Form A in THF / water (2:1, 12 vols) using 1 mol. equivalent of naphthalene-2-sulfonic acid. The reaction mixture was stirred, and temperature cycled between ambient temperature (of from 15°C to 30°C) and 50°C for 60 hours before returning to ambient temperature. The mixture was stirred for a further 18 hours. Solids were isolated by centrifugation to afford Napsylate Salt Form B, analysed by XRPD. 156 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0659] Napsylate Salt Form C was prepared by storing Napsylate Salt Form B under ambient conditions, which completed the conversion to Napsylate Salt Form C. Napsylate Salt Form C was analysed by XRPD.

[0660] Napsylate Salt Form D was prepared by drying Napsylate Salt Form B under vacuum for 1 hour, which completed the conversion to Napsylate Salt Form D. Napsylate Salt Form D was analysed by XRPD and TGA-DSC analysis.

[0661] Scheme 25. Synthesis of Napsylate Salt Form B, Napsylate Salt Form C, and Napsylate Salt Form D

[0662] The XRPD patterns of Napsylate Salt Forms A, B, C, and D are shown in FIG. 69: Napsylate Salt Form A (top); Napsylate Salt Form B (2ndfrom top); Napsylate Salt Form C (2ndfrom bottom); and Napsylate Salt Form D (bottom).

[0663] The XRPD pattern of Napsylate Salt Form D is shown in FIG.70. 157 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0664] The thermograms for Napsylate Salt Form D are provided in FIG.71. The TGA (right side y-axis) showed 1.97% weight loss from 30°C to 83°C, 25.77% weight loss from 86°C to 124°C, and 0.93% weight loss from 151°C to 175°C. As shown in FIG.71 (left side y-axis), the DTA endotherm in the TGA exhibited a peak onset at 98.4°C (in the DTA signal).

[0665] Synthetic Examples 28-29. Synthesis and characterization of Succinate Salt Form A (Synthetic Example 28) and Succinate Salt Form B (Synthetic Example 29)

[0666] Succinate Salt Form A and Succinate Salt Form B were prepared by salt formation reactions with Free Base Form A and succinic acid (1 mol. equivalent) in THF. The reaction mixture was stirred at 40°C for 60 hours then cooled to 5°C and stirred at this lower temperature for 18 hours before Succinate Salt Form A solids were isolated by centrifugation. After drying the solids for 1 hour under vacuum, XRPD analysis showed that Succinate Salt Form A converted to Succinate Salt Form B. Succinate Salt Form B was stressed at 40°C / 75% relative humidity (RH) and was converted back to Succinate Salt Form A material. Succinate Salt Form A was analysed by XRPD. Succinate Salt Form B was analysed by XRPD and TGA-DSC. 158 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0667] Scheme 26. Synthesis of Succinate Salt Forms A and B

[0668] are Free Base Form A (top); Succinate Salt Form A obtained after stressing Succinate Salt Form B at 40°C / 75% RH for 1 week (2ndfrom top); Succinate Salt Form B (2ndfrom bottom); and Succinate Salt Form A formed from the reaction in THF (bottom).

[0669] The XRPD pattern of Succinate Salt Form A is shown in FIG.73.

[0670] The thermograms for Succinate Salt Form B are provided in FIG.74. The TGA (right side y-axis) showed 1.55% weight loss from 34°C to 214°C. As shown in FIG. 74 (left side y- axis), the DTA endotherm in the TGA exhibited peak onsets at 77.4°C and 208.6°C (in the DTA signal). 159 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0671] Synthetic Example 30. Synthesis and characterization of Succinate Salt Form C

[0672] Succinate Salt Form C was prepared by salt formation with Free Base Form A in THF / water (2:1, 12 vols) using 1 mol. equivalent of succinic acid. The reaction mixture was stirred, and the temperature was cycled between ambient temperature (of from 15°C to 30°C) and 50°C for 60 hours before being returned to ambient temperature and stirred for a further 18 hours. Solids were isolated by centrifugation and air dried under vacuum for 1 hour to afford Succinate Salt Form C. Succinate Salt Form C was analysed by XRPD and TGA-DSC.

[0673] Scheme 27. Synthesis of Succinate Form C

[0674]

[0675] The thermograms for Succinate Salt Form C are provided in FIG.76. The TGA (right side y-axis) showed 23.6% weight loss from 75°C to 153°C, and 3.37% weight loss from 235°C to 302°C. As shown in FIG.76 (left side y-axis), the DTA endotherm in the TGA exhibited peak onsets at 99.4°C and 209.6°C (in the DTA signal).

[0676] Scheme 28. Preparation of amorphous solid dispersion with HPMCAS-H 160 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0677] The components of amorphous solid dispersion with HPMCAS-H can be found below. The quantities of Fumarate salt Form A and HPMCAS-H are adjusted according to target a 20% (w / w) as free base concentration in the amorphous solid dispersion. Batch Quantity, 2 kg Components Theoretical Basis Com osition (w / w%)1. Dispensing a total of 6% (w / w) solids of Fumarate Salt Form A and HPMCAS-H in a solvent mixture of DCM:MeOH (4:1 ratio) 2. Mixing to effect dissolution of Fumarate Salt Form A and HPMCAS-H in a solvent mixture of DCM:MeOH (4:1 ratio) 3. Spray-drying 4. Secondary drying

[0678] Scheme 29. Preparation of amorphous solid dispersion with Eudragit L-100

[0679] The components of amorphous solid dispersion with Eudragit L-100 can be found below. The quantities of Fumarate salt Form A and Eudragit L-100 are adjusted according to target a 20% (w / w) as free base concentration in the amorphous solid dispersion. Batch Quantity, 2 kg Theoretical B i1. Dispensing a total of 4% (w / w) solids of Fumarate Salt Form A and Eudragit L-100 in a solvent mixture of DCM:MeOH (4:1 ratio) 2. Mixing to effect dissolution of Fumarate Salt Form A and Eudragit L-100 in a solvent mixture of DCM:MeOH (4:1 ratio) 3. Spray-drying 4. Secondary drying 161 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT

[0680] The spray drying was conducted using BüChi B-290 (ID: RD-038). The secondary drying was conducted using a VWM tray dryer (1370FM). The spray drying and secondary drying parameters can be found below. Nozzle Type Two-Fluid -1.5 mm Air Cap, 0.7 mm Liquid Tip Drying Gas Mode Recycle luatey y p p . p us materials give an “amorphous halo” diffraction pattern, absent of discrete peaks that are found in crystalline material. See FIG.77 for XRPD diffractograms of amorphous solid dispersion of Fumarate Salt Form A with Eudragit L-100 under different storage conditions over one month period. Samples were irradiated with monochromatized Cu Kα radiation and analyzed from 5° and 40° with a continuous scanning mode. Samples were rotated during analysis to minimize preferred orientation effects.

[0682] DSC was performed using a TA Instruments Discovery DSC2500 or X3 differential scanning calorimeter equipped with a TA instruments Refrigerated Cooling System (RCS) 90 operating in either modulated or ramp mode. DSC was used to measure thermodynamic properties of amorphous solid dispersion, including the following: glass transition temperature (Tg) defined as the temperature at which amorphous materials transition from a low mobility glassy state to a high mobility rubbery state, cold crystallization temperature (Tc), defined as a crystallization event at a temperature lower than the melt temperature, and melting temperature (Tm). The system was purged by nitrogen flow at 50 mL / min to ensure inert atmosphere through the course of measurement. See summary of modulated DSC parameters below: Parameter Value162 1102898093\2\AMERICASAttorney Docket No.121843.00291 NU-3500 PCT Parameter Value Scanning Mode ModulatedA with Eudragit L-100 under different storage conditions over a two-week period.

[0684] The embodiments and examples described above are intended to be merely illustrative and non-limiting. Those skilled in the art will recognize or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials and procedures. All such equivalents are considered to be within the scope and are encompassed by the appended claims. 163 1102898093\2\AMERICAS

Claims

AMENDED CLAIMS received by the International Bureau on 15 July 2025 (15.07.2025)1. A free base of a compound of Formula (I):Formula (I), that is Free Base Form A, Free Base Amorphous Form, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, or Free Base Form J; wherein the Free Base Form A, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, or Free Base Form J exhibits at least two diffraction peaks at about 17.0-25.0°20 in its X-ray powder diffraction pattern; and wherein the Free Base Amorphous Form is amorphous and exhibits one endotherm in the differential scanning calorimetry thermogram with an endotherm maximum between about 30°C and about 100°C.

2. The free base of a compound of Formula (I) according to claim 1, wherein the FreeBase Form A, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, or Free Base Form J exhibits a diffraction peak at about 17.0-21.0° 29 in its X-ray powder diffraction pattern.

3. The free base of a compound of Formula (I) according to claim 1 or 2, wherein theFree Base Form A, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, or Free Base Form J exhibits a diffraction peak at about 19.O-2O.O°20 in its X-ray powder diffraction pattern.

4. The free base of a compound of Formula (I) according to any one of claims 1-3, wherein the Free Base Form A, Free Base Form B, Free Base Form C, Free Base Form D, Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, or Free Base Form J exhibits a diffraction peak at about 2O.O-22.O°20 in its X- ray powder diffraction pattern.

5. The free base of a compound of Formula (I) according to any one of claims 1-4, wherein the free base is a hydrate.

6. The free base of a compound of Formula (I) according to any one of claims 1-5, wherein the free base is a solvate.

7. The free base of a compound of Formula (I) according to any one of claims 1-6, wherein the Free Base Form A, Free Base Form B, Free Base Form C, or Free Base Form D is a solvate and the solvate is a tetrahydrofuran (THF) solvate, a methyl ethyl ketone (MEK) solvate, a dimethyl sulfoxide (DMSO) solvate, a dimethylformamide (DMF) solvate, a diethyl ether solvate, an acetone solvate, a dimethylacetamide (DMAc) solvate, or a combination thereof.

8. The free base of a compound of Formula (I) according to any one of claims 1-6, wherein the Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, or Free Base Form J is a solvate and the solvate is an isostructural solvate.

9. The free base of a compound of Formula (I) according to any one of claims 1-6 and8, wherein the Free Base Form E, Free Base Form F, Free Base Form G, Free Base Form H, or Free Base Form J is a solvate and the solvate is an acetonitrile solvate, a tetrahydrofuran solvate, a dioxane solvate, an ethanol solvate, an ethyl acetate solvate, a methanol solvate, a 2-methyl-tetrahydrofuran solvate, an isopropanol solvate, a toluene solvate, a dimethylacetamide solvate, a dimethylsulfonamide solvate, or an anisole solvate.

10. The Free Base Form A of any one of claims 1-7, wherein the Free Base Form A exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.96, 14.26, 15.86, 18.90, 19.98, 22.12, 23.68, and 25.00 ±O.2°20.

11. The Free Base Form A of any one of claims 1-7 and 10, wherein the Free Base Form A exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.96, 14.26, 15.86, 17.00, 18.04, 18.90, 19.98, 22.12, 23.68, and 25.00 ±O.2°20; optionally wherein the Free Base Form A exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 1.

12. The Free Base Form A of any one of claims 1-7 and 10-11, wherein the Free Base Form A exhibits a differential scanning calorimetry thermogram with four endotherms, wherein the first endotherm has an endotherm maximum between about 60°C and about 70°C, the second endotherm has an endotherm maximum between about 95°C and about 105°C, the third endotherm has an endotherm maximum between about 210°C and about 220°C, and the fourth endotherm has an endotherm maximum between about 225°C and about 235°C.'13. The Free Base Form A of any one of claims 1-7 and 10-12, wherein the Free Base Form A exhibits a differential scanning calorimetry thermogram with four endotherms, where the first endotherm has an endotherm maximum at about 64°C, the second endotherm has an endotherm maximum at about 100°C, the third endotherm has an endotherm maximum at about 213°C, and the fourth endotherm has an endotherm maximum at about 231°C; optionally wherein the Free Base Form A exhibits a differential scanning calorimetry thermogram that is substantially similar to that of FIG. 2.

14. The Free Base Form A of any one of claims 1-7 and 10-13, wherein the Free Base Form A exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 0.1% to about 5% when heated from about 25°C to about 75°C.

15. The Free Base Form A of any one of claims 1-7 and 10-14, wherein the Free Base Form A exhibits a weight loss in a thermogravimetric analysis (TGA) of about 3.46% when heated from about 25°C to about 75°C; optionally wherein the Free Base Form A exhibits a thermogravimetric analysis (TGA) pattern that is substantially similar to that of FIG. 2.

16. The Free Base Amorphous Form of claim 1, wherein the Free Base Amorphous Form is shown to be amorphous by X-ray powder diffraction; optionally wherein Free Base Amorphous Form exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 4.

17. The Free Base Amorphous Form of claim 1 or 16, wherein the Free Base Amorphous Form exhibits a differential scanning calorimetry thermogram with one endotherm, wherein the endotherm has an endotherm maximum at about 65°C; optionally wherein the Free Base Amorphous Form exhibits a differential scanning calorimetry thermogram that is substantially similar to that of FIG. 7.

18. The Free Base Amorphous Form of any one of claims 1 and 16-17, wherein the Free Base Amorphous Form exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 0.1% to about 1% when heated from about 35°C to about 190°C.

19. The Free Base Amorphous Form of any one of claims 1 and 16-18, wherein the Free Base Amorphous Form exhibits a weight loss in a thermogravimetric analysis (TGA) of about 0.5% when heated from about 36°C to about 184°C; optionally wherein the Free Base Amorphous Form exhibits a thermogravimetric analysis (TGA) pattern that is substantially similar to that of FIG. 6.

20. The Free Base Form B of any one of claims 1-7, wherein the Free Base Form B is a DMSO solvate.

21. The Free Base Form B of any one of claims 1-7 and 20, wherein the Free Base Form B exhibits an X-ray powder diffraction pattern with diffraction peaks at about 16.46, 17.98, 21.22, 21.70, 22.92, and 24.46 ±O.2°20.

22. The Free Base Form B of any one of claims 1-7 and 20-21, wherein the Free Base Form B exhibits an X-ray powder diffraction pattern with diffraction peaks at about 15.80, 16.14, 16.46, 17.98, 21.22, 21.70, 21.96, 22.92, 24.46, and 24.70 ±O.2°20; optionally wherein the Free Base Form B exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 11.

23. The Free Base Form B of any one of claims 1-7 and 20-22, wherein the Free Base Form B exhibits a differential scanning calorimetry thermogram with three endotherms, wherein the first endotherm has an endotherm maximum between about 120°C and about 130°C, the second endotherm has an endotherm maximum between about 220°C and about 230°C, and the third endotherm has an endotherm maximum between about 230°C and about 240°C.

24. The Free Base Form B of any one of claims 1-7 and 20-23, wherein the Free Base Form B exhibits a differential scanning calorimetry thermogram with three endotherms, wherein the first endotherm has an endotherm maximum at about 124°C, the second endotherm has an endotherm maximum at about 226°C, and the third endotherm has an endotherm maximum at about 236°C; optionally wherein the Free Base Form B exhibits a differential scanning calorimetry thermogram that is substantially similar to that of FIG. 12.

25. The Free Base Form B of any one of claims 1-7 and 20-24, wherein the Free Base Form B exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 10% to about 15% when heated from about 25°C to about 175°C.

26. The Free Base Form B of any one of claims 1-7 and 20-25, wherein the Free Base Form B exhibits a weight loss in a thermogravimetric analysis (TGA) of about 13.4% when heated from about 25°C to about 175°C; optionally wherein the Free Base Form B exhibits a thermogravimetric analysis (TGA) pattern that is substantially similar to that of FIG. 12.

27. The Free Base Form C of any one of claims 1-7, wherein the Free Base Form C is a DMF solvate.

28. The Free Base Form C of any one of claims 1-7 and 27, wherein the Free Base Form C exhibits an X-ray powder diffraction pattern with diffraction peaks at about 6.40, 8.40, 12.76, 16.76, and 17.98 ±O.2°20.

29. The Free Base Form C of any one of claims 1-7 and 27-28, wherein the Free Base Form C exhibits an X-ray powder diffraction pattern with diffraction peaks at about 5.80, 6.40, 8.40, 12.76, 15.18, 16.76, 17.34, 17.98, 19.68, 20.58, and 23.28 ±O.2°20;optionally wherein the Free Base Form C exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 13.

30. The Free Base Form C of any one of claims 1-7 and 27-29, wherein the Free Base Form C exhibits a differential scanning calorimetry thermogram with two endotherms, wherein the first endotherm has an endotherm maximum between about 60°C and about 70°C, and the second endotherm has an endotherm maximum between about 195°C and about 205°C.

31. The Free Base Form C of any one of claims 1-7 and 27-30, wherein the Free Base Form C exhibits a differential scanning calorimetry thermogram with two endotherms, wherein the first endotherm has an endotherm maximum at about 64°C, and the second endotherm has an endotherm maximum at about 202°C; optionally wherein the Free Base Form C exhibits a differential scanning calorimetry thermogram that is substantially similar to that of FIG. 14.

32. The Free Base Form C of any one of claims 1-7 and 27-31, wherein the Free Base Form C exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 10% to about 15% when heated from about 25°C to about 200°C.

33. The Free Base Form C of any one of claims 1-7 and 27-32, wherein the Free Base Form C exhibits a weight loss in a thermogravimetric analysis (TGA) of about 11.4% when heated from about 25°C to about 200°C; optionally wherein the Free Base Form C exhibits a thermogravimetric analysis (TGA) pattern that is substantially similar to that of FIG. 14.

34. The Free Base Form D of any one of claims 1-7, wherein the Free Base Form D exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.18, 17.20, 17.52, and 19.64 ±O.2°20.

35. The Free Base Form D of any one of claims 1-7 and 34, wherein the Free Base Form D exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.18, 17.20, 17.52, 18.06, 19.32, 19.64, and 24.84 ±O.2°20.

36. The Free Base Form D of any one of claims 1-7 and 34-35, wherein the Free Base Form D exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 15.

37. The Free Base Form D of any one of claims 1-7 and 34-36, wherein the Free Base Form D exhibits a differential scanning calorimetry thermogram with three endotherms, wherein the first endotherm has an endotherm maximum between about 50°C and about 60°C, the second endotherm has an endotherm maximum between about 155°C and about 165°C, and the third endotherm has an endotherm maximum between about 170°C and about 180°C.

38. The Free Base Form D of any one of claims 1-7 and 34-37, wherein the Free Base Form D exhibits a differential scanning calorimetry thermogram with three endotherms, wherein the first endotherm has an endotherm maximum at about 57°C, the second endotherm has an endotherm maximum at about 162°C, and the third endotherm has an endotherm maximum at about 177°C; optionally wherein the Free Base Form D exhibits a differential scanning calorimetry thermogram that is substantially similar to that of FIG. 16.

39. The Free Base Form D of any one of claims 1-7 and 34-38, wherein the Free Base Form D exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 0.1% to about 5% when heated from about 25°C to about 75°C.

40. The Free Base Form D of any one of claims 1-7 and 34-39, wherein the Free Base Form D exhibits a weight loss in a thermogravimetric analysis (TGA) of about 1.9% when heated from about 25°C to about 75°C, and / or of about 2.97% when heated from about 43°C to about 193°C; optionally wherein the Free Base Form D exhibits a TGA pattern that is substantially similar to that of FIG. 16 and / or FIG. 17.

41. The Free Base Form E of any one of claims 1-6 and 8-9, wherein the Free Base Form E is an ethanol solvate, an ethyl acetate solvate, a methanol solvate, a 2- methyl-tetrahydrofuran solvate, an isopropanol solvate, or a dioxane solvate.

42. The Free Base Form E of any one of claims 1-6, 8-9, and 41, wherein the Free Base Form E exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.6, 14.6, 17.4, 20.0, and 24.5 ±O.2°20.

43. The Free Base Form E of any one of claims 1-6, 8-9, and 41-42, wherein the Free Base Form E exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.6, 14.6, 15.7, 17.4, 20.0, 22.1, and 24.5 ±O.2°20; optionally wherein the Free Base Form E exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 18.

44. The Free Base Form E of any one of claims 1-6, 8-9, and 41-43, wherein the Free Base Form E exhibits an differential thermal analysis thermogram with an endotherm, wherein the endotherm has an endotherm maximum between about 169°C and 190°C.

45. The Free Base Form E of any one of claims 1-6, 8-9, and 41-44, wherein the Free Base Form E exhibits a differential thermal analysis thermogram with an endotherm, wherein the endotherm has an endotherm maximum at about 175°C; optionally wherein the Free Base Form E exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 20.

46. The Free Base Form E of any one of claims 1-6, 8-9, and 41-45, wherein the Free Base Form E exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 0.1% to about 5% when heated from about 40°C to about 150°C.

47. The Free Base Form E of any one of claims 1-6, 8-9, and 41-46, wherein the Free Base Form E exhibits a weight loss in a thermogravimetric analysis (TGA) of about 2.42% when heated from about 44°C to about 150°C; optionally wherein the Free Base Form E exhibits a TGA pattern that is substantially similar to that of FIG. 20.

48. The Free Base Form F of any one of claims 1-6 and 8-9, wherein the Free Base Form F is a toluene solvate.

49. The Free Base Form F of any one of claims 1-6, 8-9, and 48, wherein the Free Base Form F exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.3, 9.5, 16.8, 18.5, and 19.8 ±O.2°20.

50. The Free Base Form F of any one of claims 1-6, 8-9, and 48-49, wherein the Free Base Form F exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.3, 9.5, 14.0, 15.6, 16.8, 17.4, 18.5, 18.9, 19.2, 19.8, 21.3, 21.6, 22.9, 24.4 ±O.2°20; optionally wherein the Free Base Form F exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 21.

51. The Free Base Form G of any one of claims 1-6 and 8-9, wherein the Free Base Form G is a dimethylacetamide solvate.

52. The Free Base Form Gof any one of claims 1-6, 8-9, and 51, wherein the Free Base Form G exhibits an X-ray powder diffraction pattern with diffraction peaks at about 7.8, 16.0, 16.5, 18.2, and 21.9 ±O.2°20.

53. The Free Base Form G of any one of claims 1-6, 8-9, and 51-52, wherein the Free Base Form G exhibits an X-ray powder diffraction pattern with diffraction peaks at about 7.8, 10.1, 16.0, 16.5, 18.2, 21.6, 21.9, and 25.5 ±0.2°26»; optionally wherein the Free Base Form G exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 22.

54. The Free Base Form G of any one of claims 1-6, 8-9, and 51-53, wherein the Free Base Form G exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum between about 120°C and about 167°C, and the second endotherm has an endotherm maximum between about 209°C and about 247°C.

55. The Free Base Form G of any one of claims 1-6, 8-9, and 51-54, wherein the Free Base Form G exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum at about 145°C, and the second endotherm has an endotherm maximum at about 225°C;optionally wherein the Free Base Form G exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 24.

56. The Free Base Form G of any one of claims 1-6, 8-9, and 51-55, wherein the Free Base Form G exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 5% to about 10% when heated from about 65°C to about 295°C.

57. The Free Base Form G of any one of claims 1-6, 8-9, and 51-56, wherein the Free Base Form G exhibits a weight loss in a thermogravimetric analysis (TGA) of about 9.0% when heated from about 65°C to about 295°C.

58. The Free Base Form G of any one of claims 1-6, 8-9, and 51-57, wherein the Free Base Form G exhibits a thermogravimetric analysis (TGA) pattern that is substantially similar to that of FIG. 24.

59. The Free Base Form H of any one of claims 1-6 and 8-9, wherein the Free Base Form H exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.2, 10.2, 15.7, 16.5, and 20.9 ±O.2°20.

60. The Free Base Form H of any one of claims 1-6, 8-9, and 59, wherein the Free Base Form H exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.2, 10.2, 15.7, 16.5, 18.1, 20.9, and 23.4 ±O.2°20; optionally wherein the Free Base Form H exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 25.

61. The Free Base Form H of any one of claims 1-6, 8-9, and 59-60, wherein the Free Base Form H exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum between about 174°C and 194°C, and the second endotherm has an endotherm maximum between about 231 °C and 261 °C.

62. The Free Base Form H of any one of claims 1-6, 8-9, and 59-61, wherein the Free Base Form H exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum at about 185°C, and the second endotherm has an endotherm maximum at about 245°C;optionally wherein the Free Base Form H exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 27.

63. The Free Base Form H of any one of claims 1-6, 8-9, and 59-62, wherein the Free Base Form H exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 5% to about 10% when heated from about 44°C to about 302°C.

64. The Free Base Form H of any one of claims 1-6, 8-9, and 59-63, wherein the Free Base Form H exhibits a weight loss in a thermogravimetric analysis (TGA) of about 8.77% when heated from about 44°C to about 302°C; optionally wherein the Free Base Form H exhibits a thermogravimetric analysis (TGA) pattern that is substantially similar to that of FIG. 27.

65. The Free Base Form J of any one of claims 1-6 and 8-9, wherein the Free Base Form J exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.6, 9.9, 14.2, 15.7, and 17.0 ±O.2°20.

66. The Free Base Form J of any one of claims 1-6, 8-9, and 65, wherein the Free Base Form J exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.6, 9.9, 14.2, 15.7, 17.0, 19.6, and 20.3 ±Q.2°2d optionally wherein the Free Base Form J exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 28.

67. The Free Base Form J of any one of claims 1-6, 8-9, and 65-66, wherein the Free Base Form J exhibits a differential thermal analysis thermogram with an endotherm, wherein the endotherm has an endotherm maximum between about 192°C and 214°C.

68. The Free Base Form J of any one of claims 1-6, 8-9, and 65-67, wherein the Free Base Form J exhibits a differential thermal analysis thermogram with an endotherm, wherein the endotherm has an endotherm maximum at about 205°C; optionally wherein the Free Base Form J exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 30.

69. The Free Base Form J of any one of claims 1-6, 8-9, and 65-68, wherein the Free Base Form J exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 5% to about 10% when heated from about 54°C to about 299°C.

70. The Free Base Form J of any one of claims 1-6, 8-9, and 65-69, wherein the Free Base Form J exhibits a weight loss in a thermogravimetric analysis (TGA) of about 7.80% when heated from about 54°C to about 299°C; optionally wherein the Free Base Form J exhibits a thermogravimetric analysis (TGA) pattern that is substantially similar to that of FIG. 30.

71. A salt of a compound of Formula (I):Formula (I).

72. The salt of claim 71, wherein the salt is crystalline or semi-crystalline.

73. The salt of claim 71 or 72, wherein the salt exhibits at least one diffraction peak at about 5.O-4O°20 in its X-ray powder diffraction pattern.

74. The salt of any one of claims 71-73, wherein the salt exhibits at least two diffraction peaks at about 17.0-25.0°20 in its X-ray powder diffraction pattern.

75. The salt of any one of claims 71-74, wherein the salt exhibits a5diffraction peak at about 17.0-21 ,0°20 in its X-ray powder diffraction pattern.

76. The salt of any one of claims 71-75, wherein the salt exhibits a diffraction peak at about 19.O-2O.O°20 in its X-ray powder diffraction pattern.

77. The salt of any one of claims 71-76, wherein the salt exhibits a diffraction peak at about 2O.O-22.O°20 in its X-ray powder diffraction pattern.

78. The salt of any one of claims 71-77, wherein the salt is a hydrate.

79. The salt of any one of claims 71-78, wherein the salt is a solvate.

80. The salt of any one of claims 71-79, wherein the salt is a solvate, and the solvate is a tetrahydrofuran (THF) solvate, a methyl ethyl ketone (MEK) solvate, a dimethyl sulfoxide (DMSO) solvate, a dimethylformamide (DMF) solvate, a diethyl ether solvate, an acetone solvate, a dimethylacetamide (DMAc) solvate, or a combination thereof.

81. The salt of claim 71, wherein the salt is a fumarate salt.

82. The salt of claim 71 or 81, wherein the salt is of Formula (I- A):Formula (I- A).

83. The salt of any one of claims 71-82, wherein the salt is Fumarate Salt Form A.

84. The Fumarate Salt Form A of claim 83, wherein the Fumarate Salt Form A exhibits an X-ray powder diffraction pattern with diffraction peaks at about 14.18, 16.04, 18.00, 18.48, 19.18, 21.16, and 22.56 ±O.2°20.

85. The Fumarate Salt Form A of claim 83 or 84, wherein the Fumarate Salt Form A exhibits an X-ray powder diffraction pattern with diffraction peaks at about 4.58, 14.18, 15.52, 16.04, 18.00, 18.48, 19.18, 19.64, 21.16, 22.56, 24.64, 25.22, and 25.58 ±O.2°20; optionally wherein the Fumarate Salt Form A exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 32.

86. The Fumarate Salt Form A of any one of claims 83-85, wherein the Fumarate Salt Form A exhibits a differential scanning calorimetry thermogram with oneendotherm, wherein the endotherm has an endotherm maximum between about 240°C and about 250°C.

87. The Fumarate Salt Form A of any one of claims 83-86, wherein the Fumarate Salt Form A exhibits a differential scanning calorimetry thermogram with one endotherm, wherein the endotherm has an endotherm maximum at about 245°C; optionally wherein the Fumarate Salt Form A exhibits a differential scanning calorimetry thermogram that is substantially similar to that of FIG. 37.

88. The Fumarate Salt Form A of any one of claims 83-87, wherein the Fumarate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 0.1% to about 5% when heated from about 25°C to about 125°C, and in the range of about 10% to about 15% when heated from about 125°C to about 275°C.

89. The Fumarate Salt Form A of any one of claims 83-88, wherein the Fumarate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) of about 1.7% when heated from about 25°C to about 125°C, and from about 10.0% to about 12.3% when heated from about 125°C to about 275°C; optionally wherein the Fumarate Salt Form A exhibits a TGA pattern that is substantially similar to that of FIG. 37.

90. The salt of any one of claims 71 and 81-82, wherein the salt is amorphous.

91. The salt of any one of claims 71, 81-82, and 90, wherein the salt is Fumarate Salt Amorphous Form.

92. The Fumarate Salt Amorphous Form of claim 91, wherein the Fumarate Salt Amorphous Form is shown to be amorphous by X-ray powder diffraction; optionally wherein the Fumarate Salt Amorphous Form exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 39.

93. The Fumarate Salt Amorphous Form of claim 91 or 92, wherein the Fumarate Salt Amorphous Form exhibits a differential scanning calorimetry thermogram with one endotherm, where the endotherm has an endotherm maximum between about 30°C and about 130°C.

94. The Fumarate Salt Amorphous Form of any one of claims 91-93, wherein the Fumarate Salt Amorphous Form exhibits a differential scanning calorimetry thermogram with one endotherm, where the endotherm has an endotherm maximum at about 77°C; optionally wherein the Fumarate Salt Amorphous Form exhibits a differential scanning calorimetry thermogram that is substantially similar to that of FIG. 42.

95. The Fumarate Salt Amorphous Form of any one of claims 91-94, wherein the Fumarate Salt Amorphous Form exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 1% to about 10% when heated from about 35°C to about 180°C.

96. The Fumarate Salt Amorphous Form of any one of claims 91-95, wherein the Fumarate Salt Amorphous Form exhibits a weight loss in a thermogravimetric analysis (TGA) of about 4.66% when heated from about 37°C to about 179°C; optionally wherein the Fumarate Salt Amorphous Form exhibits a TGA pattern that is substantially similar to that of FIG. 41.

97. The salt of any one of claims 71-82, wherein the salt is Fumarate Salt Form B.

98. The Fumarate Salt Form B of claim 97, wherein the Fumarate Salt Form B exhibits an X-ray powder diffraction pattern with diffraction peaks at about 6.60, 7.54, 7.67, 8.57, 16.42, 18.18, and 21.56±O.2°20.

99. The Fumarate Salt Form B of claim 97 or 98, wherein the Fumarate Salt Form B exhibits an X-ray powder diffraction pattern with diffraction peaks at about 6.02, 6.60, 7.54, 7.67, 8.57, 11.74, 14.97, 16.42, 17.19, 18.18, 18.49, and 21.56±O.2°20; optionally wherein the Fumarate Salt Form B exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 45 (2ndfrom bottom).

100. The salt of any one of claims 71-82, wherein the salt is Fumarate Salt Form C.

101. The Fumarate Salt Form C of claim 100, wherein the Fumarate Salt Form C exhibits an X-ray powder diffraction pattern with diffraction peaks at about 6.14, 7.69, 8.08, 8.18, 12.14, 15.44, 20.89, 21.13, and 24.03±O.2°20.

102. The Fumarate Salt Form C of claim 100 or 101, wherein the Fumarate Salt Form C exhibits an X-ray powder diffraction pattern with diffraction peaks at about 6.14, 8.44, 7.69, 8.08, 8.18, 11.37, 12.14, 13.53, 15.44, 19.28, 20.47, 20.89, 21.13, 23.59, and 24.O3±O.2°20; optionally wherein the Fumarate Salt Form C exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 47 (2ndfrom bottom).

103. The salt of any one of claims 71-82, wherein the salt is Fumarate Salt Form D.

104. The Fumarate Salt Form D of claim 103, wherein the Fumarate Salt Form D exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 49.

105. The Fumarate Salt Form D of claim 103 or 104, wherein the Fumarate Salt Form D exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum between about 220°C and about 250°C.

106. The Fumarate Salt Form D of any one of claims 103-105, wherein the Fumarate Salt Form D exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum at about 225°C; optionally wherein the Fumarate Salt Form D exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 50.

107. The Fumarate Salt Form D of any one of claims 103-106, wherein the Fumarate Salt Form D exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 30% to about 40% when heated from about 30°C to about 300°C.

108. The Fumarate Salt Form D of any one of claims 103-107, wherein the Fumarate Salt Form D exhibits a weight loss in a thermogravimetric analysis (TGA) of about 34.0% when heated from about 32°C to about 295°C;optionally wherein the Fumarate Salt Form D exhibits a TGA pattern that is substantially similar to that of FIG. 50.

109. The salt of any one of claims 71-82, wherein the salt is Fumarate Salt Form E.

110. The Fumarate Salt Form E of claim 109, wherein the Fumarate Salt Form E exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 51.

111. The Fumarate Salt Form E of claim 109 or 110, wherein the Fumarate Salt Form E exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum between about 200°C and about 240°C.

112. The Fumarate Salt Form E of any one of claims 109-111, wherein the Fumarate Salt Form E exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum at about 225°C; optionally wherein the Fumarate Salt Form E exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 52.

113. The Fumarate Salt Form E of any one of claims 109-112, wherein the Fumarate Salt Form E exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 5% to about 15% when heated from about 40°C to about 215°C.

114. The Fumarate Salt Form E of any one of claims 109-113, wherein the Fumarate Salt Form E exhibits a weight loss in a thermogravimetric analysis (TGA) of about 9.08% when heated from about 41°C to about 213°C; optionally wherein the Fumarate Salt Form E exhibits a TGA pattern that is substantially similar to that of FIG. 52.

115. The salt of claim 71, wherein the salt is a maleate salt, a tosylate salt, a besylate salt, a cyclamate salt, a malate salt, a malonate salt, a napsylate salt, or a succinate salt.

116. The salt of claim 71 or 115, wherein the salt is of Formula (I-B), Formula (I-C), Formula (I-D), Formula (I-E), Formula (I-F), Formula (I-G), Formula (I-H), or Formula (I- J):Formula (I-E);Formula (I- J).

117. The salt of any one of claims 71 and 115-116, wherein the salt is amorphous.

118. The salt of any one of claims 71-80 and 115-116, wherein the salt is Maleate Salt Form A.

119. The Maleate Salt Form A of claim 118, wherein the Maleate Salt Form A is a THF solvate.

120. The Maleate Salt Form A of claim 118 or 119, wherein the Maleate Salt Form A exhibits an X-ray powder diffraction pattern with diffraction peaks at about 14.20, 16.48, 18.28, 19.46, and 21.74 ±O.2°20.

121. The Maleate Salt Form A of any one of claims 118-120, wherein the Maleate Salt Form A exhibits an X-ray powder diffraction pattern with diffraction peaks at about 14.20, 16.48, 18.28, 18.92, 19.46, 21.44, 21.74, 22.74, 23.22, and 24.82 ±O.2°20; optionally wherein the Maleate Salt Form A exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 55.

122. The Maleate Salt Form A of any one of claims 118-121, wherein the Maleate Salt Form A exhibits a differential scanning calorimetry thermogram with one endotherm, where the endotherm has an endotherm maximum between about 225°C and about 235°C.

123. The Maleate Salt Form A of any one of claims 118-122, wherein the Maleate Salt Form A exhibits a differential scanning calorimetry thermogram with one endotherm, where the endotherm has an endotherm maximum at about 229°C; optionally wherein the Maleate Salt Form A exhibits a differential scanning calorimetry thermogram that is substantially similar to that of FIG. 56.

124. The Maleate Salt Form A of any one of claims 118-123, wherein the Maleate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 0.1% to about 5% when heated from about 25°C to about 175°C, and in the range of about 5% to about 10% when heated from about 175°C to about 250°C.

125. The Maleate Salt Form A of any one of claims 118-124, wherein the Maleate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) of about 2.3% when heated from about 25°C to about 175°C, and about 9.0% when heated from about 175°C to about 250°C; optionally wherein the Maleate Salt Form A exhibits a TGA pattern that is substantially similar to that of FIG. 56.

126. The salt of any one of claims 71-80 and 115-116, wherein the salt is Tosylate Salt Form A.

127. The Tosylate Salt Form A of claim 126, wherein the Tosylate Salt Form A exhibits an X-ray powder diffraction pattern with diffraction peaks at about 15.76, 19.34, 20.96, 22.86, and 24.02 ±O.2°20.

128. The Tosylate Salt Form A of claim 126 or 127, wherein the Tosylate Salt Form A exhibits an X-ray powder diffraction pattern with diffraction peaks at about 15.76°, 16.74°, 17.54°, 19.34°, 20.32°, 20.96°, 21.84°, 22.86°, 24.02°, and 25.32 ±0.2°26>; optionally wherein the Tosylate Salt Form A exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 57.

129. The salt of any one of claims 71-80 and 115-116, wherein the salt is Tosylate Salt Form B.

130. The Tosylate Salt Form B of claim 129, wherein the Tosylate Salt Form B exhibits an X-ray powder diffraction pattern with diffraction peaks at about 18.40, 19.12, 19.68, and 22.08 ±0.2°26>.

131. The Tosylate Salt Form B of claim 129 or 130, wherein the Tosylate Salt Form B exhibits an X-ray powder diffraction pattern with diffraction peaks at about 10.20, 10.54, 18.00, 18.40, 19.12, 19.68, 20.38, 20.88, 21.86, 22.08, 22.36, 22.58, 22.90, and 26.38 ±0.2°26>; optionally wherein the Tosylate Salt Form B exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 58.

132. The salt of any one of claims 71-80 and 115-116, wherein the salt is Besylate Salt Form A.

133. The Besylate Salt Form A of claim 132, wherein the Besylate Salt Form A exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 59.

134. The Besylate Salt Form A of claim 132 or 133, wherein the Besylate Salt Form A exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum between about 85°C and about 160°C, and the second endotherm maxima between about 205°C and about 255°C.

135. The Besylate Salt Form A of any one of claims 132-134, wherein the Besylate Salt Form A exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum at about 99°C, and the second endotherm has an endotherm maximum at about 218°C; optionally wherein the Besylate Salt Form A exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 60.

136. The Besylate Salt Form A of any one of claims 132-135, wherein the Besylate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 0.1% to about 5% when heated from about 30°C to about 90°C, and a weight loss in the range of about 30% to about 40% when heated from about 85°C to about 160°C.

137. The Besylate Salt Form A of any one of claims 132-136, wherein the Besylate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) of about 1.12% when heated from about 31 °C to about 88°C, and a weight loss in the range of about 34.2% when heated from about 88°C to about 155°C; optionally wherein the Besylate Salt Form A exhibits a TGA pattern that is substantially similar to that of FIG. 60.

138. The salt of any one of claims 71-80 and 115-116, wherein the salt is Cyclamate Salt Form A.

139. The Cyclamate Salt Form A of claim 138, wherein the Cyclamate Salt Form A exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 61.

140. The Cyclamate Salt Form A of claim 138 or 139, wherein the Cyclamate Salt Form A exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum between about 220° C and about 245 °C, and the second endotherm has an endotherm maximum between about 275°C to about 305°C.

141. The Cyclamate Salt F orm A of any one of claims 138-140, wherein the CyclamateSalt Form A exhibits a differential thermal analysis thermogram with twoendotherms, wherein the first endotherm has an endotherm maximum at about 223°C, and the second endotherm has an endotherm maximum at about 284°C; optionally wherein the Cyclamate Salt Form A exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 62.

142. The Cyclamate Salt Form A of any one of claims 138-141, wherein the Cyclamate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 1% to about 5% when heated from about 30°C to about 235 °C.

143. The Cyclamate Salt F orm A of any one of claims 138-142, wherein the Cyclamate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) of about 1.72% when heated from about 31 °C to about 229°C; optionally wherein the Cyclamate Salt Form A exhibits a TGA pattern that is substantially similar to that of FIG. 62.

144. The salt of any one of claims 71-80 and 115-116, wherein the salt is Malate Salt Form A.

145. The Malate Salt Form A of claim 144, wherein the X-ray powder diffraction pattern is substantially similar to that of FIG. 63.

146. The Malate Salt Form A of claim 144 or 145, wherein the Malate Salt Form A exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum between about 60°C and about 130°C, and the second endotherm has an endotherm maximum between about 220°C and about 260°C.

147. The Malate Salt Form A of any one of claims 144-146, wherein the Malate Salt Form A exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum at about 87°C, and the second endotherm has an endotherm maximum at about 230°C; optionally wherein the Malate Salt Form A exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 64.

148. The Malate Salt Form A of any one of claims 144-147, wherein the Malate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 1% to about 10% when heated from about 30°C to about 225°C.

149. The Malate Salt Form A of any one of claims 144-148, wherein the Malate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) of about 4.73% when heated from about 30°C to about 223°C; optionally wherein the Malate Salt Form A exhibits a TGA pattern that is substantially similar to that of FIG. 64.

150. The salt of any one of claims 71-80 and 115-116, wherein the salt is Malonate Salt Form A.

151. The Malonate Salt Form A of claim 150, wherein the Malonate Salt Form A exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 65.

152. The Malonate Salt Form A of claim 150 or 151, wherein the Malonate Salt Form A exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum between about 140°C and about 190°C.

153. The Malonate Salt Form A of any one of claims 150-152, wherein the Malonate Salt Form A exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum at about 159°C; optionally wherein the Malonate Salt Form A exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 66.

154. The Malonate Salt Form A of any one of claims 150-153, wherein the Malonate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 1% to about 10% when heated from about 30°C to about 140°C, about 1% to about 10% when heated from about 135°C to about 180°C, and about 1% to about 10% when heated from about 180°C to about 305°C.

155. The Malonate Salt Form A of any one of claims 150-154, wherein the Malonate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) of about 2.43% when heated from about 31°C to about 137°C, 6.30% when heated fromabout 138°C to about 180°C, and 4.48% when heated from about 181°C to about 298°C in a TGA; optionally wherein the Mai onate Salt Form A exhibits a TGA pattern that is substantially similar to that of FIG. 66.

156. The salt of any one of claims 71-80 and 115-116, wherein the salt is Napsylate Salt Form A.

157. The Napsylate Salt Form A of claim 156, wherein the Napsylate Salt Form A exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 67.

158. The Napsylate Salt Form A of claim 156 or 157, wherein the Napsylate Salt Form A exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum between about 240°C and about 280°C.

159. The Napsylate Salt Form A of any one of claims 156-158, wherein the Napsylate Salt Form A exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum at about 262°C; optionally wherein the Napsylate Salt Form A exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 68.

160. The Napsylate Salt Form A of any one of claims 156-159, wherein the Napsylate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 1% to about 5% when heated from about 30°C to about 255 °C.

161. The Napsylate Salt Form A of any one of claims 156-160, wherein the Napsylate Salt Form A exhibits a weight loss in a thermogravimetric analysis (TGA) of about 2.78% when heated from about 31 °C to about 251 °C; optionally wherein the Napsylate Salt Form A exhibits a TGA pattern that is substantially similar to that of FIG. 68.

162. The salt of any one of claims 71-80 and 115-116, wherein the salt is Napsylate Salt Form A, Napsylate Salt Form B, Napsylate Salt Form C, or Napsylate Salt Form D.

163. The Napsylate Salt Form B of claim 162, wherein the Napsylate Salt Form B exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 69 (2ndfrom top).

164. The Napsylate Salt Form C of claim 162, wherein the Napsylate Salt Form C exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 69 (2ndfrom bottom).

165. The Napsylate Salt Form D of claim 162, wherein the Napsylate Salt Form D exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 69 (bottom) and FIG. 70.

166. The Napsylate Salt Form D of claim 162 or 165, wherein the Napsylate Salt Form D exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum between about 75°C and about 140°C.

167. The Napsylate Salt Form D of any one of claims 162 and 165-166, wherein the Napsylate Salt Form D exhibits a differential thermal analysis thermogram with one endotherm, wherein the endotherm has an endotherm maximum at about 98°C; optionally wherein the Napsylate Salt Form D exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 71.

168. The Napsylate Salt Form D of any one of claims 162 and 165-167, wherein the Napsylate Salt Form D exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 1% to about 5% when heated from about 25°C to about 85°C, a range of about 20% to about 30% when heated from about 85°C to about 125°C, and a range of about 0.1% to 5% when heated from about 150°C to about 180°C.

169. The Napsylate Salt Form D of any one of claims 162 and 165-168, wherein the Napsylate Salt Form D exhibits a weight loss in a thermogravimetric analysis (TGA) of about 1.97% when heated from about 30°C to about 83°C, a range of about 25% when heated from about 86°C to about 124°C, and a range of about 0.9% when heated from about 151°C to about 175°C;optionally wherein the Napsylate Salt Form D exhibits a TGA pattern that is substantially similar to that of FIG. 71.

170. The salt of any one of claims 71-80 and 115-116, wherein the salt is Succinate Salt Form A or Succinate Salt Form B.

171. The Succinate Salt Form A of claim 170, wherein the Succinate Salt Form A exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 72 (2ndfrom top, and bottom) and FIG. 73.

172. The Succinate Salt Form B of claim 170, wherein the Succinate Salt Form B exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 72 (2ndfrom bottom).

173. The Succinate Salt Form B of claim 170 or 172, wherein the Succinate Salt Form B exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum between about 75°C and about 125 °C, and the second endotherm has an endotherm maximum between about 200°C and about 230°C.

174. The Succinate Salt Form B of any one of claims 170 and 172-173, wherein the Succinate Salt Form B exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum at about 77°C, and the second endotherm has an endotherm maximum at about 209°C; optionally wherein the Succinate Salt Form B exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 74.

175. The Succinate Salt Form B of any one of claims 170 and 172-174, wherein the Succinate Salt Form B exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 1% to about 5% when heated from about 30°C to about 215°C.

176. The Succinate Salt Form B of any one of claims 170 and 172-175, wherein the Succinate Salt Form B exhibits a weight loss in a thermogravimetric analysis (TGA) of about 1.55% when heated from about 34°C to about 214°C;optionally wherein the Succinate Salt Form B exhibits a TGA pattern that is substantially similar to that of FIG. 74.

177. The salt of any one of claims 71-80 and 115-116, wherein the salt is Succinate Salt Form C.

178. The Succinate Salt Form C of claim 177, wherein the Succinate Salt Form C exhibits an X-ray powder diffraction pattern that is substantially similar to that of FIG. 75.

179. The Succinate Salt Form C of claim 177 or 178, wherein the Succinate Salt Form C exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum between about 80°C and about 155 °C, and the second endotherm has an endotherm maximum between about 200°C and about 235°C.

180. The Succinate Salt Form C of any one of claims 177-179, wherein the Succinate Salt Form C exhibits a differential thermal analysis thermogram with two endotherms, wherein the first endotherm has an endotherm maximum at about 77°C, and the second endotherm has an endotherm maximum at about 209°C; optionally wherein the Succinate Salt Form C exhibits a differential thermal analysis thermogram that is substantially similar to that of FIG. 76.

181. The Succinate Salt Form C of any one of claims 177-180, wherein the Succinate Salt Form C exhibits a weight loss in a thermogravimetric analysis (TGA) in the range of about 20% to about 30% when heated from about 70°C to about 155°C.

182. The Succinate Salt Form C of any one of claims 177-181, wherein the Succinate Salt Form C exhibits a weight loss in a thermogravimetric analysis (TGA) of about 23.6% when heated from about 74°C to about 153°C; optionally wherein the Succinate Salt Form C exhibits a TGA pattern that is substantially similar to that of FIG. 76.

183. An amorphous solid dispersion comprising: the free base of a compound of Formula (I) according to any one of claims 1-70; orthe salt form of a compound of Formula (I) according to any one of claims 71-182.

184. The amorphous solid dispersion of claim 183, further comprising a dispersion aid selected from the group consisting of a hydroxypropyl methylcellulose acetate succinate (HPMCAS), an anionic copolymer consisting of methacrylic acid and ethyl acrylate, or a random copolymer of N-vinyl pyrrolidone and vinyl acetate (PVP / VA); optionally wherein the HPMCAS is HPMCAS-H or HPMCAS-L, the anionic copolymer consisting of methacrylic acid and ethyl acrylate is Eudragit LI 00, or the PVP / VA is PVP-VA64.

185. A pharmaceutical composition comprising: the free base of a compound of Formula (I) according to any one of claims 1-70, the salt form of the compound of Formula (I) according to any one of claims 71-182, or the amorphous solid dispersion according to claim 183 or 184, and a pharmaceutically acceptable carrier, vehicle, or adjuvant.

186. A method of treating a disease, disorder, or condition mediated by degrading Bruton’s tyrosine kinase, comprising administering to a patient or biological sample: the free base of a compound according to any one of claims 1-70, the salt form of a compound of Formula (I) according to any one of claims 71-182, the amorphous solid dispersion according to any one of claims 183-184, or the pharmaceutical composition of claim 186.

187. The method of claim 186, wherein the disease, disorder, or condition is selected from the group consisting of diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM), and primary central nervous system lymphoma (PCNSL).

188. The method of claim 187, wherein the DLBCL is non-Germinal center B-cell like subtype (non-GCB) DLBCL, and / or the MCL is non-GCB MCL.

189. The method of claim 187 or 188, wherein the disease, disorder, or condition includes secondary central nervous system (CNS) lymphoma.

90. A method of degrading splenocyte Bruton’s tyrosine kinase in a subject in need thereof, comprising the step of orally administering to the subject an amount of: the free base of a compound of Formula (I) according to any one of claims 1-70, the salt form of the compound of Formula (I) according to any one of claims 71-182, the amorphous solid dispersion according to claim 183 or 184, or the pharmaceutical composition of claim 185, wherein said free base or salt is capable of inducing proteolytic degradation of Bruton’s tyrosine kinase, and wherein said amount is effective to degrade splenocyte Bruton’s tyrosine kinase in the subject.

Images